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Abstract 
Immunological tolerance is an important aspect of immunity preventing responses 
being mounted against self-peptides and other innocuous foreign antigens. A 
breach in self-tolerance can lead to the development of autoimmune diseases such 
as Rheumatoid arthritis (RA). RA is a chronic inflammatory autoimmune disease 
that is characterised by synovial inflammation and joint erosion. CD4+ T cells have 
been shown to play a key role in disease progression, and their ability to infiltrate 
joints is associated with perpetuation of local and systemic inflammatory responses. 
A diverse range of T cell receptor (TCR) usage has been demonstrated in RA 
patients, however how such diversity arises and is shaped remains unclear. 
Understanding the development of CD4+ T cell antigen specific responses will 
therefore be important for the development and application of antigen-specific 
therapeutic tolerance regimes. 
To investigate these antigen specific responses, CD4+ T cell clonality was 
examined using the OVA induced breach of tolerance model of experimental 
arthritis, allowing the assessment of developing antigen specific responses in the 
early stages of arthritis. The initial articular CD4+ T cell response was found to be 
oligoclonal in nature, with enrichment of several TCRVβ families in the inflamed 
joint. Moreover, the enrichment for some families is associated with joint derived 
antigens. Next-generation sequencing analysis of CDR3β sequences of CD4+ T cell 
clones revealed the dynamics of clonal responses between the inflamed joint and 
its associated draining lymph node and how these responses change with the 
progression of the disease. Inflamed joints displayed similar CD4+ T cell repertoire 
diversity at early and late stages of the disease, while inflamed lymph nodes 
displayed increased repertoire diversity with disease progression. Moreover, the 
number of CD4+ T cell clones shared between the inflamed joint and lymph node 
decreased with time. However, correlation analyses of highly abundant clones 
between inflamed joints and lymph nodes suggested continued migration of CD4+ 
T cell clones from inflamed lymph nodes to the joints. The decreased diversity in 
inflamed lymph nodes at the later time point may be a reflection of epitope spreading 
to the initial inciting antigen as well as development of new responses to neo 
antigens released as a result of continued joint damage. The hypothesis is that the 
reduced CD4+ T cell diversity in the inflamed lymph nodes will eventually be 
mirrored in the joint if the disease continues untreated. 
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This research provides insight on the dynamics of the antigen specific response 
between the inflamed tissue and its draining lymph node with disease progression, 
highlighting important site specific and temporal differences in clonal diversity with 
disease development and also highlights the role autoreactive CD4+ T cell 
responses play in disease progression. By understating the evolution of CD4+ T cell 
responses in RA, more informed decisions can be made on how antigen-specific 
therapeutics should be applied and will help develop more effective regimes to 
reinstate self-tolerance, with the ultimate goal of moving towards drug free remission 
and a cure. 
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Chapter 1 Introduction 
 Overview 
The immune system is composed of innate and adaptive components that work in 
concert to provide protection against pathogens and infection. However, this 
process can go awry and can result in unwanted responses to self. Mechanisms 
such as immunological tolerance have evolved to prevent responses being mounted 
against self-peptides and other harmless foreign antigens and are a crucial aspect 
of a functioning immune system (section 1.3). However, mechanisms of tolerance 
can also breakdown, resulting in breach of tolerance and the development of 
autoimmunity and allergy. Breach of tolerance is coordinated mainly by cells of the 
adaptive immune system, such as CD4+ T cells (section 1.3.3), which have been 
strongly implicated in coordinating, maintaining, and progressing autoimmune 
diseases such as Rheumatoid Arthritis (RA) (section 1.4). 
RA is a chronic debilitating inflammatory disease affecting 1.5-2.5% of the global 
population that results in cartilage degradation and joint destruction. RA 
therapeutics have relied on broad immunosuppression strategies, but more recently 
have aimed to target specific components of the adaptive immune system, such as 
T and B cell activation, to provide a more effective form of therapy (section 1.4.5). 
Unfortunately, a significant proportion of RA patients fail to respond to current 
therapeutics and eventually have a relapse in disease. More effective forms of 
therapy are therefore required to achieve long lasting, drug-free remission in RA 
patients. 
One potential line of therapy currently being investigated for use in RA is antigen 
specific therapy, which relies on using antigens to specifically target autoreactive 
CD4+ T cells and induce mechanisms of peripheral tolerance to reinstate tolerance 
to self-antigens (sections 1.3.2 and 1.5). By targeting the pathogenic autoreactive 
CD4+ T cells, the hope is to prevent perpetuation of immune responses that lead to 
joint destruction and ultimately restore tolerance to self-antigens implicated in the 
disease. One of the main setbacks presented by autoimmune diseases in general 
is that they are diagnosed long after disease onset, which makes it difficult to 
pinpoint the CD4+ T cell specificities that were potentially involved in disease 
initiation, and ultimately, makes it difficult to choose the antigens required for 
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tolerogenic therapy. This is particularly relevant for RA, as patients display clinical 
symptoms up to 15 years after breach of tolerance has occurred1.Moreover, events 
resulting from chronic inflammation further complicate the process of finding the 
right cells and specificities to target to effectively ameliorate the disease and 
reinstate self-tolerance. The delay between disease onset and the presentation of 
clinical symptoms has made it difficult to investigate how antigen specific responses 
develop during RA; specifically, from when breach of tolerance occurs to when 
clinical symptoms are manifest.  
In an effort to investigate the development of antigen specific responses in RA, 
numerous studies have focussed on inspecting CD4+ T cell clonality and diversity 
in RA patients. This requires examining the T cell receptor (TCR) sequence and 
identifying shifts in frequencies of T cell clones, thus identifying the presence of 
antigen specific responses. The advantage of this method is it circumvents the 
necessity in knowing the antigens involved in these responses. However, the delay 
between breach of tolerance and the presentation of clinical symptoms still poses 
an issue when investigating CD4+ T cell clonality in RA patients as it difficult to 
establish when breach of tolerance has occurred in humans. And so, it is very 
difficult to monitor the initial antigen specific responses at the point when breach of 
tolerance occurs in humans. Thus, a system whereby antigen specific responses 
can be monitored from when they first occur is necessary to understand how antigen 
specific responses develop with disease progression. 
The research I have presented here aims to provide a detailed examination of the 
evolution of CD4+ T cell clonality and antigen specific responses in the OVA induced 
breach of tolerance model of experimental arthritis. These responses were 
examined from the very early stages of experimental arthritis to a later more chronic 
stage of the model. This model uses a joint irrelevant antigen to induce arthritis and 
allows for the tracking of endogenous antigen specific responses in conditions 
where autoreactive responses have been shown to occur.  The results and 
conclusions outlined in this thesis aim to further our understanding of the 
development of antigen specific responses and may emulate the antigen specific 
responses observed in RA patients. This will potentially contribute to the 
advancement of more effective tolerogenic antigen specific therapies in RA and 
toward therapies providing drug-free remission.  
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 The role of T cells in the adaptive immune system 
The hallmark of the adaptive immune system is antigen specificity and 
immunological memory – a long lasting remnant of the primary response against a 
pathogen that allows for a quicker and more intensive response upon pathogen re-
encounter. The adaptive immune system is composed of B and T lymphocytes 
which are both able to recognise specific epitopes of proteins, giving the adaptive 
immune system the unique property of mounting a response against specific 
antigens. B and T lymphocytes are able to do this via their B and T cell receptors 
respectively. This introduction will concentrate on T cells and discuss the generation 
of the T cell receptor (TCR), TCR diversity, and factors that affect this diversity which 
influence the degree of protection against infections and also influence the 
development of autoimmunity. 
 The T cell receptor (TCR) and TCR clonality 
The T cell receptor (TCR) is a protein complex found on both CD4+ and CD8+ T 
cells which allows them to recognise peptides in the context of MHC molecules2. 
Generally, TCR engagement results in a cascade of signalling events leading to T 
cell activation and onset of effector functions. TCRs are highly diverse molecules 
allowing T cell populations to recognise an immense range of  peptide/MHC (major 
histocompatibility) complexes. Generation of a diverse T cell repertoire is an 
important attribute of the adaptive immune system resulting in the protection of the 
host from numerous potential pathogens. The following sections discuss how this 
diversity is achieved by detailing the structure of the TCR and the mechanism by 
which TCRs are generated. 
1.2.1.1 Structure and generation of a functional TCR 
The TCR is a heterodimeric transmembrane protein that is made up of an α and β 
chain that are joined together by a disulphide bond. A smaller subset of T cells 
express TCRs made up of a γ and a δ chain and are adequately named γδ T cells. 
These cells have a limited antigen recognition repertoire and function differently to 
conventional αβ T cells and will not be discussed in this introduction. Each α and β 
chain are made up of constant (C), variable (V), and joining (J) segments with the 
addition of a diversity (D) segment in the β chain. Each TCR chain is divided into 
two regions; the invariable constant region made up of the C segment, and the 
  
 
19 
 
variable region which consists of the V, (D), and J segments. The constant region, 
as the name implies, is invariant across different TCRs and is encoded by one C 
segment gene for the α chain and 2 for the β chain. The V region segments are 
randomly selected from a large range of genes (human TCRα locus: 43 V genes, 
and 58 J genes, human TCRβ locus: 42 V genes, 12 J genes, and 2 D genes) and 
combined in a process called V(D)J recombination3,4. Each segment gene used to 
synthesise the V region of a TCR chain is flanked by a conserved recombination 
signal sequence (RS) that is utilised by recombination activating genes 1 and 2 
(RAG1 and RAG2) and non-homologous end joining (NHEJ) machinery to initialise 
the recombination event. The RS sequence is an AT rich sequence that is separated 
by either 12 or 23 non-conserved base pairs (bps). Recombination events only occur 
using genes that contain an RS sequence followed by 12 bps with those containing 
an RS sequence followed by 23 bps and is known as the 12/23 rule. This ensures 
that the segments assemble in the correct order; for the TCRβ chain for instance, V 
segment genes are flanked by RS sequences with a 23 bp spacer and therefore can 
only be joined to D genes but not J genes, as these TCR segment genes have RS 
sequences with 12 and 23 bp spacers respectively. Moreover, recombination events 
only occur between genes from the same chromosome, which guards against cross 
recombination events between TCRα and TCRβ chain genes. The RS sequences 
are precisely aligned during recombination to maintain an in-frame coding region. 
The alignment of the RS sequences between different gene segments creates loops 
in the chromosome that are excised during recombination along with the RS 
sequences. The variable region is then imprecisely joined by having nucleotides 
added or removed by the terminal deoxynucleotidyl transferase (TdT) enzyme or by 
exonucleases respectively. The variable region is then ligated by DNA ligase to 
leave an exon coding for the variable region. This rearranged DNA V region is then 
transcribed and spliced to a C segment to generate a mature mRNA molecule that 
encodes a complete α or β TCR chain5,6 (Figure 1-1). 
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Figure 1-1 Generation of a functional αβ TCR 
Schematic representing gene rearrangements and molecular mechanisms to generate an αβ TCR 
chain. VJ or VDJ gene segments rearrange from a large range of segment genes in a process called 
V(D)J recombination. Due to the imprecise mechanism of segment joining, base pairs are added or 
removed by TdT to ensure the coding region remains in-frame. Once the VJ or VDJ genes are 
rearranged, the mRNA is spliced to mRNA transcribed from the constant genes, which are then 
translated to form a complete αβ TCR.  
Crystal structures of TCRs interacting with peptide/MHC complexes have revealed 
TCR interaction loops known as complementarity-determining regions (CDRs) that 
serve as contact points between the TCR, peptide, and MHC molecule7,8. CDRs 1 
and 2 are encoded by V gene segments and form contacts with the MHC molecule 
with CDR1 also contacting the outer edges of the peptide. The CDR3 regions are 
formed from the VJ and VDJ junctions of α and β TCR chains respectively and were 
found to contact the centre of the peptide. The CDR3 region was predicted to be the 
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most variable region of the TCR due to the junctional diversity of the VJ and VDJ 
regions2 and was confirmed by mutagenesis studies directed against the CDR3 
sequence resulting in altered response to peptide or abolishing it altogether9,10. The 
variability in the CDR3 region is therefore critical in recognising specific peptide 
sequences within the context of MHC11,12 (Figure 1-2). 
 
Figure 1-2 αβ TCR structure 
Schematic of an αβ TCR chain highlighting the CDR3β region. A functional αβ TCR consists of an α 
and β chain joined together by a disulphide bond. The TCR contacts the peptide/MHC complex at 
several contact via complementary determining regions (CDRs) present on the TCR. CDRs 1 and 2 
are encoded by V gene segments mainly contact the MHC molecule, with CDR1 also forming 
contacts with the outer edges of the peptide. The CDR3 regions are formed from the VJ and VDJ 
junctions of α and β TCR chains respectively and were found to contact the centre of the peptide. 
The CDR3 region was predicted to be the most variable region of the TCR due to the junctional 
diversity of the VJ and VDJ regions. The Vβ chain and the CDR3β region are highlighted in this 
schematic, as antibodies against the Vβ chain and NGS methods targeting the CDR3β sequence 
were used in the research presented in this thesis. 
 
  
 
22 
 
1.2.1.2 Generation of TCR and T cell repertoire diversity 
Rearrangement of TCR genes generates diversity in 3 ways; firstly the 
recombination of different V region gene segments generates what is known as 
combinatorial diversity. Secondly, junctional diversity is generated in the V region 
during the addition and subtraction of nucleotides between V and J or between V 
and DJ regions during V(D)J recombination. Thirdly, different combinations of TCRα 
and β chains creates a remarkable range of unique TCR complexes. Due to these 
mechanisms, theoretical TCR diversity is estimated to achieve 1x1015 possible 
unique TCR complexes that is reduced to 1x1013 after thymic selection2,13. 
Theoretical TCR diversity therefore has the ability to generate an immense TCR 
repertoire pool that can essentially recognise any possible peptide sequence14. In 
reality, this diversity is limited by the physical number of T cells available in an 
organism, which in humans is approximately 2x107 T cells15. Due to the immense 
number of possible TCR sequences, the probability of organisms having the same 
TCR repertoire is very low. Indeed, a study by Bousso et. al. found that the naïve T 
cell repertoire between individual mice of the same strain overlaps by only 20-25%16 
and genetically identical mice infected with the lymphocytic choriomeningitis virus 
(LCMV) each develop unique responses to the virus17, known as private responses. 
Having a varied and more diverse T cell repertoire has been shown to be more 
effective in an organism’s capability of responding to a given pathogen and also 
reduces the possibility of mutated pathogens evading the immune system. A study 
in rhesus macaques infected with simian immunodeficiency virus (SIV) by Price et. 
al18. demonstrated that the virus evades immune detection in individuals with a TCR 
repertoire with a restricted CDR3β sequence. In addition, a study by Messaoudi et. 
al19. demonstrated how a polyclonal but not an oligoclonal CD8+ T cell repertoire – 
T cell populations that have varied versus restricted ranges of CDR3 sequences 
respectively – protected mice against the Herpesvirus hominus type I (HVH-1). 
Together, these studies provide evidence for the value in having a diverse TCR 
repertoire for immune protection. 
However, there are instances where the same TCR sequence occurs across 
individuals in response to a pathogen and this is known as a public TCR response20. 
Evidence of public responses have been found in cases of viral infection – such as 
Epstein-Barr virus (EBV), and influenza virus21,22- and autoimmunity23,24. Given the 
rarity in generating the same TCR sequence in two different individuals, a potential 
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explanation for having public responses is the possibility of specific TCR sequences 
posing a selective advantage to a given response. Indeed, deletion of the Dβ region 
from C57BL/6 mice practically ablated the CD8+ T cell response to Herpes simplex 
virus 1 (HSV-1) and reduced the cellular response to infection25. Recent evidence 
has suggested that public TCRs are positively selected in the thymus due to their 
increased ability to cross-react with different antigens26 potentially overcoming the 
restriction in TCR diversity presented by the finite number of T cells produced in an 
organism13. Although, evidence for the benefits of TCR cross-reactivity is 
controversial25,27, and the association of public TCR sequences to autoimmune 
diseases23,24 perhaps undermines the benefits of public TCR sequences. 
1.2.1.3 Factors affecting TCR and T cell repertoire diversity 
There are several factors that can affect TCR diversity. These are thymic selection, 
outgrowth of specific clones during an initial immune response and during persistent 
or chronic infection, and whether there is a public or private response against a 
pathogen. 
Several studies have demonstrated how thymic selection influences diversity of the 
T cell repertoire and have suggested that this process can reduce T cell diversity by 
3 to 100 fold13. Zerrahn et. al.28 demonstrated how this selection bias may in fact be 
encoded in germline TCR gene segments prior to any form of selection. Indeed, a 
study by Fazilleau et. al.29 demonstrated a bias in TCR gene segment selection in 
mice deficient for the TdT enzyme and found repeated selection of certain V, D, and 
J segment genes across TdT deficient animals. They and others hypothesised that 
this bias is to enrich the T cell precursors for self-MHC restriction29,30. MHC 
polymorphic restriction heavily influences TCR diversity, as precursor T cells 
selected during positive selection are only selected if they bind to the MHC 
molecules expressed by thymic cortical epithelial cells. Indeed, a complex between 
the TCR, peptide, and MHC molecule forms upon peptide recognition – named the 
trimolecular complex   ̶ which is facilitated and perhaps stabilised by TCR contacts 
with the MHC molecule8,31,32. Studies have demonstrated that mutations in MHC 
molecules have a profound impact on T cell responses and peptide recognition33,34.  
An example of the influence of MHC II restriction on the TCR repertoire perhaps 
occurs in cases of rheumatoid arthritis (RA).  Particular HLA DRB1 alleles – antigen 
presenting molecules in humans – strongly correlate with the prevalence of RA. 
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Indeed, over 80% of RA patients carry one or more HLA DRB1 alleles that have 
been found to be associated with RA35,36, suggesting that these alleles may affect 
both positive and negative selection during T cell development and bias the T cell 
repertoire generated. Another example of the influence of MHC restriction was 
shown by Dyall et. al. They demonstrated that mutations in MHC molecules of 
C57BL/6 mice selected for TCR molecules against an HSV epitope while TCRs 
specific for an ovalbumin (OVA) epitope were lost37. Moreover, some mouse models 
of autoimmunity are restricted to specific mouse strains. For instance the CIA model 
of arthritis is restricted to mouse strains with the H-2q MHC restriction such as the 
DBA/1 and the C57BL/6N.Q strains38,39. And, models of EAE are reported to have 
higher susceptibility in C57BL/6 mice compared to Balb/c mice40, which may be a 
reflection of the MHC restriction between these two strains. This again has 
implications on MHC restriction and TCR repertoire formation in patients with 
autoimmune diseases as the presence of HLA-DQ2/DR3, DQ6/DR2, and DQ8/DR4 
account for 90% susceptibility to autoimmune diseases41. 
Thymic selection affects the diversity of the naïve T cell repertoire. Antigen 
presentation and activation of T cells on the other hand affects the effector and 
memory T cell repertoires. When T cells encounter their antigen they clonally 
expand and proliferate. This naturally leads to the outgrowth of certain T cell clones 
compared to others and skews the repertoire to reflect the antigen encounter. 
Numerous studies have utilised this phenomenon to monitor the progression or 
resolution of diseases such as leukaemia42, infections such as human 
immunodeficiency virus (HIV)43 and CMV44, as well as autoimmune diseases like 
coeliac disease23, type I diabetes45, and RA46–48. Several studies have shown that 
the outgrowth of particular clones during primary infection is due in part to high 
affinity interactions between the TCR peptide-MHC complex49,50 demonstrating the 
effect a primary infection has on the resulting T cell repertoire. Chronic infections 
have been shown to narrow the T cell repertoire in several cases of infection such 
as in CMV51 and EBV21 where a selection bias during infection results in narrowing 
of the repertoire. Although, a phenomenon that does arise during chronic or 
persistent infections is epitope spreading, where an initial dominant response to a 
specific epitope diversifies into a response against subdominant epitopes of a either 
a foreign or self-protein52. Epitope spreading would therefore broaden the T cell 
repertoire in terms of the epitopes recognised evidence of which is suggested in 
cases of multiple sclerosis53,54. 
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A phenomenon known as convergent recombination is also a factor to consider 
when thinking about TCR diversity. Convergent recombination describes a situation 
where TCR CDR3 sequences have different DNA coding sequences but result in 
the same amino acid sequence due to the degeneracy in the DNA code. So, 
although there might appear to be greater diversity in the CDR3 TCR DNA 
sequence, this diversity would be reduced if the CDR3 regions code for the same 
amino acid sequence. This would also be considered as a public TCR sequence, as 
the CDR3 DNA sequences code for the same amino acid sequence. The importance 
of converged TCR sequences in an immune response is yet to be determined. 
 T cell development and selection 
T cells originate from haematopoietic stem cells located in the bone marrow that 
produce T cell precursors which migrate to the thymus to become mature T cells. T 
cell precursors undergo meticulous selection processes to ensure the production of 
a self-MHC restricted T cell population as well as a population that is tolerant to self-
peptides, known as positive and negative selection respectively. In order to be 
selected, T cells need to express a functional TCR that can bind to MHC molecules 
with a degree of affinity without compromising their ability to ignore self-peptides. 
The following sections detail the processes by which T cells are selected and 
demonstrate how these selection processes begin to shape the T cell repertoire. 
1.2.2.1 Positive selection 
T cell progenitors enter the thymus and migrate to the outer thymic cortex and begin 
to proliferate. Generation of a functional TCR begins with rearrangement of the β 
chain locus to form a complete β TCR chain. This chain then binds to an α chain 
precursor to form the pre-TCR that then provides signals and results in the 
expression of both CD4 and CD8 co-receptor molecules, thus producing double 
positive thymocytes. These double positive thymocytes then rearrange the α chain 
locus to form a complete α TCR chain, completing the formation of an αβ TCR 
complex. Once a complete TCR is formed, the double positive thymocytes 
encounter thymic cortical epithelial cells (cTECs) that express both MHC-I and 
MHC-II molecules. Double positive T cell precursors that bind to either MHC-I or 
MHC-II molecules via the TCR begin to proliferate and upregulate expression of the 
TCR. In addition, these precursors begin to upregulate one co-receptor while 
downregulating the expression of the other depending on their encounter with MHC-
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I or MHC-II; MHC-I cells upregulate expression of CD8 and downregulate CD4, 
while cells encountering MHC-II molecules do the opposite. Double positive 
thymocytes that fail to interact with thymic cortical epithelial cells or that interact with 
the MHC complexes on these cells with high affinity undergo apoptosis. Selection 
of cells via this process is called positive selection. 
1.2.2.2 Negative selection 
Single positive thymocytes, expressing either CD4 or CD8, then undergo negative 
selection in both the thymic cortex and medulla. Negative selection is a process that 
ensures the deletion of immature T cells recognising self-peptides. Medullary thymic 
epithelial cells (mTECs) express a protein called autoimmune regulator (AIRE) that 
allows them to express self-peptides from numerous tissues and present them to 
immature T cells. Immature T cells that bind strongly to mTECs as well as thymic 
dendritic cells presenting a self-peptide undergo apoptosis and are eliminated. T 
cells that survive negative selection exit the thymus as mature T cells. 
Together, positive and negative selection strike a balance in producing a T cell 
repertoire that is self-tolerant and protective against foreign pathogens. 
 Antigen recognition and clonal expansion 
T cells successfully selected by positive and negative selection mechanisms are 
now mature and exit the thymus and migrate to secondary lymphoid organs. They 
then circulate between the secondary lymphoid organs situated throughout the body  
increasing the chances of encountering their antigen and providing 
immunosurveillance. Once naive T cells encounter their antigen via antigen 
presenting cells (APCs), they become activated, proliferate, and migrate to tissues 
to execute their effector functions. T cells can only be activated once a sufficient 
signalling threshold is achieved. In order to become activated naïve T cells require 
3 signals; the first signal is provided when the TCR binds to its cognate antigen 
through an MHC molecule, which is reinforced by either the CD4 or CD8 molecule 
binding to the MHC molecule. Signal 2 is provided by co-stimulatory molecules, such 
as CD28 on the T cell interacting with CD80/86 on MHC. And finally signal 3 is 
provided by cytokines released from APCs which interact with their respective 
receptors on T cells, influencing the type of effector T cell the activated T cell will 
differentiate into. Together these signals initiate a signalling cascade resulting in the 
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up regulation of T cell activation genes to initiate proliferation and T cell 
differentiation (Figure 1-3). 
 
Figure 1-3 Signals required for complete T cell activation 
A naïve T cell requires 3 signals in order to become fully activated, proliferate, and execute their 
effector functions. The first signal is provided when the TCR binds to its cognate antigen on the 
appropriate MHC molecule. Signal 2 is provided by co-stimulatory molecule CD28 on the T cell 
interacting with CD80/86 on MHC. And finally signal 3 is provided by cytokines released from APCs 
which interact with their respective receptors on T cells, influencing the type of effector T cell the 
activated T cell will differentiate into. Together these signals initiate a signalling cascade resulting in 
the up regulation of T cell activation genes to initiate proliferation and T cell differentiation. 
Once the TCR is engaged, a signal transduction cascade is initiated via the TCR 
complex. The TCR complex consists of a TCR and CD3 proteins which in turn are 
made up of gamma, delta, epsilon, and zeta chains55. Engagement of the TCR 
causes cross-phosphorylation of the transmembrane chains of the complex, known 
as ITAMs (immunoreceptor tyrosine-based activation motifs). This causes 
recruitment of tyrosine receptor kinases such as LCK and ZAP-70, which in turn 
recruit other tyrosine kinases to continue the signalling cascade. An important 
enzyme in this cascade is phospholipase C-γ (PLC-γ). whose recruitment is 
reinforced by the binding of co-stimulatory molecules. PLC-γ causes generation of 
secondary messengers such as diacylglycerol (DAG) and inositol 1,4,5-triphosphate 
(IP3) which result in the influx of Ca2+ and the eventual activation of the transcription 
factor NFAT. Activation of PKC-γ also activates protein kinase C-theta (PKC-θ) and 
Ras eventually leading to the release of transcription factors NFκB and AP-1. 
Together, NFAT, NFκB, and AP-1 induce transcription of specific genes that lead to 
T cell proliferation and specific differentiation.  
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Activation of T cells via their TCR ensures clonal expansion of that T cell clone, 
generating many more “copies” of that T cell, which enables the immune system to 
tackle the incoming pathogen quickly and effectively. 
 Mechanisms of T cell tolerance 
As described in section 1.2.2, T cells undergo rigorous selection processes to 
ensure the production of a T cell population capable of recognising foreign antigens, 
but are also tolerant to self-peptides. In order to achieve this balance, the immune 
system has put mechanisms in place to restrict production of T cells recognising 
self-peptides while maximising the number of T cells recognising foreign peptides 
both at the development stages as well as when the cells have already exited the 
thymus and are mature. These processes will be described in detail in the following 
section. 
 Central tolerance 
Central tolerance describes the thymic process of eliminating developing T cells that 
can potentially mount an immune response against self-peptides. Central tolerance 
encompasses the processes of positive and negative selection, described in 
sections 1.2.2.1 and 1.2.2.2, which aims to delete these autoreactive precursor T 
cells, preventing them becoming part of the T cell repertoire. Conversion of T cells 
recognising self-antigens into regulatory T cells (Tregs) is another mechanism of 
tolerance. These cells modulate immune responses once they leave the thymus. 
Although generated in the thymus, these cells function to suppress the immune 
response in the periphery (see section 1.3.2) by producing anti-inflammatory 
cytokines and tempering the activation state of APCs56. Generation of thymic Tregs 
(tTregs) is dependent on a complex interplay between TCR peptide-MHC binding 
affinity57, duration of binding, and a culmination of intracellular signalling pathways 
generated from TCR peptide engagement, binding of co-stimulatory molecules58 
and cytokines59,60 (Figure 1-4). 
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Figure 1-4 Mechanisms of central tolerance 
Central tolerance eliminates developing T cells with the potential to recognise self-peptides through 
the mechanisms of positive and negative selection, described in sections 1.2.2.1 and 1.2.2.2. 
Briefly, progenitor T cells enter the thymic cortex, synthesise a TCR chain, then bind to MHC 
molecules on cTECs which generate either single positive CD4 or CD8 immature T cells depending 
on the MHC molecule bound. Cells failing to bind to MHC molecules or those that bind too strongly 
undergo apoptosis. Selection by this process is called positive selection. Immature T cells that are 
selected for then undergo negative selection in both the cortex and the thymic medulla. mTECs and 
thymic DCs (tDCs) express the autoimmune regulator (AIRE), allowing them to present self-peptides 
to immature T cells. T cells that bind to self-peptides with high affinity undergo apoptosis and are 
prevented from becoming part of the T cell repertoire. Cells that bind to self-peptides with medium to 
low affinity survive negative selection. Binding time also plays a role on T cell fate, as thymic Tregs 
(tTregs) are generated from a complex interplay of peptide affinity, binding time, and culmination of 
intracellular signalling pathways. Both tTregs and conventional T cells (Tconv) exit the thymus as 
mature T cells. 
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 Peripheral tolerance 
Peripheral tolerance is the second mode of tolerance that occurs once T cells 
mature and exit the thymus. This mechanism of tolerance serves to protect an 
organism from the cells that have escaped mechanisms of central tolerance. In 
addition, it also protects the organism from self-peptides that were not encountered 
in the thymus, as well as innocuous foreign antigens, such as antigens derived from 
foods. Numerous mechanisms of peripheral tolerance exist including induction of T 
cell death, induction of T cell anergy, and production of induced Tregs (iTregs) 
(Figure 1-5). 
Clonal T cell deletion in the periphery occurs when T cells are constantly stimulated 
by self or foreign antigens61,62. Constant stimulation of T cells activates Fas and Bim 
dependent pathways resulting in the activation of apoptosis machinery and T cell 
death. This mechanism therefore eliminates over-active T cells from the immune 
system. 
Anergy is a state of T cell hyporesponsiveness resulting from engagement of the 
TCR without receiving co-stimulatory signals, referred to as signals two and three, 
as discussed in section 1.2.3. T cell anergy can also be achieved when the T cell 
receives inhibitory signals via ligands binding to inhibitory receptors on T cells such 
as CTLA-4 and PD-163. The absence of co-stimulatory molecules and activation of 
inhibitory pathways represses TCR signalling and eventually prevents the 
upregulation of activation genes64. These signals are delivered when antigens are 
presented to T cells by tolerogenic DCs (tolDCs), which are thought to be DCs that 
have not completely matured due to the absence of danger signals from the 
environment65. Although, there is also evidence of mature DCs providing immune 
regulatory signals to T cells66.  
In addition to anergy, tolDCs are also responsible for converting T cells to Tregs, 
which are called induced Tregs (iTregs) to differentiate them from thymic Tregs  
(tTregs). iTregs are differentiated from naïve T cells and are programmed to 
synthesise inhibitory molecules such as IL-10 and TGF-β67. Unlike anergic T cells, 
iTregs are functionally programmed to be immunosuppressive. They also impart 
their functions on DCs, preventing them from maturing and promoting the 
expression of immunosuppressive molecules67. Generation of iTregs is dependent 
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on both peptide affinity for the TCR68, lack of co-stimulatory signals69, and the 
presence of cytokines such as IL-2 and TGF-β70 (Figure 1-5). 
Together, these mechanisms of peripheral tolerance aim to complete 
immunoregulation of potentially self-reactive T cells  that have escaped central 
tolerance mechanisms in the thymus, as well as preventing autoreactivity against 
antigens expressed in the periphery. 
 
 
Figure 1-5 Mechanisms of peripheral tolerance 
Several mechanisms of peripheral tolerance exist to control cells that have escaped mechanisms of 
central tolerance and from harmless peptides not encountered in the thymus. Constant stimulation 
of T cells leads to activation induced cell death and clonal deletion by apoptosis. An anergic or 
hyporesponsive state is achieved when the TCR is engaged without receiving co-stimulatory signals, 
like engagement of CD28 by CD80/86, or when inhibitory receptors are engaged, such as the 
interaction of PD-1 on the T cell with PD-L1 on an APC. T cells interacting with immature or 
tolerogenic DCs also results in a state of anergy, but also causes induction of iTregs, which secrete 
inhibitory cytokines like IL-10 and TGF-β, and also sequester IL-2, preventing effector T cell 
proliferation. In addition, iTregs supress DCs, preventing them from maturing and promoting DC 
production of immunosuppressive molecules. Thymic Tregs also function in the periphery and 
supress T cell and DC activation by the production of immunosuppressive molecules. Antigen 
specific tolerogenic therapies, discussed in section 1.5, propose to take advantage of these 
mechanisms to re-instate self-tolerance. 
 T cells in breach of tolerance and autoimmunity 
Breach of tolerance occurs when mechanisms of central and peripheral tolerance 
fail. There are several reasons for breach of tolerance, but how this phenomenon 
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arises is not fully understood. Complex interplay between genetic susceptibility, 
environmental stimuli, and immune dysregulation is thought to contribute to the 
development and progression of autoimmune diseases. Numerous studies have 
shown the importance of T cells in autoimmunity as the genetic and environmental 
factors implicated in autoimmune diseases indicate how the selection, aberrant 
activation, and dysregulation of T cells all contribute to the development and 
progression of autoimmunity. The following section will discuss the potential 
mechanisms of autoimmunity and the diseases in which they are manifest.  
1.3.3.1 Potential mechanisms of autoimmunity 
There are several suggested mechanisms of autoimmunity which encompass 
genetic and environmental factors. One of the most important genetic factors 
contributing to autoimmunity is the occurrence of certain major histocompatibility 
(MHC) alleles, or human leukocyte antigens (HLA) in humans, which are complexes 
that bind and present peptides to T cells71 . Many autoimmune diseases are 
associated with particular HLA alleles such as coeliac disease23, type I diabetes 
(TID)72, and RA73, which highlights the importance of antigen presentation and T cell 
activation in these diseases. Selection of certain HLA alleles would suggest that T 
cells that would normally be eliminated by mechanisms of central tolerance (see 
section 1.3.1) are in fact selected for. Indeed, studies have shown how changes in 
MHC alleles presented in the thymus affect the T cell repertoire and change the 
diversity of the resulting repertoire37. Moreover, C57BL/6N.Q mice are more 
susceptible to collagen induced arthritis (CIA) than C57BL/6 mice due to differences 
in MHC restriction (I-Aq vs. I-Ab for C57BL/6N.Q and C57BL/6 mice respectively), 
and develop T cell responses against the collagen II epitope CII260-270 which are 
absent in C57BL/6 mice39,74. This would suggest that mice with the I-Aq haplotype 
have collagen II reactive T cells in their repertoire. A similar observation can be 
made in non-obese diabetic (NOD) mice, a mouse model of type I diabetes where 
mutations in MHC II alleles, akin to the mutations found in diabetic patients, confer 
a major risk to diabetes onset75. 
Genetic association studies have also revealed mutations in which aberrant immune 
regulation is implied including mutations associated with defects in lymphocyte 
activation and those affecting cytokines and cytokine receptors. Mutations in the 
PTPN22 locus, which is involved in B and T cell activation76, are found across a 
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number of autoimmune diseases including RA, multiple sclerosis (MS), TID, and 
systemic lupus erythematosus (SLE)71. The PTPN22 gene codes for a tyrosine 
phosphatase and is involved in attenuating T cell activation by inhibiting parts of 
activation pathways77. Mutations in the gene are therefore associated with T cell 
hyperactivity and aberrant T cell activation in autoimmunity. Other mutations 
causing aberrant lymphocyte activation include those found in CTLA-4 and 
CD2/CD58 loci are associated with RA, TID, and MS. In terms of cytokines and 
cytokine receptors, the IL12/23 pathway has a clear role in inflammatory bowel 
disease (IBD) and psoriasis78,79 with genetic wide association studies (GWAS) 
identifying strong genetic links of this pathway to both autoimmune diseases80,81. 
Other mutations in cytokine related genes affecting autoimmune diseases are 
mutations in the TNF region which were found to be associated with SLE, psoriasis, 
and RA71. A combination of defective HLA alleles and mutations in T cell regulatory 
genes together increase the chances of autoimmune disease onset. Indeed, 
autoimmune diseases are generally not governed by single mutations, but rather 
are a culmination of many SNPs82,83. 
Genetics play an important role in the disposition of autoimmune diseases and the 
examples above demonstrate that genetic mutations causing immune dysregulation 
are attributable to autoimmune diseases. However, genetics alone are not sufficient 
to initiate autoimmune diseases and environmental factors have been shown to 
contribute to the onset of autoimmunity. Indeed, studies involving identical 
(monozygotic) and non-identical (dizygotic) twins have demonstrated the degree to 
which different autoimmune diseases are affected by environmental factors. For 
instance, twin studies to determine the degree of genetic association with TID have 
shown the concordance rate of TID in monozygotic twins is in the range of 13-47% 
and is between 4-12% in dizygotic twins84. While in RA, the concordance rate of the 
disease is in the range of 12-21% in monozygotic twins and 4-9% in dizygotic 
twins84,85. These studies therefore indicate that genetics have a stronger influence 
on the onset of TID than in RA, and the environment plays a bigger role in initiating 
RA than in TID. 
One of the environmental mechanisms that potentially contributes to the 
development of autoimmunity is cross reactivity due to molecular mimicry. This 
occurs when a TCR cross-reacts with other peptides due to structural similarities 
between the peptides86. One postulated mechanism for the initiation of 
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autoimmunity is B and T cell priming to bacterial and viral antigens that have 
structural similarities to self-peptides, thus priming the immune system to react to 
self-peptides. This mechanism has been postulated to explain the occurrence of 
flares in multiple sclerosis (MS) patients87,88 and has been shown in animal models 
to be sufficient in triggering experimental allergic encephalomyelitis (EAE), a mouse 
model of MS89. Viral infections have also been implicated in triggering SLE; EBV 
epitopes have been found to have amino acid sequence similarities to ribonuclear 
proteins Sm B/B’, Sm D1, and Ro, proteins to which autoantibodies are generated 
against in SLE90. In addition, strong correlations have been demonstrated between 
SLE patients and previous EBV infections91,92. 
Another mechanism implicated in the initiation of autoimmunity is epitope spreading. 
As mentioned in section 1.2.1.3, epitope spreading is a phenomenon that occurs 
during chronic inflammation where an initial dominant response to a specific epitope 
diversifies into a response against subdominant epitopes of a either a foreign or self-
protein52. This can result from the release of self-peptides as a result of tissue 
damage, presentation of sub-dominant epitopes in an inflammatory environment, 
and the size of the T cell population that can recognise these epitopes93,94. Chronic 
viral infections for instance can create an environment to encourage epitope 
spreading to self-peptides which is also a postulated mechanism for the 
development of MS . Indeed, Lehmann et. al95 demonstrated epitope spreading to 
other MBP peptides in chronic EAE and, when Vanderlugt et. al96 tolerised naïve 
mice using relapse associated peptides in the relapsing EAE model, mice were 
protected against EAE relapse . Epitope spreading has also been postulated in RA 
and a study by van der Woude et. al1. demonstrated that an increase in epitope 
spreading correlates with disease onset. 
An important mechanism thought to contribute to the development of autoimmunity 
is bystander activation. This entails the indirect activation of effector and memory T 
cells by cytokines and chemokines found in an inflammatory environment without 
necessarily recognising their cognate antigen. Effector and memory T cells are 
implicated in bystander activation as these cells subsets have a reduced threshold 
for activation and are less reliant on the presence of their cognate antigens to fulfil 
their effector functions97,98. Thus, in an inflammatory environment, cytokines 
released from other cell types can activate effector and memory T cells of irrelevant 
specificity to the pathogen. The relevance of this phenomenon in autoimmunity has 
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been demonstrated by Lee et. al99 in the EAE model. The study found that when 
OT-II cells polarised to the Th17 subtype were co-transferred with naïve MOG 
specific CD4+ T cells into RAG knockout mice, the mice exhibited greater EAE 
severity. In addition, the Th17 OT-II cells were able to infiltrate the spinal cord and 
produced more effector cytokines such as IL-17A, IFNγ, and GM-CSF when co-
transferred with MOG specific CD4+ T cells than if transferred on their own. What 
this experiment also showed was the requirement of the activation of antigen 
specific T cells for bystander activation as the Th17 polarised OT-II cells did not 
produce significant amounts of IFNγ, IL-17A, and GM-CSF when CFA was 
administered99. Bystander activation has also been implicated in RA as Brennan et. 
al100 found that T cells isolated from arthritic synovia had striking similarities to T 
cells activated by cytokines alone in terms of TNFα production and not to T cells 
activated by TCR stimulation. Moreover, a study by Fazou et al101 found that 
memory T cells with specificities irrelevant to joint antigens are enriched in the 
arthritic synovium and have suggested a chemokine driven mechanism of 
recruitment for the their accumulation in the joint. This is a plausible mechanism as 
Patel et. al.102 demonstrated significantly high levels of chemokines such as 
macrophage inflammatory protein (Mip)1α, Mip-1β, and IFNγ inducible protein 10 
(IP-10) in the synovial fluid of RA patients. However, whether these joint irrelevant 
memory T cells execute their effector functions and propagate an inflammatory 
response has not yet been determined. 
Finally, recognition of post-translationally modified self-proteins as foreign is yet 
another mechanism for the development of autoimmunity. Although self-peptides 
are presented in the thymus to ensure self-tolerance (see section 1.2.2.2), it is 
possible that not all peptides and the various post-translational options were 
expressed in the thymus, therefore allowing potential autoreactive T cells to exit the 
thymus. Evidence for the recognition of post-translationally modified peptides have 
been found in RA, SLE, and MS. The presence of the post-translational molecule 
citrulline on several peptides in RA have in fact made antibodies directed against 
citrullinated proteins (ACPA) a biomarker for the disease103,104. Post-translational 
modifications of peptides alter their biochemistry and, can bind more strongly to 
TCRs than the native peptide, and in some cases, the TCR recognising the modified 
peptide does not cross-react with the native peptide. This was demonstrated by 
Zamvil et. al105. who showed that only the acetylated version of myelin basic protein 
(MBP) could induce EAE in mice. 
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The mechanisms of autoimmunity discussed, which include both genetic and 
environmental factors, highlight that the development of autoimmunity is a complex 
process with many possible aetiologies. Moreover, the genetic and environmental 
factors involved demonstrate the pivotal role the adaptive immune system, 
specifically T cells, has in coordinating and propagating autoimmune diseases. The 
next section will focus on the development of RA and discuss the factors involved 
that predispose individuals to the onset of RA, the mechanisms involved in its 
development, and strategies to control and eradicate the disease. This section will 
also discuss the contribution of the adaptive immune system, with a specific focus 
on CD4+ T cells, to the development and evolution of the disease. 
 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that is 
characterised by synovial inflammation and joint and cartilage degradation106. It has 
a global prevalence of 0.24% and affects females twice as much as it does males107. 
RA primarily affects the joints, but is classified as a systemic disease as extra-
articular manifestations, involving for example the cardiovascular and respiratory 
systems, are prevalent in RA patients108. Moreover, not only does RA inflict chronic 
pain and disability, it has also been shown to reduce life expectancy by 10 years. 
RA is diagnosed by the presence of class switched anti-citrullinated protein 
antibodies (ACPA) and Rheumatoid Factor (RF) – an antibody generated against 
the Fc portion of an antibody. These autoantibodies are the primary biomarkers of 
RA, as they have been strongly correlated with disease severity and increase in titre 
before disease onset1,109,110. However, RA is also classified as either seropositive 
or seronegative, which reflects the respective presence or absence of ACPAs and 
RF111. The risk factors associated with seropositive and seronegative RA are 
different and seronegative RA patients respond differently to therapeutics than those 
with seropositive RA111. Increasing evidence would suggest that seronegative RA is 
clinically different to seropositive RA and should be considered a distinct 
disease82,111,112. Therefore, the focus of this introduction will be on seropositive RA. 
RA aetiology is complex, heterogenous, and poorly understood, although genetic 
and environmental factors have shown strong links to the immune system, mainly 
adaptive immunity – as a key factor in the initiation and development of the 
disease82. Like all autoimmune diseases, a breach of tolerance occurs in RA by an 
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unknown mechanism. All potential mechanisms of autoimmunity mentioned in 
section 1.3.3.1 have been found in different cases of RA113–115. The following 
sections will discuss RA disease aetiology and development, the role adaptive 
immunity- specifically CD4+ T cells – play in disease progression, and current 
therapeutics available to treat RA patients. 
 Genes implicated in RA pathogenesis 
RA has long been associated with mutations in HLA alleles, specifically to the HLA-
DRB alleles where 80-90% of RA patients display mutations35. More specifically, the 
HLA-DRB alleles 0401, 0404, 0101, and 1402 have a shared sequence known as 
the shared susceptibility epitope which has been found in the majority of RA 
patients73,82. This shared epitope is a 5 amino acid motif with a QKRAA sequence73. 
It is not fully understood how this shared epitope contributes to RA development, 
but it is thought that it may result in more efficient presentation of self-peptides116,117 
and may alter T cell selection37,118. Indeed, the HLA-DRB alleles associated with RA 
were found to bind more efficiently to altered self-peptides117,119. 
Genetic wide association studies (GWAS) have highlighted the importance of other 
SNPs outside the HLA-DRB alleles in implicating RA susceptibility. These mutations 
cluster around genes associated with immunity and suggest strong associations 
with immune dysregulation and RA120. As mentioned in section 1.3.3.1, there are 
many SNPs that lead to aberrant lymphocyte activation and dysregulation of 
cytokine signalling pathways in autoimmunity including in RA. The PTPN22 gene is 
the second most associated genetic risk factor for RA77 and is a gene involved in T 
cell receptor signal attenuation which ultimately regulates T cell activation. Another 
SNP associated with RA is in the CTLA-4 gene which is also involved in T cell signal 
modulation121. Other SNPs involving signal transduction pathways found were 
related to TNF signalling and include the TNFAIP3 and TRAF1 loci122. Mutations in 
the STAT4 locus were also associated with RA123 which is an important factor when 
considering cytokine signalling pathways as STAT4 is involved in integrating signals 
triggered by IL12 and IL23124. 
 Environmental factors contributing to RA development 
Genetic predisposition alone is not sufficient for driving the development of RA. As 
mentioned in section 1.4.1, twin studies have shown concordance rates of the 
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disease is in the range of 12-21% in monozygotic twins and 4-9% in dizygotic 
twins84, implying that environmental factors are significant contributors to RA 
pathogenesis. 
One of the most important environmental contributors to RA is smoking, as smoking 
was found to be associated with an increased production of RF125 and ACPA126. A 
study by Klareskog et. al126. demonstrated that smokers have an increased amount 
of citrullinated proteins in lung macrophages than non-smokers and also showed a 
21 fold increased risk of RA susceptibility in smokers who carry HLA-DRB RA risk 
alleles. A molecular basis for this association was provided by Scally et. al. who 
demonstrated that citrullinated peptides bound better to the product of the HLA-
DRB1*0401 allele117. In addition, smoking was found to increase the production of 
peptidylarginine deaminase (PAD) 2 - an enzyme that adds citrulline to arginine 
residues in proteins – in the lungs of smokers, providing a functional link to smoking 
and RA susceptibility127,128. Together, these studies provide evidence for the 
association of smoking with RA and plausible mechanisms as to why such a strong 
association exists.  
Due to the association of HLA-DRB alleles with citrullinated peptides in RA, it would 
follow that the generation of citrullinated peptides in general would increase the 
susceptibility to RA. Indeed, citrullinated peptides and PAD have been found in 
synovia of RA patients129. Furthermore, periodontitis (PD) is also an associated risk 
factor and its prevalence is approximately 2-fold higher in RA patients130. It was 
found that patients with PD have citrullinated proteins in the periodontium131 which 
has been associated with the presence of Porphyromonas gingivalis a pathogen 
associated with PD known to express PAD132. 
 Stages of RA and clinical manifestations 
In an effort to better stratify RA patients at different phases of the disease, the 
European League Against Rheumatism (EULAR) have set up guidelines for 
identifying the stages of RA development133. The first phase is the pre-RA or at-risk 
phase where breach of tolerance occurs. This phase is characterised by the 
presence of ACPA and RF as mentioned earlier, but also by the presence of acute-
phase reactants such as C-reactive protein (CRP), and proinflammatory cytokines 
and chemokines in peripheral blood134,135. Patients who eventually develop RA 
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remain in this stage for an average of 5 years before progressing to clinical 
stages136. Moreover, increasing levels of ACPA concomitant with joint pain, as well 
as the diversity of ACPAs present, place the patients at a much greater risk for 
progressing to clinical phases1,137. 
The transition from susceptibility or at-risk phases of RA to one where clinical 
symptoms develop is poorly understood. It is thought that the disease may have in 
fact a mucosal origin, as ACPAs develop before any joint damage is seen and ACPA 
generation is associated with increased PAD in the lungs and periodontium as 
discussed in the previous section82,138. How the generation of ACPA in mucosal 
sites link to inflammation and cellular infiltration in the joint is not understood. 
Moreover, a study by Rodríguez-Carrio et. al139. demonstrated how patients at the 
at-risk phase have altered inguinal lymph nodes compared to healthy controls in 
that the innate like cells (ILCs) in these lymph nodes shifted from a homeostatic to 
an inflammatory profile. It would have been interesting to see whether other lymph 
nodes in these at-risk patients displayed the same skewed ILC profile. It is thought 
that a second hit or re-exposure event, not necessarily to the original antigen, is 
required to push the system from the pre-articular to articular stage82. This was 
demonstrated in a mouse model of RA developed by Maffia et. al140. where 
immunisation with OVA in the footpad resulted in anti-collagen responses and 
cartilage and bone degradation after the transfer of Th1 polarised OT-II cells and 
subsequent systemic immunisation with OVA in adjuvant. In addition, several 
studies have suggested a link between EBV and RA as sera isolated RA patients 
react with EBV nuclear antigens, have higher antibody titres against EBV epitopes, 
and have higher amounts of EBV DNA in their synovia141. This would suggest that 
mounting responses against EBV may exacerbate the onset of RA. 
Clinical phases can be divided into early clinical and established RA. At the early 
clinical phases cells from both the innate and adaptive immune systems begin to 
infiltrate the joint and cause synovial inflammation. A cascade of proinflammatory 
events are instigated by the immune cell infiltrate and involve the release of pro-
inflammatory cytokines such as TNFα, IL-1, and IL-6, which perpetuate a 
proinflammatory environment and result in the recruitment and retention of cells. In 
addition, the inflammatory environment affects other cells associated with the joint, 
such as synovial fibroblasts and osteoclasts, which in turn also perpetuate the 
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inflammatory environment. Eventually, this leads to cartilage degradation and joint 
destruction, propelling the patient into the established phase of RA82. 
 Role of the CD4+ T cells in RA 
The studies discussed throughout this introduction provide ample proof for the role 
of the adaptive immune system in the development and progression of RA. 
Specifically, the evidence provided highlights the importance of antigen presentation 
and activation of adaptive immune responses, which ultimately facilitate the 
production of class switched autoantibodies – ACPA and RF ̶  by B cells. Between 
antigen presentation and production of autoantibodies, lies the CD4+ T cell which 
coordinates adaptive immune responses. In this section evidence will be provided 
highlighting the importance of CD4+ T cells in initiating and propagating RA.  
1.4.4.1 Evidence of CD4+ T cells in the initiation, coordination, and 
maintenance of RA 
The evidence implicating CD4+ T cells in RA pathogenesis is compelling. As 
discussed in sections 1.3.3.1 and 1.4.1, many genetic factors associated with RA 
implicate antigen presentation and T cell dysregulation in the perpetuation of RA. 
Moreover, infiltration of memory CD4+ T cells into arthritic joints is a common 
observation46–48,142,143 and therapeutics like Abatacept that modulate CD4+ T cell 
interactions with APC are an accepted and effective line of therapy in RA144,145. 
Experimental mouse models of arthritis have provided strong evidence for the 
importance of CD4+ T cells in disease onset and development. Kadowaki et. al146. 
demonstrated the transfer of CD4+ T cells and not CD8+ T cells from collagen 
induced arthritis (CIA) mice into severe combined immunodeficiency (SCID) mice 
initiated arthritis. Also, a study by Mauri et. al. show that monoclonal antibodies 
against CD4+ T cells reduced inflammation in the CIA model of murine arthritis147. 
A model of spontaneous arthritis known as the SKG model of arthritis develop 
chronic autoimmune arthritis due to a mutation in ZAP-70, which reduces T cells 
signalling148,149. Also, peripheral CD4+ T cells or bone marrow transferred from 
these mice to histocompatible mice were found to initiate arthritis, implying an 
inherent problem with T cell selection and the resulting T cell repertoire. 
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Different CD4+ T cell subsets have also been implicated in RA. The earliest subset 
identified in synovial tissues were Th1 CD4+ T cells as these cells were found to 
produce IFNγ which is characteristic of Th1 cells150, while no significant increase in 
cytokines suggestive of a Th2 response, such as IL-4, was observed in RA 
patients151,152. In addition, James et. al153 observed that approximately 40% of CD4+ 
T cells specific for citrullinated peptides in blood collected from RA patients were 
CXCR3+, which is another marker for Th1 cells154. Finally, the presence of IgG1 and 
IgG3 class switched antibodies to collagen II and citrullinated fibrinogen in RA 
patients again indicates the importance of Th1 CD4+ T cells in the pathogenesis of 
RA. Together, these data would suggest that RA is a Th1 driven disease. However, 
attempts to target Th1 responses to control the progression of RA did not yield the 
intended results; clinical trials investigating the efficacy of humanised anti-IFNγ 
antibody Fontolizumab in RA patients were terminated at phase II 
(ClinicalTrials.gov)155 as endpoint goals were not met, and IFNγ knock-out mice 
displayed an accelerated development of CIA156. Interestingly, acceleration of CIA 
in these mice was thought to result from an increase in IL-17 producing T cells and 
IFNγ has been suggested play a role in regulating Th17 responses157,158. Although 
clinical trials with Fontolizumab failed, anti-TNFα therapy is an efficacious line of 
therapy in RA159, which again is associated with Th1 responses. Hence, Th1 CD4+ 
T cells may play two opposing roles in RA which may be important during different 
phases of the disease; one by facilitating tissue damage through the production of 
TNFα and perhaps IFNγ at the early stages of the disease, and second by regulating 
pathogenic Th17 responses which have also been found contribute to joint 
destruction. 
The hallmark of the Th17 CD4+ T cell subset is the production of IL-17 which in turn 
has been found to stimulate the production of inflammatory cytokines IL-6, and IL-
8, as well as matrix metalloproteases MMP-1 and 3 from synovial fibroblasts isolated 
from patients with juvenile idiopathic arthritis160. In addition, IL-17 producing CD4+ 
T cells as well as Th17 inducing cytokines like IL-6, TGF-β, IL-21, and IL-23, were 
found in synovial tissues of arthritic patients161,162. IL-17 has also been associated 
with the initiation of neutrophil development163 as well as recruitment of 
neutrophils164, which is another hallmark of RA165. In addition, ablation of IL-17 was 
also found to reduce CIA in mice166,167. However, like attempts to temper Th1 activity 
clinically, therapeutics like Secukinumab and Brodalumab that target IL-17A and the 
IL-17 receptor respectively were not as effective in RA patients as they were in 
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patients with other diseases such as psoriasis, psoriatic arthritis and ankylosing 
spondylitis168–170. Results from clinical trials suggest that Th17 cells perhaps play a 
more complex role in the pathogenesis of RA, as they can also be involved in anti-
inflammatory processes171. Indeed, Th17 cells isolated from patients that have 
undergone anti-TNFα treatment acquired IL-10 production, implying that these cells 
may in fact participate in dampening inflammatory processes in RA172. 
One of the key features of RA is the production of antibodies against self-antigens 
and CD4+ T cells are likely to provide help to B cells to produce these antibodies. T 
cells isolated from synovia of RA patients were found to induce Ig production from 
B cells in vitro142 and germinal centres – where B cells undergo affinity maturation 
to generate high-affinity antibodies   ̶ were also found in synovial tissues in RA 
patients173,174. CD4+ T follicular helper cells (Tfh) are a specialised subset of CD4+ 
T cells that play a prominent role in forming germinal centres and in directly providing 
co-stimulation to B cells, resulting in their selection, proliferation, and survival175. 
Tfhs have been implicated in the progression of RA, as this subset was increased 
in peripheral blood of RA patients and Tfh frequencies were found to correlate with 
ACPA titres and disease severity176. 
In addition to the presence of proinflammatory CD4+ T cells subsets, regulatory 
CD4+ T cells have also been found in RA patients. However, the observed 
frequencies have been controversial with studies reporting higher, or lower 
frequencies of Tregs in RA patients177–179. Despite this, Tregs isolated from patients 
have been shown to be functionally impaired in some cases, and this may be a 
result of high TNFα levels in arthritic synovial tissues177,180. Indeed, a study by 
Valenica et. al181 showed that TNFα signalling inhibits Treg suppressive activity and 
studies by Ehrenstein et. al180 and Toubi et. al182 have shown that anti-TNFα therapy 
reverses these impaired Treg functions. Although, some studies have also reported 
that Tregs are in fact capable of supressing effector T cells, but the effector T cells 
found in the inflamed synovium were resistant to Treg suppression178,179. 
Together, these data reinforce the importance of CD4+ T cells in the pathogenesis 
of RA and demonstrate the complex interplay of the various CD4+ T cell subtypes 
involved in RA initiation and development. Furthermore, these studies highlight the 
fact that the varying effector responses involved in RA may be important at different 
stages of the disease and effective modulation of RA may rely on understanding 
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when these different effectors come into play. Indeed, RA therapeutics have been 
developed that target various cytokine pathways associated with different effector 
responses, details of which can be found in section 1.4.5.  
1.4.4.2 CD4+ T cell clonality in RA 
Numerous CD4+ T cell subsets are involved in propagating RA and targeting 
different subsets at different stages of the disease may help abate its progression. 
Additionally, understanding which antigen specific responses drive the effector 
responses observed will also provide a target for modulating the disease. Moreover, 
identifying antigen specific responses at different stages of disease may provide 
insight on where immune responses against certain antigens originate and how 
different tissue sites contribute to the propagation of RA. The majority of CD4+ T 
cells isolated from synovia of RA patients were shown to have an antigen 
experienced, memory phenotype142, indicating that the presence of antigen may 
explain why these cells accumulate in arthritic joints. It also suggests the joint may 
be an important tissue site for the development of antigen specific responses. 
Moreover, Wagner et al48 demonstrated that both memory and naïve T cells from 
RA patients show reduced TCR diversity, implying that RA patients have a skewed 
TCR repertoire generated from thymic selection processes. This again 
demonstrates that certain antigen specificities have been selected for in RA patients 
and that antigen presentation is clearly a factor in disease initiation and 
development. Despite this, ‘arthrogenic’ T cell clones have not been identified, and 
T cell clones common to RA patients have not been found46 . Identification of specific 
CD4+ T cell clones has also been impeded by the fact that many antigens have 
been implicated in RA such as citrullinated vimentin, α-enolase, aggrecan, and 
collagen II114,153,183,184. Furthermore, not all of the antigens implicated in the disease 
are present across patients as the ACPA profiles of RA patients were found to differ 
between individuals183,185. These factors combined have made it difficult to pinpoint 
the autoreactive CD4+ T cells involved in RA initiation and propagation and have 
also impeded finding where these cells are primed. 
One approach of determining the occurrence of an antigen specific response is to 
look for clonal expansion of T cell clones. The presence of clonal populations 
provides evidence of antigen driven clonal expansion, albeit in the absence of 
information pertaining to antigen identity. Again, this especially useful in RA as there 
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are many antigens implicated in the disease that are not necessarily the same 
across patients. Clinical observations have revealed the presence of an oligoclonal 
CD4+ T cell repertoire in the synovia of RA patients46,186,187 (Table 1-1). These 
expanded CD4+ T cell clones are likely to play a role in disease pathogenicity as 
they were found to persist two years after first being identified143. Also, the CD4+ 
TCR repertoire differs between peripheral blood and synovial tissue, indicating that 
tissue sites play a role in the retention or accumulation of CD4+ T cells possibly in 
an antigen specific manner46,187. Indeed, studies on TID have shown that islet 
specific CD4+ T cells localise to the pancreas at very early stages of the disease 
due to antigen encounter188,189 and may in fact expand due to presentation of 
insulin190. This mechanism may therefore also be relevant to RA development.  
Although important, antigen driven accumulation of CD4+ T cells in arthritic joints 
may not be the only mechanism of retention. Indeed, Prendergast et. al191 
demonstrated that joint irrelevant CD4+ T cells can be recruited to an inflamed joint 
in a mouse model of arthritis. In addition, joint irrelevant antigens such as BiP 
(immunoglobulin binding protein) have been implicated in RA192. Studies by 
Brennan et. al100,193 have shown that CD4+ T cells activated in a non-antigen 
dependent manner resembled CD4+ T cells isolated from arthritic synovial tissues 
and that these cells are capable of producing TNFα without the requirement of 
cognate antigen. Moreover, Iannone et. al194 demonstrated that non-antigen 
activated CD4+ T cells could be preferentially recruited to the inflamed synovium. 
These cells can therefore act as bystander cells (see section 1.3.3.1) propagating 
and maintaining an inflammatory environment in arthritic tissues and can skew the 
antigen driven CD4+ TCR clonality observed in arthritic joints.  
Given the possible antigen and non-antigen driven mechanisms of CD4+ T cell 
retention in arthritic joints, an important question to ask is whether the initial 
recruitment of CD4+ T cells to the inflamed joint occurs in an antigen driven manner, 
and whether the recruitment and accumulation of these antigen specific cells then 
creates a permissive environment for other CD4+ T cells to enter. Understanding 
how these antigen specific responses arise, develop, and are maintained can 
highlight their role in RA and provide an avenue for the development of antigen 
specific therapies, which will be discussed in detail in section 1.5. 
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Table 1-1 Summary of T cell clonality studies in RA 
Author Method used Key findings Comment 
Stamenkovic, 
I et. al, Proc. 
Natl. Acad. 
Sci. USA 
(1988)186 
Southern blot 
analysis of TCR β 
chains 
Limited number of IL-2 responsive 
T lymphocytes clones dominate 
the synovium, but not PB of same 
patients. Oligoclonality found in 
both RA and osteoarthritis 
patients. 
Oligoclonality not 
distinguished 
between CD4 and 
CD8 T cells. 
Ikeda, Y et. al 
Arthritis 
Rheum 
(1996)187 
RT-PCR and single 
strand 
conformation 
polymorphism 
(SSCP) analysis, 
nucleotide 
sequencing 
Distinct expansion of clonal T cells 
was detected in the synovium of 
RA patients. At least 60% of the 
same T cell clones found in two 
different samples in the same joint 
of each patient and 40% of those 
clones were found in PBL of the 
same patient. 
HLA type for each 
patient was also 
noted. 
Wagner, U. G 
et. al,  Proc. 
Natl. Acad. 
Sci. USA 
(1998)48 
TCRβ chain 
sequence cloning 
and sequencing 
TCRβ frequency analysis showed 
a significant contraction of CD4+ T 
cell clones isolated from PBMCs 
of RA patients compared to hep C 
and healthy controls. This loss in 
diversity was found in both naïve 
and memory CD4+ T cell subsets. 
Robust study 
investigating 
multiple factors 
affecting the T cell 
repertoire in RA, 
hep C, and healthy 
controls, although 
no samples from 
the synovium were 
tested 
VanderBorght, 
A. et. al 
Rheumatol. 
Oxf. Engl 
(2000)143 
TCRα and β 
specific PCR 
amplification and 
subsequent 
analysis by ELISA 
TCR V gene expression was 
compared between cells isolated 
from synovial fluid, synovial tissue, 
and PB of early RA, chronic RA, 
OA, and healthy controls. TCR V 
genes were overexpressed in 
joints but not PB of RA patients. 
Moreover, the over represented 
TCR V genes varied across RA 
patients, but were similar within 
different joints of the same patient. 
In addition, overrepresented V 
genes persist for at least 2 years.  
Excellent and well 
controlled study 
comparing T cell 
repertoires in 
different tissue 
types with 
increasing disease 
chronicity. 
Klarenbeek, 
P.L, et. al 
Ann. Rheum. 
Dis. (2012)46 
CDR3β sequencing Clonality of CD4+ T cells were 
compared between synovial fluid 
and PB of early and established 
RA patients. Highly expanded 
clones comprised 56% of the T 
cell repertoire in the joints of early 
RA patients, while highly 
expanded clones only contributed 
to 9.8% of the T cell repertoire. 
Moreover, highly expanded clones 
were shared between joints in the 
same patient.  
First study 
conducting CDR3β 
sequencing 
analysis in RA 
Zhang, F et. 
al.  Nat. 
Immunol. 
(2019)195 
Single cell RNAseq 
and mass 
spectometry 
Synovial tissue obtained from RA 
and OA patients were compared 
and specific profiling of fibroblasts, 
autoimmune associated B cells, T 
peripheral and follicular helper 
cells were identified. Specific C8 T 
cell subsets were also identified in 
RA patients. 
Bulk analysis of T 
and B cells, 
monocytes and 
fibroblasts. No 
clonality analysis. 
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1.4.4.3 Methods of measuring T cell receptor diversity and T cell clonality to 
assess T cell clonality in RA 
There are several approaches to determine T cell clonality experimentally. One 
method is to amplify regions of the TCR via PCR using region specific primers to 
capture the CDR3 region, which are then distinguished by the length of the 
products196,197. This method is rapid and robust and has been used to examine T 
cell repertoire diversity in cancers198,199 and autoimmune diseases48,200, including 
RA46,48,143,201. 
Another method of assessing T cell clonality is to use antibodies directed against 
the TCR. An example of this is the KJ1.26 antibody that specifically recognises the 
TCR of DO11.10 cells202 that are specific for the chicken ovalbumin peptide 323-
339203. TCR transgenics, such as the OTI and II systems, only express one type of 
Vα and Vβ chain and can therefore be tracked by using antibodies specifically 
against these regions204. Indeed, behaviour of clonal cells have been tracked using 
this method205,206. Because the antigen specificities of expanded T cells in RA are 
unknown, using antibodies against specific T cell clones is futile. Instead, antibodies 
against V regions of the TCR α and β chains can be used to quantify the presence 
of different V regions by flow cytometry, which would highlight biases in V region 
usage, and consequentially, identify antigen associated expansion. Quantification 
of V regions has been performed in healthy controls87,207, in patients with 
leukemia208, and in RA209. In studies where non healthy samples were used, biases 
in V region usage were observed208,209. 
Both the methods of determining T cell clonality mentioned have advantages of 
providing rapid, global assessments of changes in the T cell repertoire207,210,211. 
These methods rely on the skewed presence of different V regions to reflect 
changes in the T cell repertoire. T cells undergo clonal expansion when they 
recognise their cognate antigen via the TCR212,213. Determining frequencies of V 
chain usage does not provide clonal information per se, but it still highlights biases 
in the usage of these chains, implicating antigen driven accumulation of T cells210,214. 
Historically, the V region of the β chain of the TCR has been examined more than 
the α chain. This is because the β chain has higher combinatorial potential due to 
the presence of the D region215, and it is possible for T cells to have two α chains, 
but only one β chain216,217. This makes examining the β chain more reliable when 
assessing frequency of Vβ regions.  
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A more robust method of determining T cell clonality is to do so on a sequence 
resolution level with techniques utilizing next generation sequencing (NGS) 
methods218. This allows one to determine the sequence of the CDR3 region, the 
most variable region of the TCR that is unique in clonal T cells12,219,220 (see section 
1.2.1) 
 Current RA therapeutics 
Treatments for RA traditionally relied on relieving inflammation using nonsteroidal 
anti-inflammatory drugs (NSAIDs) and glucocorticoids, while the use of disease 
modifying anti-rheumatic agents (DMARDs) aimed to slow down or halt disease 
progression. Important DMARDs that were found to reduce extra-articular 
manifestations and joint damage are methotrexate (MTX) and sulphasalazine, but 
despite these drugs, a significant proportion of RA patients either did not tolerate or 
respond to these DMARDs. As a result, alternative targets were sought in an effort 
to push for more effective therapies. 
Biologics are a class of drug that were introduced to treat RA in the early 1990s221. 
Biologics are specific in that they are designed to target cell types, receptors, or 
cytokine signalling to modulate specific immune responses that are relevant to RA. 
These therapeutics have shown a lot of promise in the treatment of RA as well as 
other inflammatory diseases. Examples of biologics used in RA are TNFα inhibitors 
such as Adalimumab, Etanercept, and Infliximab, which have proven successful in 
RA222,223. Other biologics targeting cytokine pathways include Tocilizumab and 
Anakira, which target the IL-6 and IL-1 pathways respectively221. An example of a 
biologic targeting a specific cell type is Rituximab, which results in B cell depletion. 
Abatacept is a CTLA-4 fusion protein which interrupts T cell APC interactions and 
co-stimulation by targeting CD80/86 on APCs and is yet another effective RA 
therapeutic. 
Despite the successes of biologics, there still remains a significant number of 
patients who do not achieve remission and only partially respond to this line of 
therapy. As such, a number of groups have focussed on developing alternative 
therapies. One approach being developed is to target kinases such as JAKs which 
control numerous cytokine pathways224. Another therapeutic approach gaining 
interest is antigen specific therapy which has the potential of achieving drug free 
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remission for RA and permanent cessation of the disease. This line of therapy will 
be discussed in the next section. 
 Antigen specific therapy 
Antigen specific therapies aim to utilise the mechanisms of peripheral tolerance 
described in section 1.3.2 to target CD4+ T cells of a certain antigen specificity via 
the TCR. The strong interest in these therapies arises from the highly attractive 
prospect of specifically targeting the pathogenic CD4+ T cells while leaving the rest 
of the immune system intact, thus reinstating tolerance towards self or innocuous 
antigens like allergens. Both animal studies and historical treatments for allergies in 
humans have shown successes for antigen specific therapy. As CD4+ T cells have 
strongly been implicated in RA (discussed in sections 1.4.1 and 1.4.4), antigen 
specific therapy is considered a viable therapeutic option for treating the disease.  
Antigen specific therapy has been practiced for over 100 years for treating 
allergies225,226. Administering an escalating dose of peptides derived from the 
inciting allergen is thought to modulate the immune response to the peptides. A 
study trialling the efficacy of peptide immunotherapy to grass pollen found the 
allergic immune response to switch from an IgE to an IgG antibody response and 
also reported an increase in the regulatory cytokine IL-10227. Another study 
determining the efficacy of antigen specific therapy to bee venom also reported the 
same antibody isotype switch228 In addition to modulating the allergic response, a 
study by Wambre et. al229 found that peptide immunotherapy to grass pollen causes 
deletion of the antigen specific T cells. 
Antigen specific immunotherapy to autoimmune disease has proven difficult as the 
antigens involved in autoimmune diseases are poorly defined. And, targeting 
pathogenic CD4+ T cells in an antigen specific manner is further hampered by 
epitope spreading which arises as a consequence of disease chronicity. Despite 
these setbacks, antigen specific therapies have been attempted for some 
autoimmune diseases but have yielded conflicting results. Ruiz et. al230 
administered a DNA vaccine encoding a peptide from myelin proteolipid protein 
(PLP) and observed a reduction in paralysis and production of Th1 cytokines from 
CD4+ T cells in mice undergoing the EAE model of MS. A phase I/II trial where a 
peptide derived from myelin basic protein (MBP) was administered to MS patients 
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delayed disease progression231. However, a phase III trial with the same peptide 
failed to be effective in patients with progressive MS232, and another MBP peptide 
in an MHC complex also failed to show any efficacy in a phase I trial233. Similar 
results were observed in antigen specific therapy trials for TID234. 
Several studies have demonstrated the efficacy of oral tolerance in models of RA. 
For instance, administration of collagen II was shown to delay onset and severity of 
CIA in mice and rats235–237. Administration of collagen II orally to RA patients was 
well tolerated238, however, there was only a small improvement in RA patients 
undergoing oral tolerance trials to collagen II239. Other attempts of peptide 
tolerogenic therapy for RA was the administration of a peptide from the dnaJ protein, 
a protein that has been implicated in RA due to sequence similarities with the RA 
shared epitope discussed in section 1.4.1. The dnaJ peptide was well tolerated in 
the trial and resulted in reduced production of TNFα from T cells and a simultaneous 
increase in IL-10 production240. However, administration of another antigen 
implicated in RA – human cartilage glycoprotein-39 – did not have an effect on RA 
progression241. Other methods of inducing tolerance to self-peptides in RA involve 
the use of tolerogenic DCs (tolDCs), which have been shown to stimulate regulatory 
responses from T cells242. tolDCs pulsed with collagen II significantly reduced 
disease severity in the CIA model of arthritis243 and tolDCs loaded with antigens 
from synovial fluid of arthritic patients were tolerated when re-administered, and 
patients did not show any signs of worsening symptoms244. However, no changes 
in levels of regulatory cytokines nor in T cell phenotypes were observed in these 
patients, and so, the mechanism of action of these tolDCs in the patients is not 
understood. 
 Considerations for developing more effective antigen 
specific therapies to treat RA 
One possible reason for the conflicting results of antigen specific therapies is the 
difference in tolerising naïve CD4+ T cells to tolerising effector or memory cells. 
Unlike naïve CD4+ T cells, effector and memory subsets can be activated with lower 
levels of antigen and do not necessarily require costimulation to generate an effector 
response97,98. Considering the chronicity of autoimmune diseases, the CD4+ T cells 
that are involved and targeted in antigen specific therapies are likely to be effector 
and memory T cells. As mentioned in section 1.4.4, the majority of CD4+ T cells 
  
 
50 
 
isolated from synovial tissues of arthritic patients have an activated phenotype. Thus 
antigen specific therapies targeting naïve cells are unlikely to work for effector or 
memory CD4+ T cells and may in fact result in memory CD4+ T cell activation.  
Another factor to consider is timing of interventions using antigen specific therapies. 
A study by Mackenzie et. al245 demonstrated that effector memory CD4+ T cells had 
reduced capacity for proliferation and cytokine production compared to central 
memory CD4+ T cells after administration of tolerogenic peptide in a mouse model 
of allergic airway inflammation. This highlights the importance of considering the 
phenotype of cells targeted for antigen specific therapies and when these cell types 
dominate the immune response to an antigen.  
Anatomic location of the cells being targeted for therapy is another factor to consider 
when designing tolerogenic therapies. A study by David et. al61 demonstrated that 
memory CD4+ T cells isolated from the spleen require two rounds of antigen specific 
activation to induce death of antigen specific cells. In contrast, ongoing work by Gray 
et. al (unpublished data – personal correspondence with Dr. Joshua Gray) 
demonstrated that effector cells tolerised with NP peptide derived from influenza in 
the periphery do not undergo apoptosis and can in fact be reactivated upon re-
exposure to flu. 
Developing antigen specific therapies for RA is not an easy task as many factors 
need to be considered from the antigen specificities that would be best to target, the 
phenotypes of cells to be targeted, and the location for optimal induction of 
tolerance. As mentioned in section 1.4.4.2 there is strong evidence of antigen 
specific responses being involved in the propagation of RA which may create a 
permissive environment for other cells to enter the joint, thus perpetuating 
autoreactivity. Identifying the antigen specific CD4+ T cell clones that create these 
permissive environments will provide targets for tolerogenic therapies and provide 
more specific treatments to the ones currently available244,246.  
 The OVA induced breach of tolerance model of 
experimental arthritis  
Understanding the evolution of antigen specific responses requires the use of 
animal models as the role of antigen in RA onset is not understood and difficult to 
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pinpoint in humans. Animal models provide a setting whereby initiation and evolution 
of antigen specific responses can be observed with the progression of experimental 
arthritis. As RA is a heterogenous disease with complex aetiology, many models of 
RA have been developed to emulate different aspects of the disease. One of the 
most widely used animal models to study different aspects of RA is the collagen 
induced model of arthritis (CIA). This model requires an immunisation of collagen II 
in Freund’s complete adjuvant (CFA) in genetically susceptible mice which causes 
collagen erosion in feet and paws247,248. Other models include SKG mice and K/BxN 
that develop RA spontaneously as well as models targeting cytokine pathways such 
as the TNFα transgenic mouse line249. However, it is difficult to monitor the 
development of antigen specific responses in these models for several reasons. 
Firstly, autoreactive responses cannot be distinguished from those resulting from 
immunisation with the initial peptide. For instance, in the CIA model, one cannot 
distinguish autoreactive responses from responses induced by collagen II in CFA, 
as collagen II is an antigen found in the joint. While in models that spontaneously 
develop arthritis, it is difficult to pinpoint where and when the disease initiates, thus 
making it difficult to track the development of antigen specific responses. 
A good model to use to monitor the development of antigen specific responses is 
the OVA induced breach of tolerance model of experimental arthritis, which will also 
be referred to as the OVA model of experimental arthritis, developed by Maffia et. 
al140 which relies on the use of a joint irrelevant antigen to initiate experimental 
arthritis (described in detail in section 2.2.5 of methods). Specifically, the model 
uses TCR transgenic CD4+ T cells of known antigen specificity but of irrelevant 
specificity to the joint that have been polarised to a Th1 phenotype. Maffia et. al. 
demonstrated that transient arthritis was initiated by the transfer of Th1 polarised 
DO11.10 cells into BALB/c mice followed by immunisation with OVA in CFA and 
subsequent challenge using heat aggregated OVA (HAO) in the footpad, which was 
characterised by synovial hyperplasia and cartilage degradation. More importantly, 
the pathology observed is concomitant with breach of tolerance, evidenced by the 
production of collagen specific T and B cells responses. Experimental arthritis also 
developed when using C57BL/6 mice, but to a lesser extent250. Despite this, the 
advantage of using C57BL/6 mice as hosts is the availability of numerous 
knockouts, transgenic, and reporter strains on this background, which ultimately 
allows one to address a wider variety of questions. One other advantage of using 
this model to monitor the development of antigen specific responses is that the 
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transferred Th1 cells are trackable as they express a different congenic marker to 
the host strain (CD45.1 vs CD45.2 on OT-II and C57BL/6 mice respectively, or track 
the DO11.10 cells in BALB/c mice using the clonotypic KJ1.26 antibody) and 
therefore can be separated from endogenous CD4+ T cells. Thus, the development 
of antigen specific responses endogenous to the host strain can be monitored in 
conditions where autoreactive responses to joint antigens are most permissive, 
conditions that are difficult to ensure in RA patients and other animal models. 
The OVA model of arthritis has also been used extensively over the past decade to 
examine the various roles the adaptive immune system may play in the early phases 
of RA and in conditions favouring breach of tolerance. These include the importance 
of Th1, but not Th2 cells in breach of tolerance140, the roles conventional and 
plasmacytoid DCs play in initiating autoreactive T cells responses and their potential 
roles in early RA250,251, the development of B cell responses with the progression of 
experimental arthritis252, the impact of early therapeutic intervention on breach of 
tolerance253, and the contribution of components of the innate and adaptive immune 
system to the breach of tolerance observed254. More recently, Prendergast et. al191 
showed interaction of endogenous CD4+ T cells with DCs in inflamed joints, thus 
demonstrating CD4+ T cells recognising their cognate antigen in the inflamed joint 
tissue itself. 
 Project aims and objectives 
Despite the advancements made in RA therapeutics, there still remains an unmet 
clinical need for patients who fail or show partial remission to RA. And for those who 
do achieve remission, they are required to take the prescribed drugs indefinitely. 
Thus, the critical therapeutic objective now is to restore self-tolerance to self-
peptides and achieve drug-free remission. To achieve this, the first steps are to 
understand how antigen specific responses develop in RA, the role antigen specific 
responses play in the early phases of disease, and how these responses develop 
with disease chronicity. Moreover, it is also important to establish where these 
antigen specific responses occur in the early phases of the disease. The hypothesis 
is that antigen specific CD4+ T cell responses in the early phases of disease occur 
in the joint and create a permissive environment for cells of other specificities to 
enter, perpetuating an inflammatory environment resulting in joint damage. Using 
the OVA model of experimental arthritis, the aims of this thesis are: 
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1. To assess the TCR clonality of CD4+ T cells in the OVA model of 
experimental arthritis with the aim of finding evidence supporting antigen 
specific accumulation of CD4+ T cells in inflamed joints.  
2. To monitor the evolution of CD4+ T cell clonality from the early stages to a 
later more chronic phase of experimental arthritis in both inflamed joints and 
joint draining popliteal lymph nodes (pLNs). 
3. To identify whether antigen specific responses occur in the inflamed joint and 
whether these responses are to self-antigens. 
Addressing these aims should further our understanding of antigen specific 
responses in RA patients and identify the role of these autoreactive CD4+ T cells in 
the early phases of the disease. In addition, monitoring the antigen specific 
responses and specifically CD4+ T cell clonality can serve as a biomarker for 
specific disease stages facilitating patient stratification for more effective therapy. 
Furthermore, CD4+ T cell clonality can be used as a method to monitor response to 
therapeutics, as has been done to monitor leukemia208. Ultimately, understanding 
the development of antigen specific CD4+ T cell responses will contribute to the 
advancement of more effective tolerogenic antigen specific therapies in RA and 
toward therapies providing drug-free remission. 
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Chapter 2 Materials and Methods 
 Animals 
Seven to 12-week-old male and female C57BL/6 mice were purchased from Harlan 
(now Envigo), UK and used as adoptive transfer recipients. Nur77GFP mice 
described by Moran et. al57 were purchased from Jackson Laboratories (cat. no. 
016617) and were also used as adoptive transfer recipients. OT-II TCR transgenic 
mice contain CD4+ T cells that only express a TCR recognising peptide 323-339 
from chicken ovalbumin (OVA) in the context of MHC II molecule I-Ab 204. Mice were 
bred and maintained at the University of Glasgow’s central research facility and 
housed under standard housing conditions specified by the UK Home Office. All 
protocols were conducted under licences issued by the UK Home Office under the 
Animals (Scientific Procedures) Act of 1986 and approved by the University of 
Glasgow Ethical Review Committee.  
 OVA Models of Experimental Arthritis and Associated 
Components 
The OVA model of experimental arthritis was conducted as described by Maffia et. 
al.140. Preparation of the required components and induction of the models will be 
described in the following subsections.  
 Isolation of Cells from Lymphoid Organs 
Cells were isolated from spleens, popliteal lymph nodes, peripheral lymph nodes 
(inguinal, brachial, and axillary), superficial cervical lymph nodes, mesenteric lymph 
nodes, and lumbar lymph nodes of OT-II transgenic mice. Spleens and lymph nodes 
were mashed separately using a 70µm EASYStrainer (Greiner-Bio-One) fitted onto 
a 50mL centrifuge tube (Corning) using the flat end of a plunger from a 1mL syringe 
(Fisher Scientific). Strainer was washed with 1X MACS buffer (phosphate buffered 
saline (PBS) (Gibco) and 2% foetal calf serum (FCS) (Gibco)) to get maximum cell 
yield. Cells were then pelleted by centrifugation at 400xg for 5 minutes at 4°C. 
Splenocytes were further treated with Red Blood Cell (RBC) Lysis Buffer 
(eBioscience) using 500µL of RBC lysis buffer per spleen, incubated at room 
temperature for 3 minutes, washed then pelleted. Cells were then resuspended in 
MACS buffer to achieve the concentration required for CD4+ T cell purification. 
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 CD4+ T Cell Purification and Th1 Polarisation 
CD4+ T cells were purified by negative antibody selection (Miltenyi Biotech, 130-
104-454, Surrey, UK) from OT-II mice spleens and LNs according to the protocol 
outlined in the kit. 25x106 CD4+ OT-II T cells were cultured with complete media 
(RPMI 1640, Gibco, Thermofisher; 10% FCS; 1% Penicillin and streptomycin; 1% 
L-glutamine) in a 1:5-1:10 ratio of CD4+ OT-II T cells: mitomycin C (Sigma-Aldrich) 
treated APCs. APCs were collected from leftover cells following CD4+ T cell 
purification and from C57BL/6 spleens. APCs were treated with 0.05mg/mL 
mitomycin C (500µL 1mg/mL of mitomycin C in PBS per 10mL of cells) for 45-60 
minutes at 37°C and 5% CO2 and washed twice in PBS before being cultured with 
OT-II T cells. OT-II T cells and mitomycin C treated APCs were cultured with 
complete media containing the following Th1 polarising reagents: 1µg/mL OVA 
peptide 323-339 (Sigma-Aldrich), 10ng/mL IL-12 (Bio-Techne), and 2µg/mL murine 
monoclonal anti-IL4 antibody (2BScientific, clone 11B11). Cells were cultured in 
75cm2 vented flasks (Corning) at a tilt at 37°C, 5% CO2 for 72 hours.  After 72 hours, 
percentage of Th1 polarised cells was determined by flow cytometry using 
antibodies against Vα2, Vβ5, and CD4, details of which can be found in Table 2-3. 
 Preparation of OVA in Freund’s Adjuvant (CFA) 
Tissue culture grade OVA (Code OAC – Worthington Biochemicals) was used to 
make a 1µg/µL emulsion of OVA in CFA. OVA was prepared in PBS and was added 
to CFA diluted 1:1 in PBS. Using a 1mL syringe (Fisher Scientific) an emulsion was 
created by quickly and repeatedly taking the mixture up and releasing it back into 
the vessel. The emulsion was ready once a solid pellet formed, with no oily waves 
dissipating from it, when dropped into a dish with water or PBS.  
 Preparation of Heat Aggregated OVA (HAO) 
HAO was prepared as 20mg/mL stocks using a solution of OVA (Sigma-Aldrich) in 
PBS. 200µL of the 20mg/mL OVA solution was placed in 1.5mL Eppendorf tubes 
(Greiner Bio-One) and incubated at 100°C for 2 hours. Tubes were then spun at 
13,300 rpm for 5 minutes and supernatant removed. Aggregated OVA was washed 
with PBS and spun again. Supernatant was again removed, and 200µL of PBS was 
added. Aliquots were frozen until required for use in the model.  
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2mg/mL HAO was required for the model. Stock HAO aliquots were thawed and 
contents placed in GentleMACS c-tubes (Miltenyi Bio). 1.8mL of PBS was added to 
the c-tube per HAO stock aliquot. HAO was homogenised using a gentleMACS 
Dissociator (Miltenyi Biotec) using a customised program, details of which are in 
Table 2-1. The program was run 4-6 times and HAO was deemed ready when the 
solution passed through a 25 or 26 gauge needle. 
Table 2-1 HAO Dissociation Program 
Time 
(sec)  RPM 
Time 
(sec) RPM 
Time 
(sec) RPM 
Time 
(sec) RPM 
90 0 67 + 1000 44 + 1800 21 - 1400 
89 + 200 66 - 200 43 + 1000 20 + 1500 
88 + 500 65 - 600 42 - 200 19 - 1400 
87 + 900 64 - 1000 41 - 1700 18 + 1500 
86 + 900 63 - 1300 40 - 2100 17 - 1400 
85 + 1300 62 - 1500 39 - 3000 16 + 1500 
84 + 1600 61 - 2600 38 - 3700 15 0 
83  + 2000 60 - 3000 37 - 3900 14 0 
82 + 2500 59 - 3400 36 - 3700 13 0 
81 + 2800 58 - 3800 35 - 3200 12 0 
80 + 3100 57 - 3800 34 - 2800 11 + 1100 
79 + 3300 56 - 3200 33 - 2000 10 + 1100 
78 + 3300 55 - 2000 32 - 400 9 + 1100 
77 + 3500 54 - 800 31 - 200 8 + 1200 
76 + 3700 53 + 1000 30 + 600 7 + 1100 
75 + 3800 52 + 1600 29 + 1200 6 + 1100 
74 + 3900 51  + 2200 28 + 1500 5 + 500 
73 + 3800 50 + 2700 27 + 1300 4 + 500 
72 + 3500 49 + 3600 26 0 3 + 300 
71 + 3100 48 + 3900 25 - 1400 2 + 700 
70 + 3100 47 + 3900 24 + 1500 1 0 
69 + 2500 46 + 3900 23 - 1400  0 0  
68 + 1900 45 + 3900 22 + 1500     
 
 Induction of the OVA Model of Experimental Arthritis (Early 
Timepoint) 
2-3x106 Th1 polarised OT-II CD4+ T cells were injected i.v in C57BL/6 or Nur77GFP 
recipients. This was followed by immunisation with OVA protein (Sigma-Aldrich) in 
Freund’s complete adjuvant (CFA) (Sigma-Aldrich) subcutaneously in the scruff the 
next day. 10 days later the mice were injected subcutaneously in both footpads 
close to the ankle joint with 50µL PBS, 100µg heat aggregated OVA in 50µL (HAO), 
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or 25µg of lipopolysaccharide (LPS) (from E. coli O111 (Sigma-Aldrich)) in PBS in 
50µL. Mice were sacrificed 4 days after footpad injections, as this timepoint was 
found to have the highest number of T cell infiltration into the joints (Drs. Robert 
Benson and Catriona Prendergast unpublished data). Joints and pLNs were then 
collected for processing and cell isolation. 
 
Figure 2-1 Experimental timeline of the early timepoint of the OVA model of experimental 
arthritis 
Illustration of the experimental timeline of the OVA model of experimental arthritis terminating at the 
early timepoint. Timeline is centred around day of periarticular challenge. Model setup begins with 
the polarisation of OT-II cells to the Th1 phenotype for 72 hours. 2-3x10^6 Th1 polarised OT-II cells 
are transferred into C57BL/6 or Nur77GFP recipients, which is followed by an immunisation of OVA 
in CFA in the scruff. 10 days later mice are challenged with HAO in the periarticular tissue to induce 
breach of tolerance and the initiation of experimental arthritis. PBS or LPS are administered to other 
mice as controls. Mice were sacrificed 4 days after periarticular challenge and joint draining popliteal 
lymph nodes (pLNs) and joints were collected for processing and cell isolation.     
 
 Induction of Inflammation in Non-Arthritic Tissues (Ears) 
The OVA model of experimental arthritis was adapted to induce inflammation in non-
articular tissues to determine differences in TCR use in these tissues compared with 
articular tissues. This allows assessment of whether a bias in TCR use is due to 
accumulation of CD4+ T cells that have breached tolerance and now react to 
articular antigens. Again, 2-3x106 Th1 polarised OT-II CD4+ T cells were injected 
i.v in C57BL/6 recipients, which was followed by immunisation with OVA in CFA in 
the hind limbs. 10 days later mice were injected with 100µg HAO in 25µL in the ear 
pinnae. Control mice were injected with 25µL of PBS. Mice were sacrificed 4 days 
later to be consistent with the OVA model of arthritis. Super cervical lymph nodes 
(scLNs) and ears were then collected and processed for cell isolation. 
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 Induction of the OVA Model of Experimental Arthritis (Late 
Timepoint) 
One of the aims of the project is to determine the evolution of the antigen specific 
response with the progression of experimental arthritis. To do this, a model of 
relapsing arthritis, developed by Conigliaro et. al.252 was modified for the purposes 
of project. The model of relapsing arthritis is also based on the OVA model 
developed by Maffia et. al. and will be referred to as the late model of OVA 
experimental arthritis. The late model of experimental arthritis was developed to 
investigate the anti-collagen antibody response in a more chronic setting. In the 
study, Conigliaro et. al determined that the model begins to resolve after 21 days 
and so, the endogenous CD4+ T cells response was examined within that time 
frame and is discussed in Chapter 3 section 3.2.1.5. The initial model set up is the 
same as that for the early timepoint up to the point of periarticular administration of 
either HAO or PBS. A second periarticular challenge of 100µg of HAO in incomplete 
Freund’s adjuvant (IFA) (Sigma-Aldrich) is administered 30 days after the primary 
HAO challenge. Mice were then sacrificed, 4, 11, or 17 days after the second 
periarticular challenge and pLNs and joints were then collected for processing and 
cell isolation. In order to verify that the observed response is due to the second 
periarticular challenge, several controls were required at each timepoint, details of 
which can be found in the following table: 
Table 2-2 Experimental and control groups in the late model of experimental arthritis 
 
Group name Group type 
Primary 
periarticular 
challenge 
Secondary 
periarticular 
challenge 
Late inflamed Experimental HAO HAO+IFA 
Non-specific (NS) 
inflammation Control HAO IFA 
Primary Control PBS HAO 
Memory Control HAO PBS 
Baseline Control PBS PBS 
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Figure 2-2 Experimental timeline of the late timepoint of the OVA model of experimental 
arthritis and controls 
Illustration of the experimental timeline of the OVA model of experimental arthritis to determine a late 
timepoint. Timeline is centred around day of primary periarticular challenge. Model setup begins with 
the polarisation of OT-II cells to the Th1 phenotype for 72 hours. 2-3x10^6 Th1 polarised OT-II cells 
are transferred into C57BL/6 or Nur77GFP recipients, which is followed by an immunisation of OVA 
in CFA in the scruff. 10 days later mice are challenged with HAO or PBS in the periarticular tissue to 
induce breach of tolerance and the initiation of experimental arthritis. Mice were given a second 
periarticular challenge of either HAO+IFA, IFA, HAO, or PBS depending on the experimental or 
control group 30 days after primary periarticular challenge. Mice were sacrificed 4, 11, or 17 days 
after secondary challenge and pLNs and joints were collected for processing and cell isolation. 
 Power calculations 
To determine the number of animals required for each experiment, the following 
power calculations were performed using G*Power software version 3.1.9.6. 
Power calculations indicate that 5 animals per group are required to detect large 
effects (d=2.34) with 95% power and alpha set to 0.05 using Student’s t-test to 
determine differences between two independent means. Using one-way ANOVA, 
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power calculations indicate that 9 animals per group are required to detect an 
effect size of f=2 with 80% power and an alpha set to 0.05.  
 Assessment of Joint Inflammation 
Inflammation was assessed by measuring footpad thickness after HAO, PBS, or 
LPS administration daily until experiment termination using C-Serie IP67 electronic 
callipers (Kroeplin GmbH). 
 
 Isolation of Cells from Tissues 
 pLNs and scLNs 
Popliteal lymph nodes (pLNs) or super cervical lymph nodes (scLNs) were forced 
through 40µm Nitex mesh (Cadisch Precision Meshes) to obtain single cell 
suspensions and shaken at 110 rpm at 37°C for 25 minutes with 2.68mg/mL 
collagenase D (Roche). Collagenase D reaction was quenched using complete 
media (RPMI 1640, Gibco, Thermofisher; 10% FCS; 1% Penicillin and streptomycin; 
1% L-glutamine). Single cell suspensions were washed in PBS and pelleted by 
centrifugation at 400xg for 5 mins at 4°C. Dead volumes of pLN samples were 
measured and cells counted by trypan blue (Sigma Aldrich) exclusion using a 
haemocytometer (Fisher Scientific), and subsequently stained for flow cytometry. 
pLNs and scLNs were pooled per mouse for analysis. 
 Spleens 
Spleens were forced through 40µm Nitex mesh (Cadisch Precision Meshes) or 
through a 70µm EASYstrainer mesh (Greiner-Bio-One) to obtain single cell 
suspensions and shaken at 110 rpm at 37°C for 25 minutes with 2.68mg/mL 
collagenase D (Roche). Collagenase D reaction was quenched using complete 
media. Single cell suspensions were washed with FACS buffer (PBS + 2mM EDTA 
+ 2% FBS) and pelleted using centrifugation at 400xg for 5 mins at 4°C. Splenocytes 
were the treated with RBC lysis buffer (eBioscience) using 500µL of RBC lysis buffer 
per spleen. Samples were briefly vortexed and incubated for 3 mins at room 
temperature, then washed in FACS buffer. Samples were resuspended in 10mL 
PBS, cells were counted by trypan blue (Sigma Aldrich) exclusion using a 
haemocytometer (Fisher Scientific), and subsequently stained for flow cytometry. 
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 Joints 
Skin and muscle tissue were removed from mouse feet. Ankle and joints were 
teased apart and shaken at 110 rpm at 37°C for 25 minutes with 2.68mg/mL 
collagenase D (Roche) in RPMI 1640 (Gibco, Thermofisher). Collagenase D 
reaction was quenched using complete media. Tibias and fibulas were removed and 
joint tissue was then homogenised in gentleMACS C tubes (Miltenyi Biotech) using 
a gentleMACS Dissociator (Miltenyi Biotech) set at 3000 rpm for 15 seconds 3 times. 
Homogenised tissue was then strained using 70µm EASYstrainer mesh (Greiner) 
and pelleted by centrifugation at 400xg for 5 mins at 4°C. Dead volumes were 
measured and cells counted by trypan blue exclusion using a haemocytometer. 
Single cell suspensions were then washed in PBS and subsequently stained for flow 
cytometry. Joints were pooled per mouse for analysis. 
 Ears 
Ears were cut up into small pieces and shaken at 110rpm at 37°C for 25 minutes 
with 2.68mg/mL collagenase D (Roche) and 2mg/mL hyaluronidase (Sigma Aldrich) 
in RPMI 1640 (Gibco, Thermofisher). Collagenase D and hyaluronidase reactions 
were quenched using complete media. Tissues were then homogenised in 
gentleMACS C tubes (Miltenyi Biotech) using a gentleMACS Dissociator (Miltenyi 
Biotech) set at 3000 rpm for 15 seconds 3 times. Homogenised tissue was then 
strained using 70µm EASYstrainer mesh (Greiner) and pelleted by centrifugation at 
400xg for 5 mins at 4°C. Dead volumes were measured and cells counted by trypan 
blue exclusion using a haemocytometer. Single cell suspensions were then washed 
in PBS and subsequently stained for flow cytometry. Ears were pooled per mouse 
for analysis. 
 Flow Cytometry 
Background staining was controlled for using both isotype and fluorescence minus 
one (FMO) controls. For Vβ antibodies, antibodies were used, for other extracellular 
antibodies e.g. ICOS, an FMO was used. 
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 Extracellular Staining 
Cells resuspended in PBS were transferred to 96 well round-bottom plates (Corning) 
for staining. All cells from pLNs, joints, scLNs, and ears were transferred to plates. 
For spleens, approximately 5x106 cells were transferred for staining. Cells were 
pelleted by centrifugation at 400xg for 5 mins at 4°C, resuspended in 100µL viability 
dye, and incubated for 30 mins at 4°C. Cells were then washed in FACS buffer (PBS 
+ 2mM EDTA + 2% FBS) and resuspended in 50µL FcR block (generated in house 
using supernatant from the 2.4G2 cell line) and incubated at 4°C for 10 mins. 
Appropriate flow cytometry antibodies were added in FACS buffer and samples 
were incubated for a further 15 mins at 4°C. Cells were then washed in FACS buffer 
and filtered through Nitex mesh (Cadisch Precision Meshes) prior to running on BD 
LSR II, BD Fortessa, or BD FACS Celesta analysers (BD Biosciences). Data was 
then analysed using FlowJo software (Treestar version 10, Oregon, USA). Details 
of antibodies used are listed in Table 2-3 
 Intracellular Staining 
Cells were stained intracellularly after samples were incubated with antibodies 
staining extracellular proteins. Samples were washed in PBS before staining for 
intracellular proteins. To account for background staining, isotype controls were 
included for all intracellular stains used, except for anti-GFP, where a fluorescence 
minus one (FMO) control was used. 
2.5.2.1 Intracellular Cytokine Staining 
To stain for intracellular cytokines, cells were fixed and permeabilised using 100µL 
of Cyotofix/Cytoperm solution (BD Bioscience) for 1 hour at 4°C then washed in 
100µL Perm/Wash buffer (BD Bioscience). Cells were then stained with 100µL of 
the appropriate antibodies prepared in Perm/Wash buffer and stained for 1 hour at 
4°C. Cells were then washed once in Perm/Wash buffer and then in FACS buffer, 
filtered through Nitex mesh and analysed on flow cytometers.  
2.5.2.2 Staining of Transcription Factors and Other Nuclear Proteins 
Staining of transcription factors and nuclear proteins were performed on Nur77GFP 
cells and to maintain the GFP signal, staining protocols were adjusted depending 
on the antibodies used. When Nur77GFP cells were stained with an anti-GFP 
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antibody as well as antibodies staining transcription factors, the staining protocol 
used was adapted from methods developed by Grupillo et. al. and Heinen et. 
al.255,256. Cells were fixed using 100µL of 2% formaldehyde (10% formalin with 4% 
formaldehyde (Sigma Aldrich) diluted 1:1 in PBS) for 45-60 mins at 4°C. Cells were 
then washed twice in 1X permeabilisation buffer (eBioscience) and stained with the 
appropriate antibodies prepared in permeabilisation buffer at 4°C overnight. 
Samples were then washed once in permeabilisation buffer then in FACS buffer and 
analysed on flow cytometers. 
 Vβ Antibody Titration 
Optimal dilutions of the Vβ antibodies for flow cytometry were determined by testing 
1:50, 1:100, and 1:200 antibody dilutions prepared in FACS buffer and tested on 
lymphocytes collected from naïve C57BL/6 mice. Some Vβ antibodies were 
conjugated to biotin, therefore optimal streptavidin dilutions were also determined 
for biotin conjugated Vβ antibodies. Streptavidin dilutions were optimal when 
matched with the dilutions used for the biotin conjugated Vβ antibodies. Dilutions 
used are outlined in Table 2-3. 
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Table 2-3 List of Antibodies Used for Flow Cytometry 
Marker Fluorochrome Clone 
Concentration 
in sample Manufacturer Cat. No. 
CD4 BUV395 GK1.5 1:200 BD Biosciences 563790 
CD4 BUV737 GK1.5 1:200 BD Biosciences 564298 
CD4 eVolve 605 RM4-5 1:20 eBioscience 83-0042-41 
CD4 eFluor 450 RM4-5 1:200 eBioscience 48-0042-82 
CD44 
APC eFluor 
780 IM7 1:200 eBioscience 47-0441-82 
CD44 PerCP Cy5.5 IM7 1:200 eBioscience 45-0441-82 
CD45 PE Cy7 30-F11 1:200 eBioscience 25-0451-82 
CD45.1 eFluor 450 a20 1:200 eBioscience 48-0453-82 
CD278 
(ICOS) BV785 C398.4A 1:200 BioLegend 313539 
GFP AlexaFluor 647 Polyclonal 1:400 ThermoFisher A31852 
IFNγ PE XMG1.2 1:400 BD Biosciences 554412 
IL-2 BV711 JES6-5H4 1:200 BioLegend 503837 
MHC-II APC M5/114.15.2 1:800 eBioscience 17-5321-82 
RORγT PE AFKJS-9 1:100 eBioscience 12-6988-82 
Streptavidin PerCP Cy5.5 - 1:200 eBioscience 45-4317-82 
Tbet PE Cy7 4B10 1:100 eBiosceince 25-5825-82 
TNFα  BV605 MP6-XY22 1:100 BioLegend 506329 
Vβ2  FITC B20.6 1:50 BD Pharmingen 553280 
Vβ3  Biotin KJ25 1:200 BD Pharmingen 553207 
Vβ4  Biotin KT4 1:200 BD Pharmingen 553364 
Vβ4  FITC KT4 1:200 BD Pharmingen 553365 
Vβ4  PE KT4 1:200 BD Pharmingen 553366 
Vβ5.1/5.2  APC MR9-4 1:100 BioLegend 139506 
Vβ5.1/5.2  FITC MR9-4 1:200 eBioscience 11-5796-82 
Vβ6  PE RR4-7 1:200 BD Pharmingen 553194 
Vβ7  FITC TR310 1:200 BD Pharmingen 553216 
Vβ8.3 FITC 8C1 1:200 BioLegend 118603 
Vβ9 PE MR10-2 1:200 BD Pharmingen 553201 
Vβ10[b] PE B21.5 1:200 BD Pharmingen 553285 
Vβ11 Biotin RR3-15 1:200 BD Pharmingen 553196 
Vβ11 FITC RR3-15 1:200 BD Pharmingen 553197 
Vβ12 Biotin MR11-1 1:200 BD Pharmingen 553299 
Vβ13 APC MR12-3 1:200 BD Pharmingen 561542 
Vβ14 Biotin 14-2 1:200 BD Pharmingen 553257 
Viability eFluor 506 - 1:1000 eBiosceince 65-0866-14 
 
 CDR3β Amplification by PCR 
Vβ CDR3 clonality was assessed using SuperTCRExpressTM (BioMed Immunotech, 
Florida, US) on endogenous CD4+ T cells sorted from inflamed joints and popliteal 
LNs using the BD FACS ARIAIII. Sorted cells were lysed and the RNA extractions, 
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cDNA synthesis and PCR performed as per the manufacturer’s instructions. PCR 
products were run on a 4% agarose gel and visualized on a GelDoc system (BioRad, 
Hertfordshire, UK). 
 Fluorescence Activated Cell Sorting (FACS) and 
CDR3β Sequencing 
 Sorting Endogenous CD4+ T Cells from Tissues 
Cells were isolated from pLNs, joints, scLNs, and ears as described in section 
2.2.1. Cells were stained for viability and with antibodies against CD4, CD45, 
CD45.1, and CD44 and sorted using either the BD AriaIIU or BD Aria III FACS 
sorters (BD Biosciences) using a 100µm nozzle. Sorters were prepared for an RNA 
free sort by cleaning with nuclease free water Samples were run in FACS buffer and 
gated on live, single cells that were CD4+, CD45+, and CD45.1- to ensure only the 
endogenous CD4+ T cells were collected. Endogenous CD4+ T cells were then 
further gated on CD44 and CD44hi cells were collected. Sorters were set up for a 
4-way sort, 4-way purity precision, and on a continuous setting. Cells were collected 
in 1.5mL Eppendorf tubes (Greiner-Bio-One) containing Lysis Buffer (Purelink RNA 
micro kit, Thermofisher, cat.no. 12183-016) with 1% β-mercaptoethanol (Sigma-
Aldrich) and lysed by passing 3 times using 29G insulin syringes (VWR, 613-4897). 
Sorting chamber was cleaned with nuclease free water (Roche) using the ‘sample 
line backflush’ program once before every sample. Cells were then frozen at -80°C 
before RNA purification. 
 RNA Purification 
RNA was purified using the Purelink RNA micro kit (Thermofisher) as per 
manufacturer’s instructions. RNA was eluted from columns using 10µL of Elution 
Buffer. For all joint and ear samples, and pLN PBS samples, carrier RNA was added 
as per manufacturer’s instructions. RNA concentration was determined using a 
Nanodrop 1000 spectophotometer (Thermofisher) and quality was determined by 
measuring A260/280. Purified RNA was frozen at -80°C before CDR3β sequencing. 
RNA concentrations ranged from 1.3-48ng/µL. 
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 CDR3β Sequencing 
CDR3β sequencing was performed by iRepertoire Inc. (Huntsville, AL, USA) on the 
Vβ TCR chain. Frozen RNA samples were shipped on dry ice, and each sample 
was PCR amplified using barcoded primers covering the V-J TCR region, enabling 
sequencing data to be tracked back to a specific sample. Amplified samples were 
pooled together and sequenced using the Illumina MiSeq platform using 150 paired 
end reads (PER) primers. PBS joint and PBS pLN samples did not pass 
iRepertoire’s quality control and these samples were generated again and 
sequenced using the same parameters. Unlike the other samples, PBS pLN and 
PBS joint sample replicates were pooled, resulting in having one biological replicate 
for each PBS challenged tissue.  
 CDR3β Sequencing Analysis 
Basic data analysis was performed by iRepertoire (Huntsville, AL, USA) and data 
was available on iRepertoire’s data web viewer iRweb. Sequencing data was also 
prepared for analysis using MiXCR developed by Bolotin et. al.257 and analysed 
using tcR developed by Nazarov et. al.258. 
 Calculation of D50 diversity index using iRepertoire 
generated data 
Repertoire diversity can be calculated in several ways, but the diversity index (DI) 
used in this thesis is based on the calculation used by iRepertoire and is called D50 
(from iRepertoire’s data analysis guide). The D50 value represents the cumulative 
percentage of T cell clones that accounts for 50% of the total CDR3β sequence 
reads. The higher the diversity, the closer the value is to 50. Two formulae exist to 
calculate the D50 value depending on the number of total unique CDR3β sequences 
generated; 10,000 unique CDR3β and above, or below 10,000 unique CDR3β 
sequences, which are found below: 
No. of unique CDR3β sequences ≥ 10,000: 
1. Obtain the total number of reads of the top 10,000 unique CDR3β sequences. 
2. Calculate 50% of this value 
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3. Find the rank of unique CDR3β sequence up to which the total value of reads 
approximately matches the value obtained in point 2. 50% of the total number 
of reads usually falls between 2 ranks, and the lower rank is chosen to 
calculate the D50 value. I.e. if 50% of total number of reads falls between 
unique CDR3β sequences at positions 14 and 15, 15 is chosen to calculate 
D50. 
4. Calculate D50: 
(rank of unique CDR3β sequence where 50% of the top 10,000 total reads 
falls x 100) / 10,000 = D50 
No. of unique CDR3β sequences <10,000: 
1. Calculate the total number of reads of all unique CDR3β sequences 
2. Calculate 50% of the total number of reads 
3. Find the rank of unique CDR3β sequence up to which the total value of reads 
approximately matches the value obtained in point 2. 50% of the total number 
of reads usually falls between 2 ranks, and the lower rank is chosen to 
calculate the D50 value. I.e. if 50% of total number of reads falls between 
unique CDR3β sequences at positions 14 and 15, 15 is chosen to calculate 
D50. 
4. Calculate D50: 
(rank of unique CDR3β sequence where 50% of the total reads falls x 
100) / no. of unique CDR3β sequences = D50 
 Preparation of Sequencing Data by MiXCR 
Demultiplexed sequencing data was downloaded onto University of Glasgow 
servers and prepared for analysis using MiXCR using the following Linux code: 
#!/bin/bash 
 
read1=$1 
read2=$2 
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name=$3 
 
/export/projects/bioinfo3/to16r/bin/mixcr-2.1.5/mixcr align -f -t 12 -s mmu -r 
$name.align.report.log $read1 $read2 $name.vdjca 
 
/export/projects/bioinfo3/to16r/bin/mixcr-2.1.5/mixcr assemble $name.vdjca 
$name.clns 
 
/export/projects/bioinfo3/to16r/bin/mixcr-2.1.5/mixcr exportClones $name.clns 
$name.txt 
 
This code aligns, assembles, and creates .clns (clone) files. .clns files were then 
converted to .txt files for subsequent analysis using the tcR R package258. 
 Analysis of Sequencing Files with the tcR R package 
The tcR R package was specifically designed to analyse sequencing data generated 
by several software including MiXCR. The package was used in the R statistical 
software framework (R version 3.4.3) and the code detailed below was used for 
visualising and analysing TCR sequencing data. 
2.8.3.1 Organisation of Data 
Individual sample text files were compiled into lists using the following code: 
List_name <- list(sample_name1=sample_name1, 
sample_name2=sample_name2,…,sample_nameN=sample_nameN) 
2.8.3.2 Top proportion charts 
To obtain figures such as Figure 4-3 A, use the following code: 
vis.top.proportions(“name of list”, c(10, 25, 500, 3000, 10000), 
.col = "Read.count") 
 
2.8.3.3 PCA Plots 
To make a PCA plot of V-gene usage such as Figure 4-7, use the following code: 
vis.pca((pca.segments(“name of list”, .cast.freq.seg = T, .text = 
F, .do.plot = F)),  
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        .groups = list(“name of group within list_1” = c(1, 2, 3, 
4, 5), “name of group within list_2” = c(6, 7, 8, 9, 10)) 
 
2.8.3.4 Heatmaps Showing CDR3β Sequence Overlap 
vis.heatmap(repOverlap(“name of list”, 'exact', 'aa', .vgene = F, 
.norm = T, .verbose = F), .title = "No. Shared Clonotypes pLN 
Samples",  
.scientific = T, .labs = c(" "," "), .legend = "# clonotypes", 
.size.text = 2.5, .signif.digits = 3) 
 
2.8.3.5 Searching for specific CDR3β Sequences Across Data Frames 
This code was used to look for the top 10 clones in joint samples and to check 
whether the same CDR3β sequences could be found in respective pLN samples, 
and how those sequences ranked in the pLN samples. In order to do this, the data 
set being searched needed to be ranked using this code: 
“List_name” <- set.rank(“List_name”) 
 
Then, the top 10 clones in a joint sample were found and the sequences searched 
in the respective pLN sample: 
new_variable_name <- find.clonotypes(“name of pLN dataset to be 
searched”, .targets = “name of joint data set” [1:10, 
c('CDR3.amino.acid.sequence', 'V.gene')],  
.method = c("exact"), .col.name = c("Read.count", "Rank"), 
.target.col = c("CDR3.amino.acid.sequence", 'V.gene'), .verbose = 
T) 
 
The results were then written into tab delimited text files: 
write.table(“new variable name”, file = "’Desired name to be given 
to file’.txt", sep = "\t") 
 
 In vitro T Cell Stimulations 
To test for Nur77GFP expression in vitro, 96 well round-bottom plates were coated 
with 50µL 0.1-10 µg/mL anti-CD3 antibody (NA/LE hamster anti-mouse CD3e, clone 
145-2C11, BD Biosciences) prepared in PBS and incubated overnight at 4°C. The 
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anti-CD3 solution was removed by flicking and tapping the plates onto tissue paper. 
Lymphocytes from Nur77GFP mice were collected and forced through 70µm 
EASYstrainer mesh (Greiner-Bio-One) and washed with PBS. Cells were then 
counted by trypan blue exclusion using a haemocytometer and resuspended in PBS 
to obtain a concentration of 1.5x106 cells/mL. 200µL of the cell suspension was 
added to respective wells in triplicate and incubated for either 3 or 24 hours for 
Nur77GFP expression and Nur77GFP time-course experiments respectively. Cells 
were cultured at 37°C and 5% CO2. 
 T Cell DC Co-cultures 
 Generation of BMDCs 
BMDCs were generated by culturing bone marrow obtained from femurs and tibias 
of C57BL/6 mice in complete media supplemented with 5% GM-CSF (RPMI 1640, 
Gibco, Thermofisher; 10% FCS; 1% Penicillin and streptomycin; 1% L-glutamine, 
GM-CSF made in house from X63 GM-CSF cell line). Bone marrow was removed 
from bones by forcing Hank’s balanced salt solution (HBSS, No Ca2+, No Mg2+, no 
phenol red, ThermoFisher) into bones using a 25G needle. Bone marrow was then 
pipetted several times then pelleted by centrifugation at 400xg for 5 mins at 4°C. 
Cells were then treated with 1mL RBC lysis buffer per mouse and incubated for 2 
mins at RT. Cells were then washed, pelleted, and counted by trypan blue exclusion 
using a haemocytometer. 1.5x106 cells were added to 6-well non-TC treated plates 
(Corning) and cultured for 7 days at 37°C and 5% CO2. Cells were fed with complete 
media supplemented with GM-CSF on days 3 and 6. 
 T cell DC Co-culture for Testing Nur77GFP Re-
stimulation with OVA 
BMDCs were pulsed with OVA prior to culture with T cells. On day 7 of BMDC 
culture, BMDCs were cultured with complete media supplemented with 100µg/mL 
OVA protein (Code OAC – Worthington Biochemicals) for 24 hours at 37°C at 5% 
CO2. DCs were harvested by incubating cells with cold HBSS supplemented with 
2mM EDTA for 10 mins at room temperature, then washed in HBSS, and 
resuspended in complete media. CD4+ T cells were purified from brachial and 
axillary lymph nodes of mice (as described in section 2.2.1) immunised with 1µg/mL 
OVA in CFA (described in section 2.2.3) in the scruff 7 days prior, and from naïve 
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Nur77GFP mice. CD4+ T cells were purified by negative antibody selection (Miltenyi 
Biotech, 130-104-454, Surrey, UK), and counted by trypan blue exclusion using a 
haemocytometer. 1x106 purified CD4+ T cells were co-cultured with OVA pulsed 
DCs in a 5:1 ratio in 48 well plates (Corning) for cytokine analysis, or in 24 well 
plates for proliferation analysis. For cytokine analysis T cell DC co-cultures were 
cultured for 6 hours at 37°C and 5% in complete media. 2 hours into the culture, 
Golgistop (BD Biosceinces) diluted 1:1000 in complete media (BD Biosciences) was 
added to the wells. For positive controls, cells were stimulated with 10ng/mL PMA 
(Sigma Aldrich) and 500ng/mL ionomycin (Sigma Aldrich) and cultured with 
complete media supplemented with 1:1000 Golgistop. Cells were then analysed by 
flow cytometry. Method of measuring proliferation is detailed in the following section. 
 Cell Proliferation Assay 
Purified CD4+ T cells were pelleted and resuspended in warmed PBS (37°C) 
supplemented with 2% FCS to a concentration of 1x106 cells/mL. Approximately 
1x106 CD4+ T cells were incubated for 20 mins at 37°C and 5% CO2with 1uL/mL of 
CellTrace Violet (Invitrogen), prepared according to manufacturer’s instructions. 
10mL complete media was added and the cells were incubated for a further 3 mins. 
Cells were then washed, pelleted, and resuspended in complete media and cultured 
with OVA pulsed DCs in a 5:1 ratio in 24 well plates. Cells were cultured for 96 hours 
at 37°C and 5% CO2 and then prepared for analysis by flow cytometry. 
 CD4+ T Cell DC Co-culture with Joint and Candidate RA 
Antigens 
Cells were isolated from pLNs and joints of Nur77GFP mice as described in 
sections 2.4.1 and 2.4.3. Cells were pooled per sample per group prior to CD4+ T 
cell purification. CD4+ T cells were purified by negative selection using EasySep 
Mouse CD4+ T cell Isolation Kit (Stemcell Technologies) as per manufacturer’s 
instructions. CD4+ T cells isolated from joint samples needed to go through two 
rounds of purification before use in co-culture experiments. 20,000-30,000 purified 
CD4+ T cells were cultured with DCs in a 5:1 ratio which were simultaneously pulsed 
with either 100µg/mL OVA protein (Code OAC – Worthington Biochemicals), a 
combination of 100µg/mL bovine collagen II (Sigma Aldrich) and 100µg/mL bovine 
aggrecan (Sigma Aldrich), or 50µL joint extract, which is the supernatant of LPS 
challenged or IFA challenged homogenised joints. Non-pulsed DCs were also 
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included to determine baseline Nur77GFP expression. Each group was cultured in 
duplicate. Cells were cultured in 48 well plates for 6 hours at 37°C and 5% CO2. 
GolgiStop (containing Brefeldin A) (BD Biosciences) was added to each well to 
obtain a final dilution of 1:1000. Cells were cultured for a further 6-12 hours before 
preparation for flow cytometry analysis. 
 Enzyme-Linked Immunosorbent Assays (ELISAs) 
Anti-OVA and anti-collagen II antibody concentrations were determined from serum 
samples of mice undergoing the early and late models of OVA experimental arthritis. 
Blood was collected from each mouse and allowed to clot at room temperature for 
up to 6 hours. Samples were then spun at 13,300 rpm for 5 mins. Supernatants 
were then transferred to 1.5mL Eppendorfs (Greiner-Bio-One) and frozen at -80°C. 
96 transparent flat bottom plates (Costar) were coated with 50µL of 20µg/mL OVA 
(Sigma Aldrich) or 4µg/mL bovine collagen II (Sigma Aldrich) diluted in carbonate 
buffer (Sigma Aldrich) and incubated at 4°C overnight. Plates were then washed in 
0.05% PBS-T (PBS + Tween20), blocked with 50µL animal free serum (Vector labs 
SP5030) for 1 hour at 37°C, then washed again in 0.05% PBS-T. Serum samples 
were diluted to the appropriate concentration in PBS and added to the plates in 
duplicate. Samples were incubated at 37°C for 1 hour. Plates were washed in 0.05% 
PBS-T and incubated with an HRP conjugated rabbit anti-mouse total IgG antibody 
(Sigma Aldrich) diluted to 1:10,000 in PBS at 37°C for 1 hour then washed again in 
0.05% PBS-T. Antibodies were detected using 100µL of SigmaFAST OPD solution 
(Sigma Aldrich) for 10-30 mins at room temperature. Plates were covered in 
aluminium folder during the detection period. Reaction was stopped using 10% 
sulphuric acid. Absorbance was measured at 492nm using a Tecan Sunrise plate 
reader (Tecan). Values were subtracted from blank controls and normalised to a 
standard control well. 
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Chapter 3 Assessment of CD4+ T cell clonality in 
a mouse model of experimental arthritis 
 Introduction 
As discussed in section 1.4.4 of the introduction, CD4+ T cells play an important 
role in the initiation, coordination, and maintenance of Rheumatoid Arthritis (RA) and 
their ability to infiltrate joints is associated with perpetuation of local and systemic 
inflammatory responses. Several research groups have investigated the diversity of 
these cells in RA patients to better understand how antigen specificity and CD4+ T 
cells are involved in disease progression. Oligoclonal CD4+ T cell populations have 
been found in joints of RA patients, demonstrating that antigen specific CD4+ T cell 
responses have occurred in these patients46,201,259. Such expanded CD4+ T cell 
populations are envisioned to persist with the progression of disease; indeed 
expanded clones were found in RA patients more than 2 years after they were first 
identified143. However, the antigen specificities of these cells remain unclear, and 
how such T cell responses arise and evolve with disease progression remains 
poorly understood. Investigating the antigen specificities of these T cells has 
important implications for antigen specific tolerogenic therapies, as these 
pathogenic cells represent the targets that will lead to prevention of further damage 
and disease remission. Indeed, several studies employing antigen specific 
tolerogenic therapies have shown promise in dampening allergic and autoimmune 
responses229,240,243,260. Moreover, understanding how these responses evolve with 
disease chronicity will better inform where and when these therapies will be most 
effective. 
Antigen specific responses can be assessed by determining the presence of biases 
in TCR usage, which can be done on both a sequence and protein level. Methods 
utilising PCR to amplify regions of the TCR transcript have demonstrated changes 
in TCR diversity in cancers198,199 and autoimmune diseases48,200, including 
RA46,48,143,201. Using antibodies directed against the TCR is also a valid method for 
assessing T cell clonality and can be used to identify specific T cell clones202 203. 
Because the antigen specificities of expanded T cells in RA are unknown, antibodies 
against relevant, specific T cell clones do not exist. Instead, antibodies against V 
regions of the TCR β chain can be used to quantify the presence of different V 
regions by flow cytometry, which would highlight biases in TCR frequencies, and 
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consequentially, suggests antigen associated retention and accumulation. 
Quantification of V regions has been performed in healthy people87,207, in patients 
with leukemia208, and in RA patients209. Both these methods have the advantage of 
providing rapid, global assessments of changes in the T cell repertoire207,210,211, 
which rely on the skewed presence of different V regions to reflect changes in the T 
cell population. Determining frequencies of V chain usage does not provide clonal 
information per se, but it still highlights biases in the usage of these chains, 
implicating antigen driven proliferation of T cells210,214. 
As initiation of the antigen specific responses are poorly understood in patients, a 
murine model of early arthritis was used to investigate the clonality of the initial 
CD4+ T cell infiltrate and provide evidence for antigen specific responses at the 
earliest stages of disease. The OVA model of early experimental arthritis uses a 
joint irrelevant antigen to cause breach of tolerance and recapitulates the pre-
articular phase of RA140, details of which can be found in section 1.4.3 of the 
introduction. This model is therefore ideal for monitoring the dynamics of the initial 
CD4+ T cell joint infiltrate during conditions for which developing autoreactivity to 
articular antigens is most permissive.  
 Chapter aims and summary 
The aims of this chapter are twofold: Firstly, to assess the clonality of CD4+ T cells 
in a model of early experimental arthritis with the aim of finding evidence supporting 
antigen specific accumulation of CD4+ T cells in the joints during early phases of 
the disease. Secondly, to monitor how these antigen specific responses evolve with 
disease progression. In order to do this, I have established the models, techniques, 
tissues, and time points necessary for assessing CD4+ T cell clonality. These 
populations were subsequently analysed for biases in TCR Vβ usage using both the 
PCR and flow cytometry techniques mentioned earlier. 
CD4+ T cells were isolated from both joints and joint draining popliteal lymph nodes 
(pLNs),  analysed, and compared to assess differences in antigen specific 
responses between these two sites. The CD4+ T cell population was also analysed 
in the context of non-antigen driven inflammation to determine the degree an 
inflammatory environment contributes to the recruitment of CD4+ T cells, and how 
this influences biases in the T cell repertoire. Previous studies have demonstrated 
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the ability of antigen experienced CD4+ T cells to infiltrate and accumulate in tissues 
in the absence of their cognate antigen191,193,194 and so changes to the CD4+ T cell 
repertoire could arise as a result of the inflammatory environment as well as the 
presence of antigen driven responses. Comparisons were also made between 
articular and non-articular tissues to evaluate the degree joint derived antigens 
shape the CD4+ T cell repertoire. All of this was done in an early model of 
experimental arthritis. To address the evolution of the antigen specific response, a 
model of relapsing polyarthritis, developed by Conigliaro et al252 was used and a 
time point for disease chronicity was established, and CD4+ TCR clonality assessed 
(Figure 3-1 A). 
Overall my findings indicate the presence of a bias in the CD4+ T cell repertoire in 
early experimental arthritis that is associated with an antigen driven response and 
is influenced by joint derived antigens. Moreover, the biases in the TCR repertoire 
found at the later timepoint mirror those found in the early phases, suggesting the 
presence of clones in early arthritis that play role in propagating the disease. 
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Figure 3-1 - The OVA experimental arthritis model illustrating the early and late model 
timepoints and modifications and assessment of Th1 polarised OT-II cells used for adoptive 
transfer  
A) Early and late model timepoints, described in detail in methods sections 2.2.5 and 2.2.7 are 
adaptations of the OVA experimental arthritis model described in introduction section 1.6. Briefly, 
Th1 polarised OT-II cells are transferred in to C57BL/6 mice which is followed by immunisation of 
OVA in CFA in the scruff 24 hours after the adoptive transfer. 10 days after OVA+CFA immunisation, 
mice are given a periarticular immunisation of either HAO or PBS as a control. To assess the effects 
of an inflammatory environment on CD4+ clonality, an additional group of mice were challenged with 
LPS in the joints. To compare the influence of articular antigen on the CD4+ T cell population, a 
group of mice were immunised with HAO or PBS in the ear. For the early timepoint, mice are 
sacrificed 4 days after this primary periarticular challenge. To establish the late timepoint, mice are 
given a 2nd periarticular challenge 30 days after the primary HAO challenge with either HAO in IFA 
or IFA alone as a control. The mice are then sacrificed 4, 11, or 17 days after the 2nd periarticular 
challenge. B) Representative flow cytometry plots illustrating identification of Th1 polarised OT-II 
cells, described in detail in methods section 2.2.2. Briefly, 72 hours after naïve OT-II cells were 
cultured with IL-12, anti IL-4, and OVA peptide 323-339, percentage of Th1 polarisation was 
determined by gating on blasting, CD4+ T cells that were Vα2, Vβ5 double positive. For the adoptive 
transfer, the cell concentration was adjusted – using the percentage of blasting, Vα2, Vβ5 double 
positive CD4+ T cells  ̶  to ensure 2-3x106 Th1 polarised cells were transferred into C57BL/6 or 
Nur77GFP hosts. The percentage of Th1 polarised OT-II cells ranged from 75%-97% across 
experiments.  C) A representative flow cytometry plot of Th1 polarised cells stimulated with 
PMA/Ionomycin. Briefly, a sample of Th1 polarised cells was taken for to determine production of 
IFNγ and TNFα and reaffirm polarisation to the Th1 phenotype. Cells were cultured with 20ng/mL 
PMA and 10µg/mL ionomycin for 1 hour at 37°C in complete media, then for a further 3 hours after 
addition of GolgiStop diluted 1:1000 in complete media. Cells were then stained for flow cytometry 
analysis. Polarised CD4+, Vα2+, Vβ5+ cells were 92% IFNγ and TNFα double positive on average.    
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 Results 
 Establishing the OVA arthritis model for CD4+ T cell clonality 
assessment 
Before investigating CD4+ T cell clonality and determining the presence of antigen 
specific responses in the OVA model of experimental arthritis, conditions for the 
assessment of CD4+ T cell clonality first needed to be established. This would allow 
for the accurate evaluation of CD4+ TCR clonality and antigen specific responses 
in early experimental arthritis in addition to assessing how CD4+ T cell clonality 
evolves with disease severity. 
3.2.1.1 Isolation and Identification of endogenous CD4+ T cell populations 
and Vβ families from pLNs and joints 
Evaluating the presence of any biases in Vβ chain use is dependent on the accurate 
identification of the endogenous CD4+ T cell population in joints and the joint 
draining popliteal lymph nodes (pLNs). The congenic marker CD45.1 was used to 
distinguish the transferred OT-II cell population from the endogenous CD4+ T cell 
population and was sufficient in doing so in both pLNs (Figure 3-2 A) and joints 
(Figure 3-2 B). Moreover, the naïve (CD44lo) and antigen experienced (CD44hi) 
populations were identified within the endogenous CD4+ T cell population of pLNs, 
and the naïve population was then used to identify the different Vβ families (Figure 
3-3). The different gates were then applied within the antigen experienced 
populations in pLNs and joints. 
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Figure 3-2 - Gating strategy to identify endogenous antigen experienced CD4+ T cells from 
pLNs and joints. 
Cells were isolated from A) pLNs, and B) joints as described in methods and stained with antibodies 
for flow cytometry also described in methods. Endogenous antigen experienced cells are identified 
as CD44hi CD4+ CD45- cells and were isolated by gating on lymphocytes, single cells, live cells, 
CD45+ CD4+ cells, CD4+ CD45.1- cells, and finally CD44hi cells. flow cytometry plots are 
representative of pLNs and joint cells. 
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Figure 3-3 - Identification of Vβ families from the naïve (CD44lo) population from pLNs 
Vβ populations were identified from the CD44lo population of pLNs as the naïve population should 
contain cells representing all Vβ chains and also be present in high enough numbers to be accurately 
detected by flow cytometry. These gates were then applied and adjusted to the CD44hi repertoire in 
both pLNs and joint samples. Vβ antibodies were split amongst 4 panels and 2 panels were used 
per sample. Panel one Vβ3, 7, and 8.3. Panel two Vβ4, 9, and 10. Panel 3 Vβ2, 5, 12, and 13. Panel 
4 Vβ6, 11, and 14. flow cytometry plots are representative of pLN samples. 
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3.2.1.2 HAO challenge induces joint inflammation, and accumulation of 
antigen experienced endogenous CD4+ T cells 
To determine whether the model was successful in inducing experimental arthritis, 
joint thickness was measured each day after administration of HAO or PBS until 
experiment termination (Figure 3-4). In addition, the total cell number, total number 
of endogenous CD4+ T cells, and the number of antigen experienced CD4+ T cells 
(CD44hi) cells was determined in both the joints and respective pLNs (Figure 3-5). 
HAO challenged mice footpads were significantly larger than PBS controls on all 
days following immunisation until experiment termination (Figure 3-4). Mice 
challenged with HAO also showed a significant increase in cell number in both the 
joint and pLN samples compared to PBS challenged controls (Figure 3-5) The 
number of endogenous CD4+ T cells is also greater than the number of OT-II cells 
in both HAO challenged pLNs and joints (Figure 3-5 B), which demonstrates that 
HAO challenge elicits an endogenous response. Taken together, this data suggests 
that HAO causes local inflammation, and accumulation of antigen experienced 
(CD44hi) endogenous CD4+ T cells in both the joints and pLNs. 
 
Figure 3-4 - Footpad thickness of HAO and PBS challenged mice. 
Both footpads were measured daily after HAO or PBS administration for 4 days until experiment 
termination. Graphs represent 1 experiment with n=4 for both HAO and PBS groups. Groups were 
compared using repeated measures 2 way ANOVA. Bars represent mean ±SD.  Stars represent the 
following p values: **** <0.0001 
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Figure 3-5 - Number of cells in the joints and respective pLNs in HAO and PBS challenged 
mice. 
Cells were isolated from both joints and respective pLNs of HAO and PBS challenged mice. 
Transferred cells were identified using the CD45.1 marker and were excluded from analysis, leaving 
only the endogenous CD4+ T cells A) Total cell number, B) Total endogenous CD4+ T and OT-II 
cells, C) Total CD44hi, CD4+ T cells in HAO and PBS challenged joints and pLNs. Each symbol 
represents one mouse. Graphs represent 3 experiments with n=13 and 10 for the HAO and PBS 
groups respectively. Graphs with two groups were compared using unpaired Student’s t test. Graphs 
with more than two groups were compared using 2 way ANOVA. Bars represent mean ±SD. Stars 
represent the following p values: ** <0.01; **** <0.0001; ns: not significant 
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3.2.1.3 Assessing the influence of an inflammatory environment on the 
accumulation of CD4+ T cells in inflamed pLNs and joints 
Previous studies have shown how an inflammatory environment is capable of 
recruiting activated CD4+ T cells without their cognate antigen191,193,194. To 
accurately determine the presence of antigen specific responses in the early phases 
of experimental arthritis, conditions where inflammation is induced in the absence 
of antigens needed to be established, as this would determine the relative 
contributions of antigen specific and non-specific inflammation to the initial CD4+ 
joint infiltrate. To address this, mice were challenged with either HAO, PBS, or LPS. 
LPS is a non-specific inflammatory mediator that causes the release of 
proinflammatory cytokines via the TLR4 receptor, and so any recruitment or 
retention of CD4+ T cells would not be due to antigen since the TCR is not 
engaged261. A previous study by Nickdel et. al. demonstrated how innate responses 
initiated by LPS contribute to the inflammatory environment in early experimental 
arthritis and facilitate damage to the joint without the development of an autoreactive 
response254. By administering an LPS footpad challenge, the initial CD4+ T cell 
infiltrate could be investigated in the context of a non-antigen driven inflammatory 
environment and in the absence of conditions permissive to the development of 
autoreactive responses, thereby clarifying the clonality of endogenous CD4+ T cells 
involved in propagating breach of tolerance and the development of an autoreactive 
response. 
Two doses of LPS isolated from E.coli (see methods section 2.2.5) were initially 
tested in the model to evaluate which dose was better at causing a significant 
infiltration of cells in pLN and joints. It was found that 5µg of LPS failed at inducing 
cell accumulation in the joints (data not shown), but 25µg was sufficient. Moreover, 
in the same model Nickdel et. al. demonstrated that 25µg of LPS lead to cell 
infiltration and moderate cartilage erosion254. Considering this, 25µg of LPS was 
used in all experiments requiring the use of LPS. Mice were challenged with either 
HAO, PBS, or LPS and their footpads were measured 1, 2, and 4 days after 
periarticular challenge to assess footpad swelling (Figure 3-6). LPS did not increase 
footpad swelling on days 1 and 3 compared to PBS controls, but by day 4 footpads 
were more swollen than PBS controls. The total cell number, the number of CD45+ 
CD4- cells, endogenous CD4+ T cells, and the number of CD44hi CD4+ 
endogenous T cells from joints and pLNs were also compared to determine the 
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effect LPS has on cell accumulation in both these sites (Figure 3-7). The total cell 
number and the number of CD45+ CD4- cells were significantly higher in the LPS 
group than PBS controls in both pLNs and joints (Figure 3-7 A and D), but the 
number of endogenous CD4+ T cells, as well as the number of CD44hi CD4+ T cells 
were comparable to PBS controls (Figure 3-7 B and C). Despite this, the increase 
in total cell number and CD45+ CD4- cells indicates that the LPS was functioning 
as expected and the increase in cell number observed may be attributed to an 
increase in the number of innate cells. Indeed, LPS has been shown to attract 
neutrophils, macrophages and DCs261. Administration of 25µg of LPS was therefore 
deemed sufficient for evaluating the clonality of the CD4+ T cell infiltrate in the 
context of non-antigen induced inflammation. 
 
 
Figure 3-6 - Footpad thickness of HAO, PBS, and LPS challenged mice. 
Both footpads were measured one, three, and four days after HAO, PBS, or 25µg of LPS 
administration until experiment termination. Graphs represent 1 experiment with n=5 for HAO, PBS, 
and LPS groups per experiment. Groups were compared using repeated measures 2 way ANOVA. 
Bars represent mean ±SD. Stars represent the following p values: * <0.05; *** <0.001; **** <0.0001. 
Green stars represent comparisons between HAO and LPS groups, blue stars represent 
comparisons between HAO and PBS groups, and black stars represent comparisons between LPS 
and PBS groups. 
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Figure 3-7 - Number of cells in the foot joints and respective pLNs of HAO, PBS, and LPS 
challenged mice. 
Cells were isolated from both foot joints and respective pLNs of HAO, PBS, and LPS (25µg) 
challenged mice. Transferred cells were identified using the CD45.1 marker and were excluded from 
analysis, leaving only the endogenous CD4+ T cells A) Total cell number, B) endogenous CD4+ T 
cells, C) CD44hi, CD4+ T cell number, and D) CD45+ CD4- cell number in HAO, PBS, and LPS 
challenged joints and pLNs. Each symbol represents one mouse. Graphs represent 2 experiments 
with n=11 for the HAO groups, and n=10 for the PBS and LPS groups. Groups were compared using 
one way ANOVA. Bars represent mean ±SD. Stars represent the following p values: * <0.05; ** 
<0.01; **** <0.0001; ns: not significant 
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3.2.1.4 Assessing the influence of articular antigens on the accumulation of 
CD4+ T cells in inflamed pLNs and joints 
Another aim of the chapter was to determine whether breach of tolerance to joint 
derived antigens plays a role in initiating and propagating antigen experimental 
arthritis via autoreactive responses. A number of studies provide evidence for the 
role of articular antigens, such as collagen and human cartilage gp-39 (HC gp-39), 
as the targets of antigen specific T cell responses in RA 262,263. A method to 
determine whether antigen specific responses observed are restricted to the joint is 
to immunise a site other than the joint, such as the ear. The composition of ear 
cartilage is different to the joint, and the ear is not affected in RA264,265, so the 
damage that is caused by HAO should – in theory – expose a different set of 
antigens. Other members of the lab have immunised the ear to compare 
endogenous CD4+ T cell retention mechanisms between the inflamed joint and ear 
in the model. The OVA experimental arthritis was initiated as normal, but instead of 
periarticular administration of HAO, mice were injected with 100µg of HAO in the 
ear pinnae. Ears and the superficial cervical lymph nodes (scLNs) that drain the 
ear266 were collected and cell numbers determined (Figure 3-8). The total, 
endogenous CD4+ T cell, and endogenous CD44hi cell numbers were all 
significantly higher than their PBS counterparts in both the scLNs and ears (Figure 
3-8 A-C). In addition, the endogenous CD4+ T cell number is significantly greater 
than the OT-II cell numbers in HAO challenged scLNs and ears (Figure 3-8 B). This 
indicates that HAO challenge in the ear results in an increase in antigen experienced 
endogenous CD4+ T cells similar to the joint. 
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Figure 3-8 - Number of cells in ears and respective draining superficial cervical lymph nodes 
(scLN) in HAO and PBS challenged mice. 
Cells were isolated from both ears and respective scLNs of HAO and PBS challenged mice. 
Transferred cells were identified using the CD45.1 marker and were excluded from analysis, leaving 
only the endogenous CD4+ T cells A) Total cell number, B) Total endogenous CD4+ T and OT-II 
cells, C) Total CD44hi, CD4+ T cells in HAO and PBS challenged ears and scLNs. Each symbol 
represents one mouse. Graphs represent 3 experiments with n=15 in total for the HAO and PBS 
groups respectively. Graphs with two groups were compared using unpaired Student’s t test. Graphs 
with more than two groups were compared using 2 way ANOVA. Bars represent mean ±SD. Stars 
represent the following p values: * <0.05; *** <0.001; **** <0.0001; ns: not significant 
 
3.2.1.5 Establishing a late timepoint to assess the evolution of the antigen 
specific CD4+ T cell response in the late model of inflammatory 
arthritis 
Another aim of the chapter is to investigate how CD4+ T cell clonality would change 
with the progression of experimental arthritis, which suggests how antigen specific 
responses may change with the development of the disease. The OVA model of 
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experimental arthritis represents an early timepoint of RA and models the initial 
cellular infiltrate into the joint. To monitor progression of antigen specific responses, 
a model of relapsing arthritis was used – hereafter referred to as the late model of 
inflammatory arthritis. The late model of inflammatory arthritis was developed by Dr. 
Paola Conigliaro to more resemble human RA and to investigate the anti-collagen 
antibody response in a more chronic setting252. The development of the CD4+ T cell 
response has not yet been examined in this model. As such, a time point for 
chronicity needed to be established before attempting to assess CD4+ T cell 
clonality in this late setting. 
Mice display clinical signs of disease for greater than 3 weeks in this late model of 
inflammatory arthritis252. As such, the T cell response was examined within that time 
frame at 4, 11, and 17 days (referred to as D4, D11, and D17 respectively) after 
secondary periarticular challenge (Figure 3-1 and Chapter 2 Figure 2-2 for 
details). A number of controls needed to be included to evaluate whether the 
inflammation and cell accumulation observed is due to the 2nd periarticular challenge 
with antigen (see section 2.2.7 for clarification). In this chapter I will refer to the 
experimental group that received a 2nd periarticular challenge of HAO in IFA as “late 
inflamed”. 
Cell numbers were determined at all three time points in late inflamed pLNs and 
joints and controls. The pLNs of late inflamed mice displayed the highest number of 
total, endogenous CD4+ T cell, and endogenous CD44hi CD4+ T cell numbers at 
all three time points compared to controls (Figure 3-9 A-C). The same was 
observed in late inflamed joints, but only at D11 and D17 (Figure 3-9 D-F). This 
increase in total and endogenous CD4+ T cell numbers is sustained by D17 in pLNs 
(Figure 3-10 A and B) and joints (Figure 3-10 D and E) of the late inflamed group, 
while the control groups show an overall decrease in cell numbers by D17. This data 
therefore suggests that D17 is the best timepoint to use to determine changes in 
CD4+ T cell clonality with the knowledge that the cells retained at this point are 
assumed to be antigen specific This timepoint will be referred to as the late timepoint 
from now on. 
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Figure 3-9 - Number of cells from pLNs and joints of late inflamed mice and controls within 
each timepoint 
The late model of inflammatory arthritis was induced as described in methods. Cells were isolated 
from both pLNs and joints at 4 (D4), 11 (D11), or 17 (D17) days after secondary challenge. Groups 
are named depending on the 1st and 2nd periarticular challenges represented as 1st periarticular 
immunisation/2nd periarticular immunisation: late inflamed (HAO/HAO+IFA); non-specific (NS) 
inflammation (HAO/IFA+PBS); primary (PBS/HAO); memory (HAO/PBS), and baseline (PBS/PBS). 
Number of A) total cells, B) endogenous CD4+ T cells, and C) endogenous CD44hi, CD4+ T cells 
from mouse pLNs  and number of D) total cells, E) endogenous CD4+ T cells, and F) endogenous 
CD44hi CD4+ T cells from joints . Graphs represent 1 experiment with n=5 for the late inflamed 
group, n=4 for the NS inflammation group, primary, and memory groups, and n=3 for the baseline 
group at each timepoint. Groups were compared using 2 way ANOVA Data presented as mean ±SD. 
Stars represent the following p values: * <0.05; ** <0.01; *** <0.001; **** <0.0001 
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Figure 3-10 - Number of cells from pLNs and joints from late inflamed mice and controls 
across three timepoints. 
The late model of inflammatory arthritis was induced as described in methods. Cells were isolated 
from both pLNs and joints 4 (D4), 11 (D11), or 17 (D17) days after secondary challenge. Groups are 
named depending on the 1st and 2nd periarticular challenges represented as 1st periarticular 
immunisation/2nd periarticular immunisation: late inflamed (HAO/HAO+IFA); non-specific (NS) 
inflammation (HAO/IFA+PBS); primary (PBS/HAO); memory (HAO/PBS), and baseline (PBS/PBS). 
Number of A) total cells, B) endogenous CD4+ T cells, and C) endogenous CD44hi, CD4+ T cells 
from mouse pLNs and number of D) total cells, E) endogenous CD4+ T cells, and F) endogenous 
CD44hi CD4+ T cells from joints. Graphs represent 1 experiment with n=5 for the late inflamed group, 
n=4 for the NS inflammation group, primary, and memory groups, and n=3 for the baseline group at 
each timepoint. Groups were compared using 2 way ANOVA Data presented as mean ±SD. Stars 
represent the following p values: * <0.05; ** <0.01; *** <0.001; **** <0.0001 
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 Assessment of CD4+ T cell clonality in the OVA model of 
experimental arthritis 
In the previous section I established the OVA model of experimental arthritis as well 
as the conditions in which changes in CD4+ T cell clonality can be attributed to joint 
associated antigen driven responses. In addition, I have established a timepoint to 
investigate how antigen specific responses change with the progression of 
experimental arthritis. Now, CD4+ T cell clonality can be assessed in these contexts 
and evidence for the presence of antigen specific responses in the early phases of 
experimental arthritis, as well as their development over time, can be evaluated. 
3.2.2.1 Oligoclonal presence of CDR3β regions in the endogenous CD4+ T cell 
population in arthritic mice  
As an increase in endogenous CD4+ T cells was observed in section 3.2.1.2, the 
question that followed is whether there is a restriction in clonality in the CD4+ T cells 
present in the affected joints and pLNs. This in turn would indicate the presence of 
antigen specific responses at the early stages of experimental arthritis. CD4+, 
CD44hi T cell were isolated from joints and pLNs and were sorted via FACS as 
described in methods. cDNA was collected from these cells and a PCR was 
performed to determine the diversity of CDR3β regions in the antigen experienced 
CD4+ T cell repertoire from pLNs and joints (Figure 3-11 A and B). The CDR3β 
region, as mention in section 1.2.1.2 of the introduction, is the most diverse region 
of the TCR and is unique to each T cell clone220. As a control, PCR was also 
performed on CD44hi cells isolated from the pLNs of a naïve C57BL6 mouse 
(Figure 3-11 C). As expected, the CD44hi cohort in the naïve C57BL6 mice 
displayed a polyclonal phenotype, whereby all Vβs are represented and multiple 
CDR3β bands can be seen per Vβ chain. In the CD44hi cells isolated from the joints 
and pLNs of arthritic mice, a clear reduction in the number of CDR3βs per Vβ chain 
is observed, but each Vβ chain is represented apart from Vβ13 in both joint and 
pLN, and Vβ17 in the joint. This reduction in CDR3β regions, or oligoclonality, 
suggests a bias in the CD4+ TCR repertoire present in the joint and the pLN and 
could be an indication antigen specific retention, recruitment, or expansion at the 
tissue site. 
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Figure 3-11 - CDR3β amplification of endogenous CD44hi, CD4+ T cells in HAO challenged 
and C57BL6 mice. 
TCR diversity in HAO challenged mice was determined by CDR3β analysis of CD44hi, CD4+ T cells. 
A) CD44hi, CD4+ T cells from HAO challenged mouse pLNs and B) joints were sorted by FACS. C) 
CD44hi, CD4+ T cells from C57BL6 pLNs were also isolated as controls. CDR3β analysis was done 
by end point PCR using the SuperTCRExpress Mouse T Cell Receptor Vβ Repertoire Clonality 
Detecting Kit from BioMed Immunotech. Endogenous CD4+ T cells were pooled for each PCR (Naïve 
C57BL6 n=3; pLN HAO n=20; joint HAO n=20). 
3.2.2.2 Increased number and frequency of the Vβ4 TCR chain in HAO 
challenged mice 
The PCR performed was an end point PCR, which can only provide semi 
quantitative information on the presence of a given clone rather than the degree to 
which it is represented within the population. As a result, I opted to determine 
frequencies of cells with a given Vβ TCR chains via flow cytometry. This enabled 
me to determine the degree each Vβ chain contributes to the CD44hi repertoire of 
CD4+ T cells. Although this approach does not provide clonal information per se, it 
still highlights biases in Vβ usage, implicating preferential antigen driven 
recruitment, retention, or expansion of endogenous CD4+ T cells. The pLNs of HAO 
challenged mice showed an increase in the number of CD4+ T cells for 
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approximately half of the Vβ chains examined compared to PBS challenged mice, 
while in the joint, Vβ4 is the only chain that is present in significantly higher numbers 
than PBS challenged mice (Figure 3-12 A and B). This is further demonstrated 
when looking at the percentage contribution of each Vβ chain to the CD44hi 
repertoire (Figure 3-12 C and D); in both pLNs and joints of HAO challenged mice 
Vβ4 is present at a higher frequency compared to PBS controls. One thing to 
consider is how any bias in Vβ chain frequency in the naïve repertoire contributes 
to the CD44hi pool of cells and whether this influences the increases observed in 
HAO challenged mice. To address this, Vβ chain frequencies were determined in 
the naïve repertoire in pLNs. The naïve repertoire was in fact found to have unequal 
representation of TCR Vβ chains in both HAO and PBS challenged mice, with Vβ14 
contributing the most, and Vβ9 the least (Figure 3-13). Vβ4 is present at a high 
frequency in the naïve repertoire, but not higher than Vβ14, which demonstrates 
that the naïve repertoire does not influence the increase in Vβ4 usage in HAO 
challenged mice Together with the increase in cell number and frequency, this data 
indicates that Vβ4 specifically accumulates in HAO challenged mice. 
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Figure 3-12 - Number and frequency of CD44hi, CD4+ T cells expressing a given Vβ TCR chain 
in pLNs and joints of HAO and PBS challenged mice. 
Cells were isolated from both foot joints and respective pLNs of HAO and PBS challenged mice and 
Vβ chains were identified by flow cytometry as described in methods. Number of CD44hi, CD4+ T 
cells with the outlined Vβ TCR chains isolated from A) pLNs, and B) joints from the same mice, and 
percentage of Vβ TCR chains in C) pLNs and D) joints. Bars represent 3 experiments with n=5 for 
each of HAO and PBS groups (total n=15), except for Vβ2, 12, 5, 13, 11, and 6 where total n= 14 
and 13 for the HAO and PBS groups respectively. Vβ groups were compared using 2 way ANOVA. 
Bars represent mean ±SD. Stars represent the following p values: * <0.05; ** <0.01; *** <0.001; **** 
<0.0001 
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Figure 3-13 - Percentage contribution of the Vβ TCR chains to the CD44lo, CD4+ T cell subset 
in pLNs of  HAO and PBS challenged mice. 
Frequencies of Vβ TCR chains from the CD44lo, CD4+ T cell repertoire were determined in HAO 
and PBS challenged mice. Bars represent 3 experiments with n=5 for each of HAO and PBS groups 
(total n=15), except for Vβ2, 12, 5, 13, 11, and 6 where total n=14 and 13 for the HAO and PBS 
groups respectively. Groups were compared using 2 way ANOVA. Bars represent mean ±SD. Stars 
represent the following p values: * <0.05. 
3.2.2.3 Vβ chain usage is due to HAO challenge and is associated with the 
joint 
Part of the model involves using Freund’s adjuvant (CFA) in combination with OVA 
protein as the primary OVA challenge. One thing to consider is whether the 
observed enrichment is in fact due to the induction of arthritis and not an artefact of 
the model i.e. the observed Vβ chain usage is simply the response to mycobacterial 
antigens in the CFA component. To verify this, pLNs were isolated from the PBS 
controls of the OVA arthritis model as well as naïve C57BL6 mice, and their Vβ 
profiles were compared (Figure 3-14 A). The data of each mouse is presented as 
a ratio of CD44hi cells to CD44lo to normalise any biases in the number of cells with 
a given Vβ chain introduced by the naïve repertoire. No significant accumulation of 
Vβ chains in the PBS mice were observed when compared to C57BL6 mice, 
indicating that the accumulation of Vβ chains in the HAO challenged mice is due to 
HAO challenge. This accumulation in the joint does not appear to reflect a systemic 
change as no Vβ chains were enriched in spleens of HAO and PBS challenged mice 
(Figure 3-14 B). 
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Figure 3-14 - Vβ chain enrichment in C57BL6 mouse pLNs and spleens of HAO and PBS 
challenged mice 
Enrichment was determined by dividing the number of CD44hi, CD4+ T cells of a particular Vβ chain 
by the respective CD44lo, CD4+ T cell cohort (CD44hi:CD44lo) isolated from pLNs per mouse. This 
ratio of CD44hi:CD44lo cells were compared between A) PBS challenged mice and unchallenged 
(naïve) C57BL6 pLNs, B) spleens of HAO and PBS challenged mice. For figure A, bars represent 3 
experiments with n=3 and 5 for the C57BL6 and PBS groups respectively. For figure B, bars 
represent 1 experiment with n=5 for both the HAO and PBS challenged groups. Groups were 
compared using 2 way ANOVA. Bars represent mean ±SD. Stars represent the following p values: 
**** <0.0001; ns: not significant. 
3.2.2.4 Accumulation of endogenous Vβ4 CD4+ T cells is associated with an 
antigen driven response 
As mentioned in section 3.2.1.3, antigen experienced CD4+ T cells are capable of 
infiltrating and accumulating in tissues in the absence of their cognate 
antigen191,193,194. An enrichment of Vβ chains, in particular Vβ4, was found in HAO 
challenged mice and whether this enrichment is driven by antigen specificity or is a 
consequence of an inflammatory environment is unknown. Using the conditions 
established in section 3.2.1.3, mice were challenged with either HAO, PBS, LPS 
and the Vβ profile of the joints and pLNs was compared to address the influence of 
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an inflammatory environment to the Vβ enrichment observed. In both the pLN and 
joint, the number and frequency of endogenous CD4+ T cells with the Vβ4 TCR 
chain is significantly higher than in LPS challenged mice (Figure 3-15 A-D), 
suggesting that Vβ4 accumulation is associated with an antigen driven response. 
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Figure 3-15 - Number an frequency of CD44hi, CD4+ T cells expressing a given Vβ TCR chain 
from joints and pLNs of HAO, PBS, and LPS (25µg) challenged mice. 
Cells were isolated from both foot joints and respective pLNs of HAO, PBS, and LPS (25µg) 
challenged mice. Transferred cells were identified using the CD45.1 marker and were excluded from 
analysis, leaving only the endogenous CD4+ T cells. Vβ chains were identified by flow cytometry as 
described in methods. Number of CD44hi, CD4+ T cells with the outlined Vβ TCR chains isolated 
from A) pLNs, and B) joints from the same mice, and frequency of Vβ chains isolated from C) pLNs, 
and D) joints. Graphs represent 2 experiments with n=11 for the HAO groups, and n=10 for the PBS 
and LPS groups. Groups were compared using 2 way ANOVA. Bars represent mean ±SD. Stars 
represent the following p values: * <0.05; ** <0.01; *** <0.001; **** <0.0001. 
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3.2.2.5 Vβ4 usage is partly associated with joint derived antigens  
So far, it has been demonstrated that Vβ4 usage is due to HAO challenge and 
associated with an antigen driven response. Whether the antigen recognised is joint 
tissue specific, OVA specific, or both remains unknown. One approach to narrow 
down the antigens the Vβ4 family may recognise is to immunise a site other than 
the joint, such as the ear as mentioned in section 3.2.1.4. As with the pLNs and 
joint, Vβ chain numbers and frequencies were determined in the scLNs and ears to 
assess the presence of any biases in Vβ use (Figure 3-16). In both HAO challenged 
scLNs and ears, endogenous CD4+ T cells with the Vβ4 TCR chain were present in 
the highest numbers (Figure 3-16 A and B) and frequencies (Figure 3-16 C and 
D) compared to PBS controls, similar to that observed for HAO challenged pLNs 
and joints. But when comparing Vβ chain frequencies between the two HAO 
challenged tissues, all Vβ chains are present in similar frequencies between those 
sites, except for Vβ4, which is present at a higher frequency in the joint compared 
to the ear (Figure 3-17 and Figure 3-18 B). These observations indicate that the 
Vβ4 family may contain clones that specifically recognise joint derived antigens. 
However, it is important to note that despite the significant increase in Vβ4 frequency 
in the inflamed joint compared to the ear, the overall Vβ usage pattern is in fact 
similar between the two sites. This indicates that antigen specific responses 
between these two sites may be similar.  
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Figure 3-16 - Number and frequency of CD44hi, CD4+ T cells with the outlined Vβ TCR chains 
from scLNs and ears of HAO and PBS challenged mice. 
Cells were isolated from both ears and respective scLNs of HAO and PBS challenged mice and Vβ 
chains were identified by flow cytometry as described in methods. Number of Vβ TCR chains in 
CD44hi, CD4+ T cells isolated from A) scLNs, and B) ears from the same mice, and percentage of 
Vβ TCR chains in C) scLNs, and D) ears of HAO and PBS challenged mice. For Vβs 5-13 graphs 
represent 3 experiments with n=15 for the HAO groups, n=15 (Vβs 6, 11, and 13), and n=14 (Vβs 5 
and 12) for the PBS groups. For Vβs 3 and 4, graphs represent 2 experiments with n=10 and 9 for 
the HAO and PBS groups respectively. For Vβ14, graphs represent 1 experiment with n=5 for each 
of the HAO and PBS groups. Vβ groups were compared using 2 way ANOVA. Bars represent mean 
±SD. Stars represent the following p values: ** <0.01; *** <0.001; **** <0.0001 
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Figure 3-17 - Percentage contribution of the Vβ TCR chains to the CD44hi, CD4+ T cell subset 
in HAO challenged mouse ears, joints, and respective dLNs. 
Cells were isolated from both HAO challenged ears and joints and their respective scLNs and pLNs. 
Vβ chains were identified by flow cytometry as described in methods. Percentage of Vβ TCR chains 
in CD44hi, CD4+ T cells isolated from A) scLNs and pLNs and B) ears and joints from HAO 
challenged mice. For Vβs 5-13 graphs represent 3 experiments with n=15 for ears and scLNs and 
n=13 for joints and pLNs. For Vβs 3 and 4, graphs represent 2 experiments with n=10 ears and 
scLNs and n=8 for joints and pLNs. For Vβ14, graphs represent 1 experiment with n=5 for ears, 
scLNs, joints, and pLNs. Vβ groups were compared using 2 way ANOVA. Bars represent mean ±SD. 
Stars represent the following p values: **** <0.0001 
 
Figure 3-18 - Percentage contribution of the Vβ4 TCR chain to the CD44hi, CD4+ T cell subset 
in ears, joints, and dLNs of HAO and PBS challenged mice. 
Cells were isolated from both HAO and PBS challenged ears and joints and their respective scLNs 
and pLNs. Vβ4 was identified by flow cytometry as described in methods. Percentage of the Vβ4 
TCR chain in CD44hi, CD4+ T cells isolated from A) scLNs and pLNs and B) ears and joints from 
HAO and PBS challenged mice. Graphs represent 2 experiments with n=10 for HAO and PBS 
challenged ears and scLNs and n=8 and 5 for joints and pLNs challenged with HAO and PBS 
respectively. Groups were compared using one way ANOVA. Bars represent mean ±SD. Stars 
represent the following p values: * <0.05; ** <0.01; **** <0.0001; ns: not significant. 
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3.2.2.6 Inflamed joints at the late timepoint continue to display a biased 
accumulation of Vβ4 CD4+ T cells while the pLNs at the same 
timepoint do not 
The data suggests that the Vβ4 TCR chain dominates the response in this model 
and may be associated with joint derived antigens. As this model represents an early 
arthritic time point, it would be interesting to see how the response develops with 
time and disease chronicity, and how much the initial response, namely Vβ4, 
contributes to the progression of the disease. Using the late model of experimental 
arthritis established in section 3.2.1.5, Vβ use was assessed and compared to the 
enrichment observed at the early timepoint to determine how the antigen specific 
responses evolves with disease progression. 
The number of cells with a certain Vβ chain remined unchanged between pLNs at 
the early and late timepoints, except for Vβ6, which increased in late inflamed pLNs 
(Figure 3-19 A). This is reflected when looking at frequencies of the Vβ chains, 
where Vβ6 also appears at a higher frequency in late pLNs. (Figure 3-19 B). 
Interestingly, Vβ4 appeared at a lower frequency in pLNs at the late timepoint 
compared to pLNs at the early timepoint, indicating that number of cells with the Vβ6 
are indeed increasing and therefore suggests skewing of the endogenous CD4+ T 
cell antigen specific response in the pLN. In contrast, the late inflamed joints have 
a significantly higher number of CD4+ T cells with the Vβ4 TCR chain compared to 
HAO challenged joints at the early timepoint, while the remainder of the Vβ chains 
were present in similar numbers (Figure 3-19 C). The frequencies of the Vβ chains 
remained unchanged between inflamed joints from the early and late timepoints 
(Figure 3-19 D). This “switch” in Vβ usage in the late inflamed pLNs indicates an 
evolution in the inflammatory response and a possible change in the antigens being 
recognised in late inflamed pLNs compared to those in early pLNs. In contrast, the 
joints seem to maintain the same Vβ usage as their early counterparts, suggesting 
that the cells may be recognising the same antigens that are present in the early 
stage. The continued increase in Vβ4 numbers in the joint though, is evidence that 
cells with this TCR chain are specifically retained with disease progression and may 
suggest that the Vβ4 family contains the CD4+ T cell clones that initiate and 
propagate inflammatory arthritis. The data also suggests divergent endogenous 
CD4+ T cell responses between the pLN and the inflamed joint with the progression 
of experimental arthritis. Whether this divergence is maintained, or whether the joint 
will eventually mirror the clonality observed in the pLN remains to be elucidated.  
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Figure 3-19 - Number and frequency of CD44hi, CD4+ T cells with the outlined Vβ TCR chains 
from pLNs and joints of acute and chronic arthritic mice. 
Cells were isolated from both pLNs and joints of acute and chronic (D17 after secondary HAO 
challenge) arthritic mice and Vβ chains were identified by flow cytometry as described in methods. 
Number and frequency of CD44hi, CD4+ T cells with the outlined Vβ TCR chains isolated from pLNs 
(A and B) and joints (C and D). Graphs represent 2 experiments with n=10 and 11 for the chronic 
and acute groups respectively. Each dot represents one mouse. Vβ groups were compared using 2 
way ANOVA. Bars represent mean ±SD. Stars represent the following p values: ** <0.01; **** 
<0.0001; ns: not significant 
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 Discussion 
The early events leading to RA pathogenesis remain poorly understood. More 
specifically, the roles that antigen specificity and CD4+ T cells play in early stages 
of disease are also unknown. The main objective of this chapter was to provide 
evidence for the presence of antigen specific responses in the early phases of 
experimental arthritis, as this this has important implications for the development of 
antigen specific tolerogenic therapies. To investigate the development of these 
antigen specific responses, the OVA experimental arthritis model - developed by 
Maffia et. al.140- was established to assess antigen associated changes CD4+ T cell 
clonality as well as the influence of an inflammatory environment and joint derived 
antigens to the CD4+ T cell repertoire. Once this was achieved, the model was also 
adapted to investigate how CD4+ T cell clonality changes with the progression of 
experimental arthritis. The CD4+ T cell clonal response was monitored by assessing 
biases in TCR Vβ chain use, as a bias would indicate the presence of antigen 
specific responses. Overall, a bias in Vβ chain usage was found early after the 
initiation of experimental arthritis, with the Vβ4 TCR chain being present in the 
largest numbers and highest frequency in inflamed mouse pLNs and joints at the 
early timepoint, demonstrating preferential accumulation of CD4+ T cells with the 
Vβ4 TCR chain in these tissues. Vβ4 was also found to be associated with an 
antigen driven response,  and increases in number with disease progression. 
Together, this data shows that this family may contain clones that initiate and 
propagate inflammatory arthritis and provides evidence for the presence of an 
antigen specific response in the early phases of disease. 
The model was successful in inducing local inflammation and CD4+ T cell 
accumulation at articular sites where HAO was administered. Moreover, 
endogenous CD4+ T cells were present at much higher numbers than transferred 
OT-II cells, implying that endogenous CD4+ T cells could be playing a greater role 
in perpetuating the inflammatory response by recognising antigens in addition to 
OVA. Indeed, it has been shown that when a high number (approximately 1x10^6) 
of naïve OT-I cells are transferred into C57BL6 mice, the endogenous CD8+ T cell 
response to OVA is inhibited205. Similarly, a large monoclonal naïve or effector CD4+ 
T cell population can inhibit proliferation of naïve CD4+ T cells with the same 
TCR206.  
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Evidence of antigen experienced CD4+ T cells in infiltrating inflamed sites without 
the need of their cognate antigen has been reported in the OVA model used here191 
and in RA patients100,193. An inflamed site can therefore obscure any evidence of 
antigen specific accumulation of CD4+ T cells. Considering this, an LPS challenge 
was administered to assess the non-antigen induced inflammatory accumulation of 
CD4+ T cells in the inflamed joint. LPS challenge was sufficient in causing an influx 
of cells into inflamed pLNs and joints, but the number of total and antigen 
experienced endogenous CD4+ T cells were comparable to PBS controls. This is 
not unusual as LPS is known to recruit innate immune cells such as DCs 
macrophages and neutrophils261 and are likely to make up the majority of the 
infiltrate in the LPS inflamed joint. It is important to note that although the number of 
CD4+ T cells is comparable to controls, the composition of the repertoire may not 
be the same. Similarly, how much the increase in endogenous CD4+ T cells in HAO 
challenged pLNs and joints can be attributed to antigen specific responses is 
unknown. Comparing the CD4+ T cell repertoire from LPS and HAO challenged 
mice will therefore elucidate how much of the response is antigen specific. 
The model was also adapted to investigate the contribution of joint derived antigens 
to the clonality of the CD4+ T cell infiltrate. Mouse ears were immunised with HAO 
and the CD4+ T cells were isolated from ears and ear draining scLNs. The total and 
antigen experienced number of endogenous CD4+ T cells is greater in HAO 
challenged ears and scLNs than PBS controls, mirroring the observations seen in 
HAO challenged pLNs and joints. This would indicate that HAO challenged in the 
ear induces similar inflammatory responses observed in the joint. 
Examining the CD4+ T cell infiltrate in these contexts allows for the accurate 
assessment of antigen specific CD4+ T cell responses in inflamed joints and pLNs 
at an early timepoint when conditions are most permissive for developing 
autoreactivity to articular antigens. Observing any changes in the evolution of these 
antigen specific responses can therefore be attributed to joint derived antigen 
specific responses. 
The late model of experimental arthritis was developed to establish a time point 
representing chronicity and to monitor the evolution of the initial articular response 
observed. The late timepoint – 17 days after the second periarticular challenge – 
was found to be the best timepoint of the late model, as the difference in 
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endogenous CD4+ T cell number was greatest between the late inflamed groups 
than the rest of the controls. This would indicate that the cells present at this 
timepoint are accumulating due to an antigen specific response rather than being 
artefacts of general inflammation. The bias seen in Vβ usage at this timepoint would 
therefore more reflect an antigen driven bias rather than a bystander or 
“background” response (see section 1.3.3.1 of the introduction), which has been 
demonstrated in several autoimmune diseases, and implicated in RA46,100,101. This 
endogenous CD4+ T cell population was also maintained in the late inflamed groups 
with time, while the numbers decreased in the control groups over time. This further 
indicates that the response observed is more likely antigen associated. One thing 
to note is the reduction in the number of antigen experienced cells at this timepoint 
compared with both the early and intermediate time points. CD44hi is a receptor of 
extra cellular matrix proteins and is found on a variety of leukocyte populations267. 
It plays many important roles in T cell survival, migration, and proliferation, and is 
used as a marker of antigen stimulated memory T cells268,269. The reduced number 
of CD44hi cells at the late timepoint is unexpected, considering that the maintained 
endogenous CD4+ T cell accumulation is considered to be a result of antigen 
recognition. A reduction in CD44hi cells could be a result of cell death, although that 
was ruled out considering the number of endogenous CD4+ T cells is not reduced. 
Furthermore, there is evidence for CD44 playing a role in T cell survival270. A 
possible explanation is the downregulation of CD44 once the cells are retained in 
the tissue. CD44 is involved in T cell extravasation into tissues, but it is not 
necessary270, and T cells can be retained in tissues via CD44 independent 
mechanisms, such as selectins271,272. Therefore, CD44 expression could be 
dependent on the other roles it plays. It could simply be that number of CD44 
molecules are reduced due cleavage of the molecule, which is a mechanism used 
by cancer cells to regulate migration273. The late model is a resolving model, and 
the mice do recover. So, reduction of CD44 could reflect the model resolving and 
that the T cells are just getting ready to leave the site. It is clear that investigating 
the biological function of these cells is necessary in understanding the role the play 
in propagating the inflammatory response. 
The PCR data demonstrated CDR3β oligoclonality in arthritic pLNs and joints, while 
maintaining broad Vβ chain usage. This is consistent with observed clinical data 
where an oligoclonal CD4+ T cell repertoire was found in the synovia of RA 
patients46. It is important to note that a substantial amount of DNA was required for 
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the CDR3β PCR and samples from 20 HAO challenged mice were pooled to obtain 
enough DNA. So, the diversity observed may have resulted from multiple private 
responses as opposed to the presence of a diverse public response (see 
introduction section 1.2.1.3). It has been shown that mice immunised with OVA 
display private responses but have some CDR3β sequence similarity274. In addition, 
the CD4+ T cell response was found to be private across RA patients46,143,275. 
In order to overcome the limitations of PCR, Vβ chain usage was determined from 
individual mice using flow cytometry. An overall increase in Vβ chain use was found 
in HAO challenged pLNs and joints and the Vβ4 TCR family was present in the 
largest numbers and frequency in these tissues. It is important to note that 
approximately 50% of the antigen experienced repertoire remains unaccounted for 
in terms of Vβ chain usage – as reagents for only 13 out of the 22 Vβ TCR mouse 
chains were available. Therefore, the presence of other dominant chains cannot be 
ruled out. Other Vβ TCR chains were present at significantly higher numbers than 
PBS controls in pLNs - namely Vβ2, 3, 6, 11, and 14, while other remained 
unchanged. This disproportionate increase again reflects a change in Vβ usage 
depending on the challenge type and also reflects narrowing of the response, 
confirming the oligoclonality observed using PCR. 
On examining Vβ use in LPS challenged mice, the results show that LPS contributes 
to the accumulation of several Vβ chains, but Vβ4 is the only chain associated with 
an antigen driven response. This highlights the possibility of an antigen specific 
response playing an early role in the accumulation of CD4+ T cells in the inflamed 
joint, which may create an ideal inflammatory environment for other cells to infiltrate. 
Indeed, HAO challenge results in a larger influx of endogenous CD4+ T cells than 
LPS challenged mice. It also reiterates how general inflammation can bring cells 
into the joint in a non-antigen specific manner. 
Vβ4 is also present in the largest numbers and the highest frequency in joints and 
ears of HAO challenged mice compared to their respective PBS controls. However, 
the percentage contribution of cells expressing Vβ4 is higher in HAO challenged 
joints than in the ear, suggesting that cells with the Vβ4 TCR chain are retained at 
a higher degree in the joint than the ear, despite the increased cell number observed 
in the ear. This preferential recruitment in the joint may suggest that the Vβ4 family 
contains clones that possibly recognise joint antigens. 
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The fact that the Vβ4 chain is also present in large numbers and in the highest 
frequency in the ear suggests that the Vβ4 family also contains CD4+ T cells clones 
that recognise OVA, proteins common to the joint and ear, or both. A more direct 
way of determining what these cells may recognise is to isolate them and re-
stimulate them with joint derived antigens and determine their cytokine production. 
This experiment has been carried out and will be elaborated on in Chapter 5. 
The data presented here demonstrates that the initial articular response is restricted 
and could be initiated by the recognition of joint associated antigens. Monitoring the 
evolution of the initial responses in this experimental model could help elucidate the 
events that lead to development of the responses observed in RA. On comparing 
Vβ usage between the early and late models, it was found that late inflamed pLNs 
displayed a different response to early, HAO challenged pLNs, while the joints 
seemed to maintain the same Vβ usage with disease progression. The switch in Vβ 
frequency between pLNs at the early and late timepoints may indicate the 
beginnings of other responses and may reflect epitope spreading, a phenomenon 
whereby both B and T cells react to epitopes other than the dominant epitope of a 
protein52. In addition, the reduced Vβ4 frequency and the maintained cell number 
could indicate the influx of cells with other Vβ chains that have not been examined 
in these experiments. The joints on the other hand show an increased accumulation 
of cells with the Vβ4 TCR chain in the late model, while the frequency of the Vβ 
chains remain unchanged. Again, this indicates that other cells with other Vβ chains 
may be accumulating in the joint. The degree of the changing response cannot be 
fully appreciated as only a subset of the Vβ chains were examined 
The different responses observed between the lymph node and joint may indicate 
that changes in antigen responses occur in the lymph node before they are reflected 
in the joint. Indeed, studies have shown changes in the pre-articular lymph node 
occur before any clinical manifestations are observed in the joint139. Whether these 
changes in the model reflect epitope spreading (see section 1.3.3.1 of introduction) 
and a continued propagation of proinflammatory responses or the development of 
regulatory responses is unknown, as the function of these cells has not been 
examined. Finally, the increasing number of cells with the Vβ4 TCR chain in the joint 
suggest that this family contains CD4+ T cell clones that initiate and propagate 
inflammatory arthritis.  
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Detecting biases in Vβ usage by flow cytometry allows for a quick assessment of 
the changes occurring due to antigen specific responses and has proven its 
usefulness in elucidating the events shaping the oligoclonal CD4+ T cell repertoire 
in this model of early arthritis. The drawback with this technique comes with the 
assessment of small or rare changes in the repertoire, as flow cytometry is more 
accurate for assessing large changes in population frequencies276–278. In addition, 
approximately 50% of the Vβ chains remain unaccounted for due to lack of available 
reagents.  
It is important to remember that biases in Vβ chain use are only a proxy for clonality 
and cannot provide information on a clonal level. In order to find the actual clones 
that initiate and propagate arthritis, a technique with higher resolution is required. 
The CDR3β sequence of the TCR, which lies at the interface of the VDJ regions of 
the β chain, is the most variable region of the TCR and is the region that confers 
peptide specificity220. Each CD4+ T cell clone will therefore have a CDR3β 
sequence specific to their cognate peptide. Next generation sequencing (NGS) 
methods can be utilised to sequence CDR3β regions of T cells and the contribution 
of individual clones can be detected in different tissue sites279. In order to fully 
appreciate the evolution of the articular response, NGS methods were used in the 
model to more accurately detect clonal CD4+ T cell dynamics between the pLN and 
joint and will be discussed in the following chapter. 
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Chapter 4 A detailed examination of the evolution 
of CD4+ T cell clonality in the OVA model of 
experimental arthritis 
 Introduction 
In the previous chapter CD4+ TCR clonality was determined using PCR and flow 
cytometry techniques which targeted the Vβ region of the TCR. Evidence was found 
to support the presence of an antigen specific response in the early phases of 
inflammatory arthritis which may represent autoreactive T cell clones that may be 
involved in initiating and/or propagating the disease. In this chapter, we employed 
next generation sequencing (NGS) techniques279 to investigate the evolution of 
CD4+ T cell clonality in the early and late models of OVA mediated inflammatory 
arthritis. (see sections 2.7 and 2.8, and Figure 4-2). 
Enrichment of specific T cell clones within the repertoire may represent previous 
encounters with specific antigens, and so, provide historical evidence of antigen 
specific responses that have occurred throughout an individual’s lifetime. As such, 
T cell repertoires have been examined to evaluate these antigen specific responses 
which in turn would mirror progression or cessation of diseases23,42,280. Indeed, TCR 
repertoire analysis has been used to monitor the development of leukaemia42, 
coeliac disease23, and systemic lupus erythematosus281. With the advent of NGS 
methods, in depth analyses can be made of the TCR repertoire and the expansion 
of individual clones can be detected and tracked23,46. Several clinical studies have 
utilised NGS methods to detect expanded clones in RA patients at different stages 
of disease46 and have attempted to functionally characterise them as well282. To 
date, there have not been any studies – clinical or otherwise – investigating the 
spatiotemporal dynamics of CD4+ T cells between arthritic tissues and their draining 
lymph nodes. Understanding these dynamics will provide further insight into the 
development of the antigen specific response in RA and determine the role 
autoreactive CD4+ T cells play in the initial phases of the disease and whether they 
create a permissive environment for other CD4+ T cells to enter. As noted in section 
1.5.1 of the introduction, understanding the development of autoreactive responses 
in RA is paramount for the development of more effective tolerogenic therapies.  
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T cell repertoires can be characterised by the number of species or clones that make 
up the repertoire and the degree to which each clone contributes to the repertoire, 
referred to as species richness and diversity respectively283,284. Together, these 
attributes describe the clonality of the T cell repertoire (Figure 4-1). Employing NGS 
methods described in section 2.7.3 of methods,   species richness and clonal 
diversity of the antigen experienced i.e. CD44hi CD4+ T cell repertoires were 
characterised and compared from inflamed joints and pLNs from the early and late 
model timepoints, established in Chapter 3 sections 3.2.2.2 and 3.2.2.6 and 
Figure 4-2. V-gene sequence frequencies and clonal overlap were also assessed 
to determine similarities in antigen specific responses and the degree specific 
clones were shared between early and late inflamed joints and pLNs. The 
distribution of high frequency clones was also compared between the two sites to 
assess the dynamics of these CD4+ T cell clones with the progression of 
experimental arthritis.  
Overall, I have demonstrated that the antigen experienced CD4+ T cell repertoire in 
pLNs shows enhanced clonality and diversity with disease progression, while 
inflamed joints maintain similar CD4+ T cell clonality and diversity over time. This 
enhanced diversity seen in inflamed pLNs at the late timepoint is a result of changes 
in TCR usage and may reflect changes and broadening of antigen specific 
responses. Furthermore, the number of clones shared between the inflamed pLN 
and joint was found to decrease with time, but the correlation of clones occurring at 
the highest frequency between the inflamed pLN and joint is indicative of ongoing 
migration and communication between these sites. Together these analyses 
demonstrate the presence of spatiotemporal differences in the antigen specific 
CD4+ T cell response with the progression of experimental arthritis and may reflect 
the evolution of these responses in RA. By understating the evolution of CD4+ T cell 
responses in RA, more informed decisions can be made on where and when 
antigen-specific therapeutics should be applied and will help develop more effective 
regimes to reinstate self-tolerance. 
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Figure 4-1 Illustration of species richness and diversity to describe T cell clonality 
Descriptors like species richness and diversity are used to describe the composition of T cell 
repertoires. Species richness refers to the number of species, or in this case clones, that make up a 
T cell population. The diversity takes into account the relative contribution of each clone to the 
population. In this study the D50 value is used to describe repertoire diversity and is calculated as 
described in section 2.8.1 of methods In A) the number of unique species, or species richness 
equates to 5, as illustrated by the 5 different coloured species. Each species is represented in equal 
frequencies and so this population is said to be diverse. In B) the number of unique species is also 
5, but each species is not represented equally and one species (red) makes up the majority of the T 
cell repertoire. In this case the population shows less diversity.  Together these descriptors describe 
the clonality of a T cell population. 
 
 
Figure 4-2 Illustration of early and late model timepoints. 
Early and late model timepoints, described in detail in sections 2.2.5 and 2.2.7 are adaptations of 
the OVA experimental arthritis model described in introduction section 1.6. Briefly, Th1 polarised 
OT-II cells are transferred in to C57Bl/6 mice which is followed by immunisation of OVA in CFA in 
the scruff 24 hours after the adoptive transfer. 10 days after OVA+CFA immunisation, mice are given 
a periarticular immunisation of either HAO or PBS as a control. For the early timepoint, mice are 
sacrificed 4 days after this primary periarticular challenge. For the late timepoint, HAO challenged 
mice are given a 2nd periarticular challenge 30 days after the primary HAO challenge with either HAO 
in IFA or IFA alone as a control. The mice are then sacrificed 17 days after the 2nd periarticular 
challenge. 
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 Results 
 CD4+ T cell repertoire displays enhanced clonal diversity in 
late inflamed pLNs compared to early inflamed pLNs  
In order to investigate the evolution of the CD4+ T cell response in the breach of 
tolerance model of inflammatory arthritis, endogenous antigen experienced CD4+ T 
cells i.e. excluding the transferred OT-II cells, were sorted from pLNs and joints of 
mice undergoing the early and late models of OVA mediated inflammatory arthritis. 
Total RNA was isolated from the endogenous CD4+ T cells and sent for CDR3β 
sequencing to iRepertoire Inc. Endogenous CD4+ repertoires were examined and 
compared in mouse pLN samples from early and late model timepoints. The number 
of unique CDR3β were determined to assess the number of different clones present 
in each sample in each group (Figure 4-3 D). pLNs at the late timepoint have a 
higher number of unique CDR3β sequences than their early counterparts, which is 
expected because late pLNs also have a greater overall number of endogenous 
CD4+ T cells (Figure 4-3 C). Repertoires were characterised by examining the 
degree that expanded clones contributed to the composition of each repertoire and 
a clear difference was observed between repertoire compositions of early and late 
pLNs (Figure 4-3 A and B). The top 10 clones – represented by the dark orange 
blocks in Figure 4-3 A and B – make up on average 18% of the early inflamed pLN 
repertoire, while the top 10 clones only contribute 2% to the total repertoire in late 
inflamed pLNs (Figure 4-3 E). Moreover, the biggest difference between the two 
groups is the contribution of low abundance clones (blue blocks) to the CD4+ T cell 
population from pLNs at the late timepoint, which on average make up the majority 
of the antigen experienced population in late inflamed pLNs. This is also reflected 
when looking at the diversity of each repertoire in each group; late pLNs display 
higher repertoire diversity compared to early inflamed pLN samples (Figure 4-3 F), 
which indicates that the clones in late pLNs are represented more equally, while 
early pLNs have a repertoire skewed towards high abundance clones. 
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Figure 4-3 Characterisation of the antigen experienced CD4+ T cell repertoire in early and late 
inflamed pLNs. 
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000, 10,000, 
and 100,000 most frequent clones contributing to the endogenous antigen experienced CD4+ T cell 
repertoire in A) early, and B) late inflamed pLNs per sample. C) Number of endogenous CD4+ T 
cells, D) number of unique CDR3β sequences in early and late inflamed pLNs. E) Percentage 
contribution of the top 10 most frequently occurring clones, and F) diversity indices (D50) of the 
antigen experienced endogenous CD4+ T cell repertoire in early and late inflamed pLNs. Graphs 
represent 1 experiment with n=5 for the early and late inflamed groups. Top proportion charts were 
generated using the tcR R package258. Groups were compared using unpaired Student’s t-test. Data 
presented as mean ± SD. Stars represent the following p values: *** <0.001; **** <0.0001.  
  
 
117 
 
 CD4+ T cell repertoires of early and late inflamed joints are 
comparable 
In contrast to observations between early and late inflamed pLNs, early and late 
inflamed joints display very skewed repertoires, where the top 25 clones dominate 
the antigen experienced CD4+ T cell population and make up on average 60% and 
56% of the repertoire (Figure 4-4 A and B). Interestingly, the repertoire composition 
is similar between early and late inflamed joints; the number of unique CDR3β 
sequences, the percentage contribution of the top 10 clones, and the diversity of the 
repertoires are similar (Figure 4-4 D-F), despite the late inflamed joints having a 
higher number of endogenous CD4+ T cells (Figure 4-4 C). This suggests that early 
and late inflamed joints display low repertoire diversity, having similar numbers of 
clones that are present in similar frequencies.  
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Figure 4-4 Characterisation of the antigen experienced CD4+ T cell repertoire in early and late 
inflamed joints. 
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000, and 
10,000 most frequent clones contributing to the endogenous antigen experienced CD4+ T cell 
repertoire in A) early, and B) late inflamed joints. C) Number of endogenous CD4 cells, D) number 
of unique CDR3β sequences, and E) percentage contribution of the top 10 most frequently occurring 
clones in early and late inflamed joints. F) Diversity indices (D50) of the antigen experienced 
endogenous CD4+ T cell repertoire in early and late inflamed joints. Graphs represent 1 experiment 
with n=5 for the early and late inflamed groups. Top proportion charts were generated using the tcR 
R package. Groups were compared using unpaired Student’s t-test. Data presented as mean ± SD. 
Stars represent the following p values: *** <0.001; ns: not significant. 
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 Early inflamed pLNs and joints display accumulation of 
select clones compared to PBS controls 
Due to low cell recovery from PBS pLN and joint controls, samples needed to be 
combined before being sequenced. Pooling samples changes the composition of 
the repertoire and affects T cell repertoire diversity, so comparisons of the PBS 
CD4+ T cell populations were made against artificially pooled early inflamed joint 
and pLN samples using the tcR R package and repertoire statistics were compared 
(Table 4-1). The data clearly shows that select clones accumulate in early inflamed 
pLNs and joints as the repertoire diversity in these samples is much lower compared 
with controls. This is further highlighted when comparing the number of unique 
CDR3β sequences to the number of endogenous CD4+ T cells in each of the 
groups. HAO and control pLNs have a similar number of unique CDR3β sequences 
but the total number endogenous CD4+ T cells is approximately 10 times greater in 
HAO pLNs. HAO joints have a higher number of endogenous CD4+ T cells and 
unique CDR3β sequences compared to controls, and yet low repertoire diversity. 
Together this is evidence for the selection and accumulation of a specific subset of 
clones in early inflamed pLNs and joints. 
Table 4-1 Descriptive statistics of the antigen experienced CD4+ T cell repertoire in early 
inflamed pLNs, joints, and PBS controls. 
 
 
HAO pLN samples and HAO joint samples were combined in R and compared with pooled pLN and 
pooled joint PBS samples. Number of endogenous CD4+ T cells were calculated using Flowjo. 
Number of unique CDR3β sequences and diversity indices (D50) of the antigen experienced CD4+ 
T cell repertoire of PBS samples were obtained from iRepertoire provided data and calculated for 
the combined HAO samples using iRepertoire’s iRweb data analysis guide. Data from early inflamed 
tissues represent combined data of 5 samples for each of the pLN and joint samples. Data for PBS 
samples represent pooled pLN and pooled joint samples from 3 mice. 
 Late pLNs show no differences in clonality and diversity 
compared to IFA controls  
It is widely accepted that disease progression in RA results in increased joint 
damage, and with that comes exposure of new antigens82,285 To confirm whether 
the changing composition of late pLNs reflects a change in the antigen specific 
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response, the repertoires of late inflamed pLNs were compared to pLNs from mice 
challenged with IFA alone i.e. in the absence of OVA. Looking at the overall 
repertoire composition (Figure 4-5 A and B), there is no significant difference 
between the two groups when comparing the contribution of the top 10 clones 
(average of 2% for each group) nor when comparing the contribution of the lowest 
frequency clones (Figure 4-5 E). Antigen specific responses cause an expansion of 
T cell clones, so to check for antigen driven expansion, clones with a frequency of 
two or more were compared between late pLNs and IFA controls. This frequency 
was selected as it represents the median frequency of “expanded” clones in the pLN 
PBS sample. No difference was found between the number of expanded clones 
between the two groups (p value 0.32 Welch two sample t-test). This test was 
repeated with a threshold frequency of >10, as this is the median frequency in the 
joint PBS sample. Again, no difference was found between the number of expanded 
clones in late pLNs and IFA controls (p value 0.23 Welch two sample t-test). 
Moreover, both groups have the same number of endogenous CD4+ T cells, similar 
number of unique CDR3β sequences, and have repertoires of similar diversities 
(Figure 4-5 C, D, and F). Together this data suggests an absence of expansion or 
accumulation of antigen specific CD4+ T cell specific clones in late pLNs and the 
changes observed are probably due to a chronic inflammatory environment. 
Whether the same observations can be said about late inflamed joints needs to be 
determined, and it is what I sought to do next. 
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Figure 4-5 Characterisation of the antigen experienced CD4+ T cell repertoire in late inflamed 
pLNs and IFA control pLNs. 
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000,10,000, 
and 100,000 most frequent clones contributing to the endogenous antigen experienced CD4+ T cell 
repertoire in A) late inflamed pLNs, and B) IFA challenged mouse pLNs. C) Number of endogenous 
CD4+ T cells in late inflamed and IFA challenged mouse pLNs. D) Number of unique CDR3β 
sequences in the CD44hi, endogenous CD4+ T cell repertoires of late inflamed pLNs and IFA 
controls. E) Proportion of the least frequently occurring clones (dark blue in top proportions charts A 
and B) in late inflamed and IFA challenged pLNs. F) Diversity indices (D50) of the antigen 
experienced endogenous CD4+ T cells from late inflamed and IFA administered mouse pLNs. 
Graphs represent 1 experiment with n=5 and 3 for the late inflamed pLNs and control IFA challenged 
pLNs respectively. Top proportion charts were generated using the tcR R package. Groups were 
compared using unpaired Student’s t-test. Data presented as mean ± SD. ns: not significant. 
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 Late inflamed joints display antigen associated accumulation 
of CD4+ T cells compared to IFA controls 
To address whether the observed clonality of the CD4+ T cell repertoire from 
inflamed joints at the late timepoint is due to a prolonged inflammatory environment 
or is due to antigen specific responses, I compared the repertoires of CD4+ T cell 
populations isolated from antigen inflamed joints at the late timepoint to joints 
inflamed without the presence of antigen i.e. with IFA only (Figure 4-6 A and B). 
The top 10 clones make up approximately 41% of the repertoire in late inflamed 
joints, while in IFA controls, the top 10 clones make up 29% of the population 
(Figure 4-6 E). Interestingly, the number of unique CDR3β sequences is 
comparable between late joints and IFA controls (Figure 4-6 D), despite the late 
inflamed joints having a much greater number of endogenous CD4+ T cells (Figure 
4-6 C). Repertoires from inflamed joints display lower population diversity compared 
with controls (Figure 4-6 F), which would indicate that select clones accumulate in 
late inflamed joints, while CD4+ T cells accumulate in more of a random fashion in 
controls. These observations would suggest that   antigen specific responses can in 
fact be detected in the inflamed joint, in contrast to what was observed in late 
inflamed pLNs. Moreover, these observations also suggest that specific CD4+ T cell 
clones may be expanding locally in the joint tissue. Whether these endogenous 
CD4+ T cell clones are OVA specific is yet to be determined. However as discussed 
in Chapter 3 section 3.3, the endogenous response to OVA may be significantly 
reduced given the large number of transferred OVA specific OT-II cells required for 
the model205,206. Thus the antigen specific accumulation of certain endogenous 
CD4+ T cell clones observed may be a reflection of breach of tolerance to joint 
specific antigens. 
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Figure 4-6 Characterisation of the antigen experienced CD4+ T cell repertoire in late inflamed 
joints and IFA controls. 
Proportion of the top 10 most frequently occurring clones, followed by the next 25, 500, 3000, and 
10,000 most frequent clones contributing to the endogenous antigen experienced CD4+ T cell 
repertoire in A) late inflamed joints, and B) IFA challenged mouse joints. C) Number of endogenous 
CD4+ T cells in late inflamed and IFA challenged mouse joints. D) Number of unique CDR3β 
sequences in the antigen experienced endogenous CD4+ T cell repertoires of late inflamed and IFA 
administered mouse joints. E) Percentage of the top 10 most frequently occurring clones (orange in 
top proportions charts A and B) in late inflamed and IFA challenged joints. F) Diversity indices (D50) 
of the antigen experienced endogenous CD4+ T cells from late inflamed and IFA administered mouse 
joints. Graphs represent 1 experiment with n=5 and 3 for the late inflamed joints and control IFA 
challenged joints respectively. Top proportion charts were generated using the tcR R package. 
Groups were compared using unpaired Student’s t-test. Data presented as mean ± SD. Stars 
represent the following p values: * <0.05; *** <0.001; ns: not significant. 
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 The CD4+ T Cell Repertoire in late inflamed pLNs diverges 
from late inflamed joints and early inflamed joints and pLNs 
in terms of V-gene usage  
Repertoires of pLNs and joints at the early and late timepoints have been 
characterised in terms of the overall composition,, but this does not provide any 
details of the antigen specificities of these clones. Looking at the frequency of V-
gene sequence usage can quickly identify how the antigen specific response 
changes in the early and late groups. A PCA analysis was performed on V-gene 
frequency in each sample in each group (Figure 4-7) and the late inflamed pLNs 
were found to have the largest range in V-gene usage, while late inflamed joints, 
and early inflamed pLNs and joints use a smaller range of V-genes, which were 
present with similar frequencies. Indeed, when quantifying these differences, late 
pLNs have significantly increased presence of V-genes 1, 2, 3, 5, and 19, while V-
genes 12-1, 12-2, and 13-1 are present in the highest frequencies in early inflamed 
pLNs (Figure 4-8). Where the individual samples are plotted on the PCA plot reflects 
differences in V-gene use and frequency between each sample i.e. the closer the 
samples are to each other on the plot, the more similar they are in terms of the V-
gene sequences used and in the frequency at which they occur and vice versa. The 
distance of the samples from the late inflamed pLN group on the PCA plot suggests 
that V-gene use is different between the samples themselves. This indicates that 
not only are the late pLNs diverging from the other groups in terms of V-genes 
usage, but the response also diverges across individuals with progression of 
experimental arthritis.  
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Figure 4-7 PCA plot of V-gene usage in the antigen experienced CD4+ T cell repertoire from 
inflamed joints and pLNs at the early and late model timepoints. 
PCA plot was generated using the tcR R package and separates samples according to V-gene 
frequency. Samples compared were from early and late inflamed joints and pLNs. Each group 
represents 1 experiment with n=5 in each group. 
 
Figure 4-8 V-gene frequencies in early and late inflamed mouse pLNs. 
V-gene frequencies were determined from sequencing data using the gene usage function in the tcR 
R package. Graphs represent 1 experiment with n=5 for both the early and late inflamed groups. 
Groups were compared using ordinary 2 way ANOVA with Sidak’s multiple comparisons test. Data 
presented as mean ±SD. Stars represent the following p values: * <0.05; ** <0.01; *** <0.001; **** 
<0.0001; ns: not significant. Table summerises significantly different V-gene frequencies between 
early and late pLNs. 
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 Reduction in number of shared clones  between pLNs and 
joints with the progression of inflammatory arthritis 
The contrast in repertoire composition and V-gene usage in late inflamed pLNs 
compared with late inflamed joints and the early inflamed groups may have 
interesting implications for the development of antigen specific CD4+ T cell 
responses between joints and their draining lymph nodes. Changes in the antigen 
specific response can be addressed more accurately by determining the distribution 
of specific clones between the sites and between mice at the early and late model 
timepoints. Because each sample was barcoded before being sequenced (see 
methods section 2.7 and Figure 4-9), clones isolated from joints can be matched 
with those from their respective draining lymph nodes – via their CDR3β amino acid 
sequence – and the distribution of CD4+ T cell clones can be monitored between 
the two sites within each animal (Figure 4-9). When comparing the degree of 
CDR3β amino acid sequence overlap between inflamed joints and their draining 
lymph nodes in early and late mice, the number of sequences shared is reduced 
with the progression of arthritis (Figure 4-10 A and B). This is indicated by the 
intersect of the pLN and joints samples in the bottom left square in Figure 4-10 A 
and B and is quantified in Figure 4-10 C. Sequence overlap between samples 
remains unchanged in early and late joint repertoires (Figure 4-10 D), but reduces 
significantly between samples when comparing inflamed pLNs at the early and late 
timepoints (Figure 4-10 E). The reduction in CDR3β amino acid sequence overlap 
with time suggests that the antigen specific responses start out by being similar 
between the sites, but then diverge as the disease progresses. 
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Figure 4-9 Illustration of barcoded sample sequencing and evaluation of clonal overlap 
between pLNs and joints 
A) Illustration of barcoded sample sequencing. Antigen experienced endogenous CD4+ T cells 
(CD4+ CD44hi CD45.1-) were sorted separately from pLNs and joints of animals undergoing model 
of experimental arthritis (1 and 2). Total RNA was isolated and a Vβ specific PCR was performed 
with barcoded primers (3 and 4). Each sample was amplified with primers with a different set of 
barcodes. Samples were then pooled and sequenced using the Illumina Miseq platform (5) and 
sequences were backtracked to the original samples vi the barcodes (6). B) Evaluation of clonal 
overlap between pLNs and joints. CDR3β amino acid sequences from samples were compared using 
the rep.overlap function in the tcR R package. The number of sequences shared between 2 
repertoires found is then normalised to the product of the repertoire sizes. Multiple pairwise 
comparisons are plotted as a heatmap representing normalised degree of overlap between 2 
samples. 
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Figure 4-10 Degree of CDR3β amino acid sequence overlap between inflamed pLNs and joints 
at the early and late model timepoints. 
Number of shared CDR3β amino acid sequences were normalised by dividing the number of shared 
clones found between two samples by the product of the repertoire sizes of the two samples. 
Heatmaps of normalised CDR3β amino acid sequence overlap counts in A) early inflamed joints and 
pLNs, and B) late inflamed joints and pLNs. C-E Normalised values obtained from the heatmap were 
plotted as bar graphs. C) Normalised overlap values between joints and the respective draining pLNs 
from the same mouse. D and E Normalised overlap values between samples within the early and 
late groups. D) Overlap values between joint samples of early and late groups, and E) between pLN 
samples of early and late groups. Graphs represent 1 experiment with n=5 for the early and late 
groups. Heatmaps were generated using the tcR R package. Groups were compared using unpaired 
students t-test. Data presented as mean ±SD. Stars represent the following p values: * <0.05; ** 
<0.01; ns: not significant. 
 Frequency of top 10 clones in joints correlate with high 
frequency clones in pLNs in late inflamed mice, but not in 
early inflamed mice 
A reduction in the number of overlapping sequences between late inflamed pLNs 
and joints would suggest that the antigen specific response changes between these 
two sites and these antigen specific responses may diverge even further with the 
progression of arthritis. To verify whether the antigen specific response truly 
diverges between the inflamed pLN and joint and to address the dynamics of 
individual CD4+ T cell clones between these sites, I looked for a correlation between 
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high frequency clones in inflamed pLNs and joints at both the early and late model 
timepoints. When searching for the top 10 ranked clones from the early inflamed 
joint samples in the respective pLNs, not all the clones are returned. By contrast, 
the top 10 clones in late inflamed joint samples are all present in their lymph node 
counterparts (Table 4-2 A and B). Moreover, the ranks of the clones correlate more 
between late inflamed joints and pLNs than in early inflamed joints and pLNs 
(Figure 4-11 A and B). Interestingly the top 10 clones from joints immunised with 
IFA alone (i.e. without OVA) do not correlate with highly ranked clones in the 
respective lymph nodes (Figure 4-11 C), suggesting that the observed dynamics 
between the joint and lymph node are due to antigen specific responses. 
Together, these results reveal ongoing communication between late inflamed joints 
and their draining lymph nodes which appears to be antigen driven rather than due 
to chronic inflammation. The reduction in the number of overlapping clones between 
the late inflamed pLNs and joints and the changes in CD4+ T cell clonality in the 
late inflamed pLN may not represent a divergence in the antigen specific response, 
but rather could reflect changes that may eventually occur in the inflamed joint, as 
suggested by clinical data examining repertoire CD4+ T cell repertoire changes in 
early and established RA patients46.  
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Table 4-2 The top 10 frequently occurring clones in early and late joint samples ranked in 
terms of frequency in respective pLNs. 
 
A) 
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B) 
 
The top 10 frequently occurring clones in the antigen experienced CD4+ T cell repertoire were found 
in each of the A) early and B) late joint samples and searched for in respective pLN samples using 
the find.clonotypes function in the tcR R package. The CDR3β amino acid sequence, associated V-
gene, read count, and rank of the clone in the pLN sample was obtained. The rank each of the top 
10 clones in the joint were also included in the table. Data from early and late tissues represent 1 
experiment with n=5 for each group. 
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Figure 4-11 Correlation of the top 10 ranked clones in early and late joints with their rank in 
respective pLN samples. 
The top 10 frequently occurring clones in the antigen experienced CD4+ T cell repertoire were found 
in each of the early and late joint samples and searched for in respective pLN samples using the 
find.clonotypes function in the tcR R package. The rank of each of the top 10 clones in A) early 
inflamed joint, B) late inflamed joint, and C) IFA control joint samples were plotted against the rank 
of that clone in respective pLN samples. Data from early and late tissues represent 1 experiment 
with n=5 for each group. Correlations were calculated using Spearman’s correlation after testing for 
normality of the data using the D’Agostino-Pearson test.  
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 Discussion 
TCR repertoire characterisation has been used to distinguish naive immune profiles 
from diseased states in cases of infection286, cancers42, and autoimmunity23,287, 
including RA46,48. Although clonality of CD4+ T cell repertoires have been 
determined in RA patients at different stages of disease46,143, how the antigen 
specific response develops from the very early stages, before clinical symptoms are 
manifest, to one where inflammation is propagated and continues is unknown. In 
this chapter, NGS methods were utilised to investigate the evolution of the antigen 
specific response in early and chronic models of inflammatory arthritis. Moreover, 
changes in CD4+ T cell clonality were monitored between the inflamed joint and its 
draining lymph node to better understand the dynamics of antigen specific CD4+ T 
cell responses between these sites with disease progression.  
The antigen experienced CD4+ T cell repertoire was found to be similar between 
early and late inflamed joints; both repertoires displayed low T cell diversity and 
were skewed by the presence of a low number of high frequency clones. By contrast, 
early and late inflamed pLNs have quite a distinct repertoire composition, where late 
inflamed pLNs have a more diverse repertoire mainly composed of low frequency 
clones. This indicates that late pLNs take on a more polyclonal phenotype compared 
to early inflamed pLNs, which may reflect changes in antigen specific responses 
due to the release of novel antigens resulting from continued joint damage, or is a 
reflection of epitope spreading - an occurrence where responses against a 
subdominant epitope of a protein develop52, a phenomenon which has been 
demonstrated in RA288. If this is the case, then it is striking that late joints and pLNs 
have very different repertoire compositions. Specifically, late pLNs have, 
comparatively, a very low number of highly expanded clones. 
Although late inflamed joints have similar repertoire compositions compared with 
their early inflamed counterparts, it is not known whether these repertoires are made 
up of the same clones. Specific sequences cannot be compared between animals 
because individual animals display different immune responses, and so, clones from 
one animal is unlikely to be found in another animal13,220. Indeed, when clonality 
analyses are conducted in human studies, the same individual has samples taken 
throughout the course of the study to track specific clones23,46, or comparisons are 
made on different criteria such as CDR3 length to describe differences between 
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individuals287. So, although repertoires from early and late joints are similar in terms 
of relative composition, the late joint may be made up of entirely different clones  
from those present in early inflamed joints. Given that the number of endogenous 
CD4+ T cells in late inflamed joints is greater than in their early counterparts, and 
given the similarity in V-gene sequence usage in both the CD4+ T cell repertoires 
in early and late inflamed joints, one could suggest that, in fact, the CD4+ T cell 
clones present in both these tissues recognise similar antigens. Additionally, the 
clones found in early inflamed joints could continue to expand and accumulate with 
disease progression, a phenomenon that has also been reported in RA 
patients143,289. 
Individual joint and pLN samples from individual animals were barcoded before 
being sequenced which allowed me to determine the distribution of individual clones 
between these two sites. In order to investigate how specific clones contribute to 
each of the repertoires from the inflamed tissues, CDR3β amino acid sequences 
were compared between these two sites in both early and late inflamed groups and 
normalised. The amino acid sequence rather than the nucleotide sequence was 
compared due to a phenomenon known as convergent recombination, where 
different CDR3 nucleotide sequences encode the same amino acid sequence and 
is postulated to feature in the generation of public T cell responses290. The amino 
acid sequence of the CDR3 region reflects the type of peptide this region, and 
therefore the TCR, has an affinity for. An overlap in amino acid sequences between 
two different CD4+ T cell repertories would indicate the degree those repertoires 
recognise the same peptides and highlight similarities in the antigen specific 
response in those populations. The CD4+ T cell repertoires of late inflamed joints 
and pLNs share fewer clones compared to early inflamed samples, indicating that 
the antigen specific responses differ between these sites with time. Moreover, the 
divergence of V-gene usage in late pLNs suggests that the difference in response 
is due to changes in late pLNs rather than late joints. It is also interesting to note 
that the late pLN samples not only diverge from the other groups in terms of V-gene 
usage, but also deviate from each other, illustrating the development of individual 
responses with disease chronicity. This has also been observed in RA patients; 
highly expanded clones within a patient with a unique CDRβ sequence were only 
found in different joints within the same individual but not shared across 
patients46,143  
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Comparisons of repertoires from early inflamed mice with those from PBS controls 
demonstrate that the restriction in diversity and clonality is a result of an antigen 
specific response in the early stages of arthritis. Interestingly, late pLNs show no 
difference in repertoire compositions compared to IFA controls, which indicates that 
pLNs mainly reflect chronic inflammation rather than the development of an antigen 
specific response. This is unexpected given that the top 10 highly expanded clones 
in the late inflamed joint correlate with highly expanded clones in the lymph node, 
while this does not occur between IFA joints and pLNs. This suggests that the lymph 
nodes in fact reflect the presence of antigen specific responses. Interestingly, there 
is no correlation between highly expanded clones in the early inflamed joint with 
highly abundant clones in respective pLNs. Whether this observation is a reflection 
of the dynamics of CD4+ T cells between the joint and pLN is also something to be 
considered and may hint to antigen specific CD4+ T cells expanding locally in the 
joint. Indeed, antigen specific expansion of memory CD8+ T cells has been 
demonstrated in sites where infections were localised290,291. Additionally, the 
differences in correlation in top ranking clones between early and late joints and 
lymph nodes may also reflect a proliferation burst in pLNs and subsequent migration 
of effector cells to the inflamed joint, which would have occurred prior to analysis of 
the repertoires. 
The general contrast in CD4+ T cell clonality between early and late inflamed mice 
- where early inflamed pLNs reflect the clonality in early inflamed joints, while late 
pLNs do not - demonstrate that CD4+ T cell repertoires can be different between 
tissues and their draining lymph nodes at different points in disease. Moreover, the 
changing composition of the late inflamed pLN may predict the responses that will 
occur in the joint. Indeed, Klarenbeek et al46 demonstrated that repertoires from 
synovial fluid of patients with chronic or established RA have fewer highly expanded 
clones compared to the synovial fluid taken from patients 6 months after showing 
clinical symptoms. This suggests that the joint may eventually mirror the 
polyclonality observed in the lymph node. This delayed response in the joints has 
important implications for antigen specific therapies, as specific pathogenic clones 
could potentially be targeted in the lymph node before accumulating in the joint. 
Indeed, Rodríguez-Carrio et. al.139 obtained inguinal lymph node samples of at-risk 
and early RA patients to determine whether lymph node composition changes prior 
to RA onset. Moreover, analysing clonal compositions early in the disease will be 
more effective in terms of identifying common antigen specific responses between 
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individuals, demonstrated by the divergence of pLN samples with disease 
development. Analysis of clonal compositions can also serve as a biomarker to 
monitor disease development and assess the therapeutic impact on changes in 
CD4+ T cell clonality. 
Together this data highlights the importance of site specific and temporal dynamics 
of antigen specific CD4+ T cell responses in inflamed tissues and their respective 
lymph nodes and is a step forward in understanding the development of the antigen 
specific response in RA. Identifying key developments in these responses will aid in 
the development of more efficient regimes to reinstate self-tolerance. 
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Chapter 5 Assessment of autoantigens and 
location of antigen recognition using the 
Nur77GFP transgenic system 
 Introduction 
Evidence of antigen presentation in RA is supported by the association of certain 
HLA-DRB alleles with the disease; over 80% of RA patients express the HLA-DRB1 
allele35,36, making HLA-DRB loci the most important risk association for developing 
RA. The presence of a CD4+ T cell TCR bias in RA patients is further evidence of 
antigen specific responses playing an role in maintaining and propagating the 
disease46,143,201,289 and these CD4+ T cells may in fact be selected for as a result of 
mutations in the HLA-DRB alleles. As such, CD4+ T cells have been proposed as a 
therapeutic target for RA292–294. However, one of the biggest hurdles in specifically 
targeting these pathogenic CD4+ T cells is that their antigen specificities are 
unknown. Moreover, data from several studies have suggested that the antigens the 
autoreactive T cells recognise are heterogenous and vary across RA 
patients82,292,295,296 (see section 1.4 of introduction), making it more difficult to 
identify the antigens these CD4+ T cells recognise. An additional impediment is the 
lack of a clearly defined location where these autoreactive responses originate and 
where exactly autoreactive CD4+ T cells recognise their cognate antigen 82,297. The 
unknown nature of antigens recognised by pathogenic CD4+ T cells and the paucity 
of information of where these CD4+ T cells encounter their antigens have impeded 
the development of antigen specific therapies for RA. 
However, the arthritic joint has been found to provide a niche for expanded CD4+ T 
cells46, and the RA synovium is enriched with citrullinated peptides183 to which CD4+ 
T cell responses have been demonstrated114,298. This would suggest that the CD4+ 
T cells infiltrating the arthritic joint may in fact encounter their cognate antigens at 
the inflamed joint. Moreover, behaviour of endogenous CD4+ T cells in the OVA 
model of arthritis would suggest that these cells also interact with their antigen in 
the inflamed joints191. A study of type I diabetes, also an autoimmune disease, has 
shown that islet specific CD4+ T cells localise to the pancreas at very early stages 
of the disease because of antigen encounter188,189, suggesting that the same 
mechanisms could be responsible for CD4+ T cell infiltration into inflamed synovial 
tissues at early stages of arthritis. Therefore, in this chapter, I wished to determine 
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whether CD4+ T cells encounter their cognate antigen in the joint itself, and whether 
these antigens originate from the joint. This will address the possible location of 
antigen recognition as well as the nature of the antigens recognised in the early 
phases of RA. To do this, the OVA model of experimental arthritis was employed in 
Nur77GFP transgenic mice, which report TCR stimulation events57. 
The Nur77GFP transgenic system developed by Moran et al is a reporter of TCR 
stimulation and was originally developed to understand how TCR stimulation 
strength affected Treg development and selection in the thymus57. Nur77 is a gene 
product of the Nr4a1 locus which is upregulated upon TCR stimulation in T cells299. 
Unlike the early activation marker CD69300, Nur77 has been found to specifically 
report on T and B cell activation via engagement of the TCR and BCR respectively, 
as opposed to cytokine driven activation57,301. This makes Nur77 ideal for 
distinguishing antigen driven activation of T cells from “bystander” activation, where 
lymphocytes are activated by the inflammatory environment. Indeed, evidence for 
cytokine activated CD4+ T cells in RA has been previously shown100,193. The 
distinction between antigen driven and bystander T cell activation is important for 
antigen specific therapies and ensures that the correct CD4+ T cells are targeted.  
There are three main aims of this chapter. Firstly, to provide evidence for antigen 
recognition in the early phases of experimental arthritis and to complement the 
findings of the first results chapter. Secondly, to determine whether CD4+ T cells 
recognise their cognate antigen specifically in the joint, and finally, to establish 
whether the antigens the CD4+ T cells recognise are joint specific, providing 
evidence of their autoreactivity. To achieve these aims, the feasibility of the 
Nur77GFP transgenic system as a reporter of antigen recognition in the early model 
of experimental arthritis was first established and I found that this system reported 
TCR stimulation events that occurred within 48 hours of TCR engagement. 
Endogenous CD4+ T cells were then collected from pLNs and joints of Nur77GFP 
mice undergoing the model and Nur77GFP expression was assessed. Finally, 
endogenous CD4+ T cells were isolated from pLNs and joints of mice undergoing 
the early and late models of arthritis and co-cultured with BMDCs pulsed with OVA, 
inflamed joint extract, and candidate RA antigens collagen II and aggrecan. This 
was done to determine which antigens these cells recognised and to demonstrate 
whether the endogenous CD4+ T cells recognised antigens that have been 
implicated in RA, namely collagen II302–304 and aggrecan305. I found that a greater 
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number of endogenous CD4+ T cells with high levels of Nur77GFP were isolated 
from inflamed pLNs and joints, but these cells did not respond to the joint derived 
antigens tested, nor to the candidate RA antigens. Despite this, the data reveals 
interesting differences in activation profiles of endogenous CD4+ T cells between 
pLNs and joints and at the early and late stages of experimental arthritis. 
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 Results 
 In vitro stimulation of Nur77GFP CD4+ T cells with anti-CD3 
results in GFP upregulation and correlates with CD69 
expression 
The primary goal of this experiment was to establish whether the Nur77GFP system 
reports T cell activation as required for the purposes of this project. A simple way of 
testing the system is to determine whether GFP expression can be detected upon 
TCR stimulation. Lymphocytes were isolated from Nur77GFP mice - along with 
C57BL/6 and Nur77GFP transgenic negative controls - and cultured overnight in 
anti-CD3 coated plates then analysed by flow cytometry (Figure 5-1). GFP was 
significantly upregulated in Nur77GFP CD4+ T cells cultured with anti-CD3 
compared to unstimulated controls. Furthermore, GFP expression was significantly 
greater compared to stimulated non transgenic controls. Moreover, GFP expression 
correlated with increasing amounts of anti-CD3 and reached maximum expression 
at 5µg/mL anti-CD3 (Figure 5-1 E and F). GFP upregulation was also compared to 
the expression of the early activation marker CD69 and it was found that both GFP 
and CD69 expression increased in a dose dependent manner (Figure 5-2). 
Upregulation of Nur77GFP can therefore be associated with CD4+ T cell activation. 
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Figure 5-1 In vitro stimulation of Nur77GFP CD4+ T cells with 1, 5, and 10µg of anti-CD3 
Lymph nodes were collected and lymphocytes isolated from Nur77GFP mice as well as C57BL/6 
and Nur77GFP negative transgenic mice as controls. Approximately 3x10^5 cells were cultured for 
24 hours in triplicate with varying amounts of anti-CD3 or PBS then analysed for GFP expression. 
Representative Flow Cytometry plots of Nur77GFP CD4+ T cells cultured with A) PBS and B) 5µg 
anti-CD3. C) Representative Nur77GFP MFI (median fluorescence intensity) histograms of C57BL/6, 
Nur77GFP transgenic negative, Nur77GFP positive CD4+ T cells cultured with PBS and 5µg anti-
CD3, and D) quantification of the MFI values from C. E) Representative Nur77GFP MFI histograms 
of Nur77GFP CD4+ T cells cultured with PBS, 1, 5, and 10µg anti-CD3, and F) quantification of the 
MFI values from E. Graphs represent 1 experiment with cells isolated from 1 mouse and plated in 
triplicate, except for cells cultured with PBS which was done as a singlet. Groups were compared 
using one-way ANOVA. Stars represent the following values: ** ≤0.01; **** <0.0001. 
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Figure 5-2 Nur77GFP and CD69 expression of Nur77GFP CD4+ T cells after In vitro stimulation 
with anti-CD3 
Lymph nodes were collected and lymphocytes isolated from Nur77GFP. Approximately 3x10^5 cells 
were cultured  for 24 hoursin triplicate with 0.1-5mug/mL anti-CD3 or PBS then analysed for GFP 
and CD69 expression. A) Representative Flow Cytometry plot of Nur77GFP CD4+ T cells cultured 
with 5ug/mL anti-CD3 and PBS and Nur77 transgenic negative controls cultured with PBS. B) 
Representative flow cytometry plot of Nur77GFP and Nur77GFP transgenic negative CD4+ T cells 
cultured with 5µg/mL and 10µg/mL anti-CD3 respectively. C) Nur77GFP and CD69 MFI (median 
fluorescence intensity) values from Nur77GFP CD4+ T cells cultured with 0.1-5µg/mL anti-CD3 along 
with a PBS control. Graphs represent 1 experiment with cells isolated from 1 mouse and plated in 
triplicate. Groups were compared using two-way ANOVA. Stars represent the following values: ** 
≤0.01; *** ≤0.001; **** <0.0001. Red and blue stars represent statistics of the CD69 and Nur77GFP 
groups respectively. 
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  In vitro stimulation time course of Nur77GFP CD4+ T with 
anti-CD3 reports on TCR stimulation events occurring within 
48 hours of TCR engagement 
As per previous experiments, CD4+ T cells were purified at day 4 after periarticular 
administration of HAO for the assessment of TCR clonality in the OVA model of 
experimental arthritis (see sections 2.2.5 and 3.2.2.2). To determine whether the 
Nur77GFP system can report T cell stimulation within this time frame, an in vitro 
time course experiment was conducted to investigate how long GFP expression 
remains upregulated after TCR stimulation. According to Moran et al. a 3 hour in 
vitro stimulation of T cells was sufficient in inducing GFP protein expression306, and 
so cells were also stimulated for 3 hours in the in vitro culture. Lymphocytes isolated 
from Nur77GFP mice were stimulated for 3 hours with 1 or 5µg/mL anti-CD3 then 
washed, re-plated, and cultured for 24-96 hours. At each timepoint, cells were 
analysed by flow cytometry and GFP expression in CD4+ T cells was determined 
(Figure 5-3). A PBS control was also included for the same time frame to monitor 
background levels of GFP. Cells were also analysed immediately after the 3-hour 
stimulation to determine peak GFP expression, represented by the red, 0 hour bar 
in Figure 5-3. GFP levels in CD4+ T cells stimulated with 1µg/mL anti-CD3 steadily 
declined over 3 days and plateaued between 3 and 4 days post stimulation. In 
contrast, CD4+ T cells stimulated with 5µg/mL anti-CD3 sustained GFP levels 24 
hours post stimulation and reduced slightly by 48 hours. By 72 hours, GFP levels 
drastically decreased and plateaued again by 96 hours. Levels of GFP from CD4+ 
T cells stimulated with 1µg/mL are comparable with those of unstimulated cells at 
the 96 hour time point, while GFP expression from CD4+ T cells stimulated with 
5µg/mL is still significantly higher compared to PBS controls at the 96 hour time 
point. This indicates that strongly stimulated CD4+ T cells will still retain some 
remnant GFP 4 days after the initial stimulation event. This data would therefore 
suggest that Nur77GFPhi expressing CD4+ T cells reflect TCR stimulation events 
that have occurred within 48 hours. This system can therefore reflect CD4+ T cell 
antigen recognition events occurring after periarticular administration of HAO. 
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Figure 5-3 Nur77GFP expression 24-96 hours after in vitro stimulation of Nur77GFP CD4+ T 
cells with anti-CD3 
Lymph nodes were collected and lymphocytes isolated from Nur77GFP. Approximately 3x10^5 cells 
were cultured in triplicate for 3 hours with 0, 1, or 5µg/mL anti-CD3 at 37C. Cells were then washed 
and transferred to new plates, and taken after 24-96 hours of culture. Cells were analysed at each 
timepoint by flow cytometry and GFP expression in CD4+ T cells was determined. Columns represent 
Nur77GFP MFI (median fluorescence intensity) of CD4+ T cells cultured with PBS (0µg/mL anti-
CD3), 1µg/mL, and 5 µg/mL anti-CD3 taken immediately after 3 hour anti-CD3 stimulation (0 hours) 
to 96 hours after stimulation in 24 hour increments. Graphs represent 1 experiment with cells isolated 
from 1 mouse and plated in triplicate. Groups were compared using two-way ANOVA. Stars 
represent the following values: * ≤0.05; **** <0.0001; ns: not significant. 
 Evidence of antigen recognition in  early inflamed joints  
The data presented so far suggests that the Nur77GFP system reflects recent 
antigen recognition events – more specifically, events that have occurred no more 
than 48 after TCR stimulation. This timeframe is adequate for determining TCR 
stimulation events and T cell activation following periarticular challenge with HAO, 
which allowed us to assess whether CD4+ T cells can potentially recognise their 
cognate antigen in the joint. The OVA model of experimental arthritis was therefore 
carried out and the number and frequency of endogenous CD4+ T cells with high 
Nur77GFP expression was determined (Figure 5-4 A and B). The number of CD4+ 
Nur77GFPhi cells were significantly higher in inflamed pLNs and joints compared to 
PBS controls (Figure 5-4 B). The frequency of Nur77GFPhi cells was also 
significantly greater in HAO challenged joints compared to controls, but not in the 
pLNs. The greater overall number of Nur77GFPhi cells would suggest that more 
cells in HAO challenged mice have had their TCR engaged. To verify that this 
increase in Nur77GFP expression reflects T cell activation due to TCR engagement 
rather than a consequence of non-specific environmental inflammatory stimuli , mice 
were also challenged with 25µg of LPS and Nur77GFP expression was determined 
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in pLNs and joints (Figure 5-5). The number of Nur77GFPhi endogenous CD4+ T 
cells was lower in pLNs from LPS challenged mice compared to pLNs from HAO 
challenged mice and was also comparable to PBS controls. This could suggest that 
of the endogenous CD4+ T cells entering the HAO challenged joint, more of them 
have seen their cognate antigen in HAO than in LPS challenged joints. 
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Figure 5-4 Number and frequency of Nur77GFPhi endogenous CD4+ T cells from pLNs and 
joints of HAO challenged mice and PBS controls 
Cells were isolated from pLNs and joints 4 days after periarticular challenge and stained for  flow 
cytometry analysis. Transferred cells were identified using the CD45.1 marker and were excluded 
from analysis, leaving only the endogenous CD4+ T cells. A) Representative flow cytometry plots of 
Nur77FP expression in endogenous CD4+ T cells isolated from pLNs (top) and joints (bottom) of 
HAO (red) and PBS (blue) challenged mice. Lymphocytes isolated from pLNs treated with anti-CD3 
as a positive control for GFP expression (black). B) Number (top) and frequency (bottom) of 
endogenous CD4+ T cells expressing high levels of Nur77GFP from pLNs and joints of HAO and 
PBS challenged mice. Graphs represent 3 experiments with n=14 for HAO challenged pLNs and 
joints, and PBS challenged pLNs, and n=13 for PBS challenged joints. Groups were compared using 
Student’s t-test. Stars represent the following values: * ≤0.05; ** <0.01; ns: not significant. 
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Figure 5-5 Number and frequency of Nur77GFPhi endogenous CD4+ T cells from pLNs and 
joints of HAO, LPS, and PBS challenged mice 
Cells were isolated from pLNs and joints 4 days after periarticular challenge and stained for flow 
cytometry analysis. Transferred cells were identified using the CD45.1 marker and were excluded 
from analysis, leaving only the endogenous CD4+ T cells. Number (top) and frequency (bottom) of 
endogenous CD4+ T cells expressing high levels of Nur77GFP from pLNs and joints of HAO, LPS 
and PBS challenged mice. Graphs represent 1 experiment with n=5 for all groups. Groups were 
compared using one-way ANOVA. Stars represent the following values: * ≤0.05; ** <0.01; *** <0.001; 
ns: not significant. 
 Endogenous CD4+ Nur77GFPhi cells isolated from HAO 
challenged pLNs are not enriched for Vβ4 expressing cells 
One of the aims of the project was to provide evidence of antigen recognition in the 
early phases of experimental arthritis. In results Chapter 3, I demonstrated that Vβ4 
was preferentially enriched in HAO challenged pLNs and joints and that Vβ4 may 
be joint antigen specific (see sections 3.2.2.2 and 3.2.2.5). To determine whether 
cells with the Vβ4 TCR chain are enriched in HAO challenged pLNs and joints as a 
consequence of TCR engagement with their cognate antigen, and to further refine 
where these cells are seeing their cognate antigen, the OVA experimental model 
was carried out in Nur77GFP mice. The number and frequencies of Nur77GFPhi 
endogenous CD4+ T cells with Vβ4, 6, and 13 TCR chains were then determined 
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from HAO and PBS challenged mouse pLNs (Figure 5-6). The number of 
Nur77GFPhi cells was too low in the joints to accurately determine frequencies and 
number of cells with a given Vβ chain (data not shown). The number and 
frequencies of Nur77GFPhi endogenous CD4+ T cells with Vβ4, 6, and 13 TCR 
chains were similar in both HAO and PBS challenged pLNs. This data suggests that 
endogenous CD4+ cells with the Vβ4 TCR chain did not have their TCR engaged 
within 48 hours of analysis. This implies that these cells did not see their cognate 
antigen within that time frame and their enrichment in the inflamed pLN may not be 
due to antigen recognition. 
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Figure 5-6 Number and frequency of cells with a given Vβ chain from the Nur77GFPhi 
endogenous CD4+ T cell population isolated from pLNs of HAO and PBS challenged mice 
Cells were isolated from pLNs and 4 days after periarticular challenge and stained for flow cytometry 
analysis. Transferred cells were identified using the CD45.1 marker and were excluded from 
analysis, leaving only the endogenous CD4+ T cells. A) Representative flow cytometry plots of Vβ4, 
Vβ6, and Vβ13 populations gated on Nur77GFPhi endogenous CD4+ T cells isolated from HAO and 
PBS challenged mice. B) Number and frequency of cells expressing a given Vβ chain from 
endogenous CD4+ T cells expressing high levels of Nur77GFP from pLNs of HAO and PBS 
challenged mice. Graphs represent 1 experiment with n=4 for all groups. Groups were compared 
using 2-way ANOVA. ns: not significant. 
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 Establishing optimal conditions for Nur77GFP CD4+ T cell 
co-coculture experiments  
Endogenous CD4+ T cells with the Vβ4 TCR chain isolated from pLNs did not show 
an increase in Nur77GFP expression, despite being enriched in HAO challenged 
joints and pLNs and being associated with joint derived antigens (see Chapter 3 
section 3.2.2.5). Another method of determining whether endogenous CD4+ T cells 
recognise joint antigens was to purify the endogenous CD4+ T cells from Nur77GFP 
mice undergoing the OVA arthritis model from pLNs and joints and co-culture them 
with BMDCs pulsed with joint antigens. The aim of using this approach was to refine 
the cohort of antigens that these cells potentially recognised, and to also 
demonstrate the possibility of joint endogenous CD4+ T cells being activated in the 
joint itself if their cognate antigens are presented there. This approach would 
address the third aim of this chapter which was to provide evidence of autoreactive 
CD4+ T cell clones that could potentially recognise their cognate antigen in the 
inflamed joint. 
Before attempting to investigate the possible antigens CD4+ T cells recognise in 
pLNs and joints of mice undergoing the experimental arthritis model, an assay to 
measure Nur77GFP expression as a result of re-stimulation with cognate antigen 
needed to be established. To develop this assay, brachial and axillary lymph nodes 
were collected from Nur77GFP mice immunised with OVA/CFA as well as from 
unimmunised mice. CD4+ T cells were then co-cultured with BMDCs pulsed with or 
without OVA and Nur77GFP expression, proliferation, and cytokine production was 
evaluated. 
CD4+ T cells were purified from brachial and axillary lymph nodes 7 days after 
Nur77GFP mice were immunised with OVA/CFA, as well as from control naive mice 
and cultured for 6 hours with BMDCs pulsed with or without OVA protein. Nur77GFP 
expression, degree of proliferation, and cytokine production of CD4+ T cells were 
then determined by flow cytometry. The percentage of Nur77GFPhi cells was similar 
in the naïve samples compared to OVA immunised mice in the cytokine expression 
experiments (Figure 5-7) and comparable across all samples in the proliferation 
experiments (data not shown). This may be a reflection of the high background of 
GFP in LNs due to continuous TCR/MHC interactions306 and together with the high 
number of Nur77GFPmid-lo CD4+ T cells, the frequency of Nur77GFPhi cells was 
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probably not great enough in OVA/CFA challenged mice to be detected. Although, 
when gating on the Nur77hi CD4+ cells, the cells isolated from OVA immunised 
mice that were then co-cultured with OVA pulsed BMDCs showed the greatest 
proliferation compared to controls (Figure 5-8 A) and also had increased expression 
of ICOS, IL-2, IFNγ, and TNFα (Figure 5-8 B and C). Interestingly, CD4+ cells 
isolated from OVA immunised mice continue to proliferate despite the absence of 
their cognate antigen (green histogram in Figure 5-8 A). When evaluating ICOS 
expression and cytokine production, cells isolated from OVA immunised mice seem 
to show a clearer difference in ICOS and overall cytokine expression when co-
cultured with OVA pulsed BMDCs compared to controls (Figure 5-8 C). This data 
would suggest that evaluating ICOS and cytokine expression is more accurate for 
reporting T cell activation and was therefore used to evaluate antigen recognition in 
co-culture experiments of cells isolated from the model. Moreover, cytokine 
expression can provide information on the type of T helper responses and therefore 
elaborate on the function of CD4+ T cells in response to antigen at the tissue site. 
Unfortunately, both proliferation and cytokine expression experiments could not be 
performed with endogenous CD4+ T cells from the model, as the yield of CD4+ T 
cells from the joints is so low that it was not feasible to do both. 
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Figure 5-7 Assessment of Nur77GFP expression in CD4+ T cells isolated from OVA 
immunised mice co-cultured with OVA 
Brachial and axillary lymph nodes were collected from a naïve Nur77GFP mouse and Nur77GFP 
mice immunised with OVA in CFA in the scruff 7 days after immunisation. 1x10^6 purified CD4 T 
cells were co-cultured in a 5:1 ratio with BMDCs pulsed with OVA protein 24 hours prior to co-culture. 
Purified CD4+ T cells were also cultured with non-pulsed BMDCs as controls. Cells were cultured 
for 6 hours then stained for flow cytometry analysis. Plots are representative flow cytometry plots of 
the frequency of Nur77GFPhi cells.  
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Figure 5-8 Proliferation and cytokine expression of Nur77GFPhi CD4+ T cells isolated from 
OVA immunised mice co-cultured with OVA 
Brachial and axillary lymph nodes were collected from a naïve Nur77GFP mouse and Nur77GFP 
mice immunised with OVA in CFA in the scruff 7 days after immunisation. 1x10^6 purified CD4 T 
cells were co-cultured in a 5:1 ratio with BMDCs pulsed with OVA protein 24 hours prior to co-culture. 
Purified CD4+ T cells were also cultured with non-pulsed BMDCs as controls. Cells were co-cultured 
for 6 and 96 hours for cytokine expression and proliferation respectively, then stained for flow 
cytometry analysis. A) Proliferation of Nur77GFPhi cells co-cultured with or without OVA pulsed 
BMDCs. Proliferation was determined by the dilution of Cell Trace Violet dye (CTV). Histograms 
represent the following: -OVA/-OVA: naïve CD4+ T cells with DCs –OVA; -OVA/+OVA: naïve CD4+ 
T cells with DCs +OVA; +OVA/-OVA: OVA immunised CD4+ T cells with BMDCs –OVA; 
+OVA/+OVA: OVA immunised CD4+ T cells with DCs +OVA. Percentages are frequency of divided 
cells. B) Representative ICOS and cytokine (IL-2, IFNγ, and TNFα) staining of Nur77GFPhi cells, 
and C) percentages of ICOS+, IL-2+, IFNγ+, and TNFα+ Nur77GFPhi cells from naïve and OVA 
immunised mice co-culture with BMDCs pulsed with or without OVA. Plots and table represent 1 
experiment with n=1. 
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 Evaluating endogenous CD4+ T cell activation in response 
to joint antigen recognition in animals undergoing the early 
model of experimental arthritis 
To determine whether the endogenous CD4+ T cells isolated from pLNs and joints 
of HAO challenged mice recognise joint derived antigens, co-cultures were set up 
and BMDCs were pulsed with joint extract from LPS challenged mice (see methods 
section 2.2.5 for details), as this would emulate inflammatory conditions without the 
presence of HAO, ensuring that the antigen specific responses observed were not 
due to recognition of OVA. BMDCs were also pulsed with OVA or with a combination 
of bovine collagen II and aggrecan, which served as candidate RA antigens. Bovine 
collagen II and aggrecan were used as a candidate RA antigens as evidence for 
antibody production and T cell proliferation in response to collagen II has been 
reported in other studies using the model140,252,254. Aggrecan is a component of 
collagen to which CD4+ T cell responses have also been demonstrated305. Having 
these antigens may also refine what type of joint antigens the endogenous CD4+ T 
cells may recognise, if the CD4+ T cells do indeed show evidence of antigen 
recognition when co-cultured with joint extract. Nur77GFP expression was 
determined in endogenous CD4+ T cells isolated from both pLNs and joints of HAO 
and PBS challenged mice to evaluate the degree of antigen recognition after the co-
cultures (Figure 5-9). Under all conditions, there was a higher frequency of 
Nur77GFPhi endogenous CD4+ T cells isolated from HAO challenged pLNs 
compared to PBS pLNs. When comparing co-culture conditions across CD4+ T cells 
isolated from HAO challenged pLNs, cells co-cultured with OVA show a significant 
increase in Nur77GFP expression compared to the DC only control, while cells 
cultured with LPS joint extract and candidate RA antigens show a decrease or no 
significant increase in Nur77GFP expression respectively. Endogenous CD4+ T 
cells isolated from the joint show no difference in Nur77GFP expression between 
PBS and HAO challenged mice, nor across any of the co-culture conditions (Figure 
5-9 C and D). 
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Figure 5-9 Percentage of Nur77GFPhi endogenous CD4+ T cells isolated from pLN and joints 
of HAO and PBS challenged mice co-cultured with joint extract, OVA, or candidate RA 
antigens 
pLNs and joints were collected from HAO and PBS challenged mice. CD4+ T cells were purified and 
co-cultured with BMDCs pulsed with joint extract from an LPS challenged mouse, OVA, or candidate 
RA antigens bovine collagen II and bovine aggrecan. Cells were also cultured with non-pulsed 
BMDCs to determine baseline Nur77GFPhi frequency. BMDCs were pulsed and simultaneously 
cultured with CD4+ T cells. Golgi plug was added 6 hours after co-culture set up and cells were 
cultured for a further 6 hours at 37C. Cells were collected and stained for flow cytometry analysis. 
Cells were cultured in duplicate for each condition. Representative flow cytometry plots of A) pLN 
and C) joint Nur77GFPhi endogenous CD4+ T cells isolated from HAO challenged mice co-cultured 
with and without OVA, and from PBS challenged mice co-cultured with OVA. Frequency of B) pLN 
and D) joint Nur77GFPhi endogenous CD4+ T cells from each experimental condition. Graphs 
represent 1 experiment with n=1 (pLNs and joints from 7 HAO and 6 PBS challenged mice were 
pooled per tissue per group. Values from each technical replicate plotted). Groups were compared 
using 2-way ANOVA. Stars represent the following values: ** ≤0.01; **** <0.0001; ns: not significant 
ICOS expression and cytokine production of endogenous CD4+ T cells from HAO 
and PBS pLNs show a similar pattern to Nur77GFP expression (Figure 5-10 A and 
B). ICOS, IL-2, and TNFα expression were all greater in cells isolated from HAO 
challenged mice compared to PBS challenged mice, but only OVA cultured HAO 
CD4+ T cells showed an increase in IFNγ production. Again, cells isolated from HAO 
challenged pLNs show an increase in IL-2, IFNγ, and TNFα production compared 
to the DC only group when cultured with OVA. Cells cultured with joint extract show 
an increase in ICOS expression, and cells cultured with candidate RA antigens show 
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an increase in IL-2 production when compared to the DC only controls. On the other 
hand, endogenous CD4+ T cells isolated form the joint show an increase in ICOS 
expression when cultured with joint extract, OVA, and RA candidate antigens 
compared to DC only and PBS controls (Figure 5-10 C and D). However, there is 
no significant difference in IL-2, IFNγ, and TNFα production.  
Overall this data shows that endogenous CD4+ T cells isolated from pLNs and joints 
of HAO challenged mice did not respond to the joint derived antigens tested in the 
assay. Moreover, a significant percentage of these cells recognise OVA antigens in 
the assays I employed and show effector responses when re-stimulated with OVA. 
However, although significant, only 15% of the total endogenous CD4+ T cell 
population purified from pLNs recognised OVA, and an even lower percentage 
produced cytokines in response to OVA, indicating that only a minority of the 
endogenous CD4+ T cells recognise OVA at this timepoint. 
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Figure 5-10 Percentage of cytokine producing endogenous CD4+ T cells isolated from pLNs 
and joints of HAO and PBS challenged mice co-cultured with joint extract, OVA, or candidate 
RA antigens 
pLNs and joints were collected from HAO and PBS challenged mice. CD4+ T cells were purified and 
co-cultured with BMDCs pulsed with joint extract from an LPS challenged mouse, OVA, or candidate 
RA antigens bovine collagen II and bovine aggrecan. Cells were also cultured with non-pulsed 
BMDCs to determine baseline cytokine expression. BMDCs were pulsed and simultaneously cultured 
with CD4+ T cells. Golgi plug was added 6 hours after co-culture set up and cells were cultured for 
a further 6 hours at 37C. Cells were collected and stained for flow cytometry analysis. Cells were 
cultured in duplicate for each condition. Representative flow cytometry plots of A) pLN and C) joint 
endogenous CD4+ T cells from HAO and PBS challenged mice showing i) ICOS, ii) IL-2, iii) IFNγ, 
and iv) TNFα expression when co-cultured with and without OVA. Frequency of ICOS+, IL-2+, IFNγ+, 
and TNFα+ in B) pLN and D) joint endogenous CD4+ T cells from each experimental condition. 
Graphs represent 1 experiment with n=1 (pLNs and joints from 7 HAO and 6 PBS challenged mice 
were pooled per tissue per group. Values from each technical replicate plotted). Groups were 
compared using 2-way ANOVA. Stars represent the following values: * ≤0.05; ** ≤0.01; *** ≤0.001; 
**** <0.0001; ns: not significant. 
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 Evaluating endogenous CD4+ T cell activation in response 
to joint antigen recognition in animals undergoing the late 
model of experimental arthritis 
In Chapter 3 section 3.2.2.6 and results Chapter 4 it was demonstrated that an 
antigen specific response appears to evolve over time, with the inflamed lymph node 
and joint showing differences in antigen specific responses with the progression of 
experimental arthritis. One of the questions that I asked is whether the changes in 
antigen specific responses is due to an increased response to joint antigens. To 
address this, co-culture experiments were performed with endogenous CD4+ T cells 
isolated from pLNs and joints of Nur77GFP mice undergoing the late model of 
experimental arthritis (see section 2.10 for more details). In these experiments, 
BMDCs were pulsed with joint extract made from IFA challenged joints, OVA, and 
the same candidate RA antigens used in the co-culture experiments discussed in 
the previous section. Nur77GFP expression was evaluated from endogenous CD4+ 
T cells isolated from pLNs and joints and ICOS and cytokine expression in response 
to the various antigens was also evaluated. 
Endogenous CD4+ T cells isolated from late inflamed and IFA only pLNs did not 
show a difference in Nur77GFP expression between the two experimental groups, 
nor in response to OVA or RA candidate antigens (Figure 5-11 A and B). 
Interestingly, Nur77GFP expression was reduced in endogenous CD4+ T cells 
cultured with joint IFA extract. By contrast, the T cells isolated from late inflamed 
and IFA only joints showed a significant increase in Nur77GFP expression when 
cultured with OVA – 35% and 28% of the endogenous CD4+ T cells isolated from 
late inflamed and IFA only joints respectively respond to OVA (Figure 5-11 C and 
D). No significant increase in Nur77GFP expression was found when cultured with 
joint IFA extract or candidate RA antigens. It is also important to note that the overall 
GFP expression is greater in pLNs than it is in the joints. 
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Figure 5-11 Percentage of Nur77GFPhi endogenous CD4+ T cells isolated from pLNs and 
joints of HAO+IFA (late inflamed) and IFA only challenged mice co-cultured with joint extract, 
OVA, or candidate RA antigens 
pLNs and joints were collected from HAO+IFA and IFA only challenged mice. CD4+ T cells were 
purified and co-cultured with BMDCs pulsed with joint extract from IFA challenged mice, OVA, or 
candidate RA antigens bovine collagen II and bovine aggrecan. Cells were also cultured with non-
pulsed BMDCs to determine baseline Nur77GFPhi frequency. BMDCs were pulsed and 
simultaneously cultured with CD4+ T cells. Golgi plug was added 12 hours after co-culture set up 
and cells were cultured for a further 6 hours at 37C. Cells were collected and stained for flow 
cytometry analysis. Cells were cultured in duplicate for each condition. Representative flow cytometry 
plots of A) pLN and C) joint Nur77GFPhi endogenous CD4+ T cells isolated from HAO+IFA 
challenged mice co-cultured with and without OVA, and from IFA challenged mice co-cultured with 
OVA. Frequency of Nur77GFPhi endogenous CD4+ T cells from B) pLNs and D) joints for each 
experimental condition. Graphs represent 2 experiment with n=1 for each experiment (pLNs and 
joints from 6 and 5 HAO+IFA challenged mice were pooled for the 1st and 2nd experiments 
respectively and pLNs and joints from 5 IFA challenged mice were pooled for both experiments. 
Values from each technical replicate plotted). Groups were compared using 2-way ANOVA. Stars 
represent the following values: * ≤0.05; **** <0.0001; ns: not significant. 
Interestingly, endogenous CD4+ T cells from late inflamed pLNs display reduced 
ICOS expression compared to IFA only controls and showed no overall difference 
in cytokine expression (Figure 5-12 A and B). However, endogenous CD4+ T cells 
isolated form the late inflamed joints contrast the pLNs in terms of activation profile 
(Figure 5-12 C and D); ICOS expression is significantly greater than in IFA only 
cells, and again, cells co-cultured with OVA have higher ICOS expression compared 
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to DC only controls. Moreover, IL-2, IFNγ, and TNFα are all increased in late 
inflamed isolated endogenous CD4+ T cells co-cultured with OVA compared to DC 
controls. It is interesting to note that IL-2 production decreases when late inflamed 
endogenous CD4+ T cells are cultured with OVA compared to cells isolated from 
IFA only joints, which may suggest that these T cells have a reduced proliferative 
capacity. It is also important to note that the IFA only cells co-cultured with OVA also 
show increased production of IL-2, IFNγ, and TNFα compared to IFA only DC 
controls, suggesting that these cells may be memory effector CD4+ T cells. Another 
method of determining the presence of responses against joint derived antigens is 
to check for IgG responses against joint antigens such as collagen II, which would 
indicate the presence of autoreactive collagen II specific endogenous CD4+ T cells 
providing help to collagen specific B cells to generate class-switched antibodies 
against collagen II. This method has been used to detect autoreactive responses in 
the model140,252,254. As expected, no differences in the OVA response was observed 
between the baseline, IFA, and late inflamed mice, as all these mice received 
immunisations of OVA/CFA. However, the absence of a response against joint 
antigens was verified in an ELISA against bovine collagen II (Figure 5-13) which 
showed no significant difference in collagen II antibody titres between mice that only 
received periarticular PBS immunisations (baseline), IFA only and late inflamed 
mice.  
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Figure 5-12 Percentage of cytokine producing endogenous CD4+ T cells isolated from pLNs 
joints of HAO+IFA (late inflamed) and IFA only challenged mice co-cultured with joint extract, 
OVA, or candidate RA antigens 
pLNs and joints were collected from HAO+IFA and IFA only challenged mice. CD4+ T cells were 
purified and co-cultured with BMDCs pulsed with joint extract from IFA challenged mice, OVA, or 
candidate RA antigens bovine collagen II and bovine aggrecan. Cells were also cultured with non-
pulsed BMDCs to determine baseline cytokine expression. BMDCs were pulsed and simultaneously 
cultured with CD4+ T cells. Golgi plug was added 12 hours after co-culture set up and cells were 
cultured for a further 6 hours at 37C. Cells were collected and stained for flow cytometry analysis. 
Cells were cultured in duplicate for each condition. Representative flow cytometry plots of A) pLN 
and C) joint endogenous CD4+ T cells from late inflamed and IFA only challenged mice showing i) 
ICOS, ii) IL-2, iii) IFNγ, and iv) TNFα expression when co-cultured with and without OVA. Frequency 
of ICOS+, IL-2+, IFNγ+, and TNFα+ in B) pLN and D) joint endogenous CD4+ T cells from each 
experimental condition. Graphs represent 2 experiment with n=1 for each experiment (pLNs and 
joints from 6 and 5 HAO+IFA challenged mice were pooled for the 1st and 2nd experiments 
respectively and pLNs and joints from 5 IFA challenged mice were pooled for both experiments. 
Values from each technical replicate plotted). Groups were compared using 2-way ANOVA. Stars 
represent the following values: * ≤0.05; ** ≤0.01; *** ≤0.001; **** <0.0001; ns: not significant. 
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Figure 5-13 OVA and collagen II serum ELISAs of mice undergoing the late model of 
experimental arthritis 
Bloods were collected from mice undergoing the late model of experimental arthritis and sera were 
isolated from each sample. Serum ELISAs were performed to detect serum antibodies against A) 
chicken ovalbumin (OVA) and B) bovine collagen II. Samples were screened in duplicate. Readings 
were normalised to a standard, averaged per sample, and plotted. Graphs represent 2 experiments 
with a total of n=9 for the HAO+IFA (late inflamed) and IFA only groups, and n=7 for the baseline 
group. Groups were compared using one-way ANOVA. ns: not significant. 
Overall, the same conclusions can be drawn from the late timepoint data as with the 
early timepoint data; the endogenous CD4+ T cells do not appear to be responding 
to the joint derived antigens tested and based on the parameters measured, a 
significant and higher proportion of these cells responded to OVA at this timepoint 
than at the early timepoint. However, the contrast in Nur77GFP and cytokine 
expression between late inflamed pLNs and joints is interesting and indicates that 
endogenous CD4+ T cells isolated from pLNs could have more of an exhausted 
phenotype compared to those isolated from the joint and also compared to 
endogenous CD4+ T cells isolated from early HAO challenged pLNs. This needs to 
be verified, as no exhaustion markers were included in the flow cytometry panel. 
These observations again highlight the differences in CD4+ T cell responses 
between the inflamed tissue and its draining lymph node at different stages of 
disease as noted in Chapter 4. 
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 Discussion 
Evidence for antigen specific responses has been demonstrated in RA46,201,289. 
Despite this, it is contentious as to where autoreactive CD4+ T cells encounter their 
antigen, especially in the early phases of disease82. Moreover, the range of antigens 
postulated to be involved in RA is large and heterogenous across patients82,183,295, 
making it more difficult to pinpoint where autoreactive responses may be occurring 
and originating from. Nevertheless, the presence of expanded cells in the inflamed 
arthritic joint46, the use of synovial fluid extract for RA tolerogenic therapies244, and 
behaviour of endogenous CD4+ T cells in the OVA model of experimental 
arthritis191, all point to the joint being an important site in which autoreactive CD4+ 
T cells may encounter their cognate antigen. In this chapter, the Nur77GFP system 
was used to further probe for evidence of antigen recognition in early phases of 
disease and determine whether antigen recognition occurs in the joint, specifically 
in response to joint derived antigens. 
The Nur77GFP system was established as an accurate reporter of TCR 
engagement and T cell activation suitable for evaluating those responses in the 
early model of experimental arthritis. Nur77GFP expression levels increased upon 
stimulation with anti-CD3 in a dose dependent manner and correlated with the early 
activation marker CD69. Moreover, expression of GFP was significantly reduced 48 
hours after strong TCR stimulation, which fits well within the timeframe of detecting 
TCR engagement of endogenous CD4+ T cells after HAO administration, as mice 
are culled 4 days after periarticular challenge (see methods section 2.2.5). This 
would imply that CD4+ T cells with high levels of Nur77GFP have seen their cognate 
antigen in the past 48 hours. 
A greater number of endogenous CD4+ T cells with high levels of Nur77GFP were 
purified from HAO challenged pLNs and joints, indicating that these cells had seen 
their cognate antigen recently in both pLNs and joints. Moreover, the higher 
frequency of these cells in HAO challenged joints compared to LPS challenged 
joints verified that these cells are activated due to TCR engagement, complementing 
the observations in Chapter 3 section 3.2.2.4. This increased endogenous 
Nur77GFPhi CD4+ T cell frequency may in fact reflect the breach of tolerance 
associated with HAO but not LPS challenge, demonstrated by Nickdel et. al.254, and 
may reflect recognition of autoantigens.  
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Although, an increase in endogenous Nur77GFPhi CD4+ T cells in the joint is not 
definitive evidence for TCR engagement in the joint itself; having Nur77GFPhi cells 
indicates that the cells have seen cognate antigen in the past 48 hours, but whether 
these cells recognised their antigen in the lymph node then migrated to the joint 
cannot be distinguished from the cells that have seen their cognate antigen in the 
joint. Several studies have demonstrated that effector T cells can migrate to 
inflamed sites within a timeframe spanning hours188 to days307,308. 
Migration of cells between the pLN and inflamed joint in the model has been 
examined in Kaede mice by members of the lab (unpublished data). Kaede mice 
developed by Tomura et al express a fluorescent protein that changes from green 
to red upon exposure to UV light309, thus allowing one to track cells migrating from 
the UV exposed site. When the OVA experimental arthritis model was conducted in 
Kaede mice, approximately 50% of photoconverted cells migrated out of the joint 24 
hours after the inflamed joint was exposed to UV light, a small proportion of which 
were CD4+ T cells (personal correspondence with Dr. Robert Benson). This would 
suggest that the CD4+ T cells that migrated to the inflamed joint were still retained 
at the site after 24 hours. Moreover, several studies have shown that antigen 
recognition impedes T cells egress from the inflamed site310,311 and a study by 
Prendergast et. al. has shown that a proportion of endogenous CD4+ T cells in the 
joint behave in a manner implying antigen recognition191. This evidence, together 
with the increased number of endogenous CD4+ Nur77GFPhi cells in the joint, 
suggests a strong possibility of endogenous CD4+ T cells recognising their cognate 
antigen in the joint. Stronger evidence for this phenomenon can be provided by 
combining a system of cell tracking with a reporter of TCR engagement; a cross 
between Kaede and Nur77GFP mice. Theoretically this would overcome the issue 
of identifying where CD4+ T cells have seen their cognate antigen, however, GFP 
and Kaede green have the same excitation and emission wavelengths making this 
cross not feasible in practise. This obstacle can be overcome, however, by 
performing RNA sequencing experiments on endogenous CD4+ T cells retained in 
the joint and on those that have migrated out of the inflamed joint to the draining 
lymph node. By performing differential gene expression analysis on genes involved 
in TCR engagement - including Nur77 - between these two groups, stronger 
evidence of CD4+ T cells engaging with their cognate antigen in the joint itself can 
be obtained. Although, a limitation to this type of experiment is recovering cell 
numbers sufficient for accurate analysis. 
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In Chapter 3, cells with the Vβ4 TCR were shown to be enriched in the early model 
of experimental arthritis, be associated with joint antigens, and possibly contain the 
clones for the progression of the disease. Too few endogenous CD4+ Nur77GFPhi 
cells were recovered from joints to accurately quantify the number of Vβ4+ CD4+ T 
cells, and cells isolated from pLNs of HAO challenged mice showed no difference 
in the number and frequency of cells with the Vβ4, 6, or 13 TCR chains. It was 
especially unexpected that endogenous CD4+ T cells with the Vβ4 TCR did not 
show increased Nur77GFP expression as it was postulated that these cells are 
retained in the joint as a consequence of antigen recognition. This perhaps is a 
reflection on the mechanism by which endogenous CD4+ T cells are retained in the 
lymph node and may not need continued antigen stimulation to be retained. The 
increase in antigen experienced endogenous CD4+ T cells expressing the Vβ4 TCR 
chain observed in Chapter 3 section 3.2.2.5 could in fact be a result of cell 
proliferation which does not necessarily require continued antigen simulation, as 
demonstrated by proliferation experiments to establish the Nur77GFP re-stimulation 
assays discussed in section 5.2.5. Moreover, Nickdel et. al. also demonstrated that 
once autoreactive responses are established, they can be perpetuated by non-
antigen specific inflammatory stimuli254. It is important to note that the observations 
of Vβ4 endogenous CD4+ T cells found in Nur77GFP mice were isolated from pLNs, 
and the mechanisms that may explain absence of Nur77GFP upregulation in Vβ4 
endogenous CD4+ T cells may not reflect the retention mechanisms in the inflamed 
joint. 
To substantiate recognition of joint antigens by endogenous CD4+ T cells, DC/T cell 
co-culture experiments with joint extract, OVA, and candidate RA antigens collagen 
II and aggrecan were conducted with cells isolated from pLNs and joints of mice 
undergoing the early and late model of experimental arthritis. It is important to note 
that the co-culture experiments were only performed once with one biological 
replicate when looking endogenous CD4+ T cell responses at the early timepoint, 
and twice at the late timepoint, due to the number of mice that needed to be pooled 
to recover sufficient number of cells. Therefore, the conclusions drawn from these 
experiments need to be verified with additional experimental repeats. 
Endogenous CD4+ T cells isolated from pLNs from HAO challenged mice at the 
early timepoint had a higher Nur77GFP expression overall and only showed 
significant increase in GFP expression when cultured with OVA. This increase is 
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verified as IL-2, IFNγ, and TNFα were also higher when endogenous CD4+ T cells 
were cultured with OVA. In contrast, endogenous CD4+ T cells isolated from the 
joint showed no significant increase in Nur77GFP expression nor in cytokine 
production when cultured with any antigens. However, increased ICOS expression 
in the T cells co-cultured with joint extract, OVA and candidate RA antigens indicates 
that these cells are activated and have received co-stimulatory signals from 
APCs312, which implies that these cells have in fact seen their cognate antigen, but 
not necessarily within the 48 hour timeframe that the Nur77GFP system was found 
to report. The contrast in ICOS and Nur77GFP expression of joint endogenous 
CD4+ T cells may reflect a limitation of the Nur77GFP system, in that it is only 
effective for reporting strong TCR stimulation events. Indeed, CD69 seemed to be 
more sensitive to TCR triggering than Nur77GFP; CD69 expression increased at a 
lower dose compared to Nur77GFP and increased more rapidly, meaning that it may 
be more sensitive in reporting T cell activation than the Nur77GFP system. In 
addition, high background of GFP expression resulting from continued T cell/MHC 
interactions306 , especially in endogenous CD4+ T cells isolated from pLN samples, 
has proved difficult in effectively determining low to medium strength TCR 
stimulation. As a result, the use of other indicators of activation, such as ICOS 
expression and production of inflammatory cytokines, was required to corroborate 
the observed GFP expression. And so, lack of cytokine production from endogenous 
CD4+ T cells isolated from the joint may in fact corroborate absence of Nur77GFP 
expression from these cells. It is important to note that in absolute terms the 
percentage of cytokine producing endogenous CD4+ T cells, cultured with OVA or 
otherwise, is low ranging from 0.20-0.78% and 1.4-7.9% in pLNs and joints 
respectively and whether these are biologically relevant values is something to 
consider. Moreover, this would indicate that the majority of the cells did not in fact 
respond to OVA or the other antigens tested in the assay and the antigen 
specificities of the endogenous CD4+ T cells still remains unknown. 
Chapter 4 discussed the evolution of the antigen specific response in the model and 
eluded to differences in endogenous CD4+ TCR diversity between late inflamed 
pLNs and joints, suggesting a change in the antigens recognised. To investigate 
whether the development of these differences resulted from endogenous CD4+ T 
cells recognising and responding to a different set of joint specific antigens, co-
culture experiments were also conducted with endogenous CD4+ T cells isolated 
from mice undergoing the late model of experimental arthritis. Nur77GFP 
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expression in endogenous CD4+ T cells isolated from late inflamed pLNs showed 
no significant increase in Nur77GFP expression nor in cytokine production 
compared to IFA only controls. In fact, whenever there was a significant difference, 
it was lower compared to the IFA only and DC only controls. The pattern of 
expression indicates T cell exhaustion which occurs when T cells are 
overstimulated313 and has been reported in cases of chronic viral infection314,315.This 
would need to be verified by the inclusion of antibodies against exhaustion markers, 
such as PD-1 and CTLA-4, in flow cytometry panels. In contrast, endogenous CD4+ 
T cells isolated from both late inflamed and IFA only joints show increased 
Nur77GFP and ICOS expression, as well as increased IL-2, IFNγ, and TNFα 
production when co-cultured with OVA pulsed BMDCs. The fact endogenous CD4+ 
T cells isolated from IFA only joints had a similar or greater percentage of cytokine 
producing cells indicates that these cells may be OVA specific effector memory T 
cells which are known to be more sensitive to activation signals and produce high 
levels of different cytokines316. This may explain the difference in activation profiles 
observed of endogenous CD4+ T cells isolated from pLNs compared to joints at this 
late timepoint, and also compared to the endogenous CD4+ T cells isolated from 
the early timepoint. 
Although it could not be shown that the cells responded to joint derived antigens 
tested, the interesting observation is the contrast in responses between the late 
inflamed pLN and joint, and how that compares to the responses observed at the 
early timepoint. Endogenous CD4+ T cells isolated from pLNs and joints at both the 
early and late model timepoints responded to OVA; 12-15% of the cells at the early 
timepoint and 20-35% at the late timepoint in pLNs and joints respectively. The 
increase in proportion of cells by the late timepoint may reflect increased 
proliferation of OVA stimulated cells, which is supported by the increase in IL-2 
production compared to CD4+ T cells cultured with non-pulsed BMDCs. Or this 
increase could be a reflection of epitope spreading with respect to OVA, a 
phenomenon where cells respond to other sub-dominant epitopes of the protein in 
addition to the dominant epitope52. 
Again, approximately 30% and 35% of the endogenous CD4+ T cells from IFA only 
and late inflamed joints respectively responded to OVA. Although this is a 
substantial increase from endogenous CD4+ T cells that responded at the early 
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timepoint, the majority of cells present in the joint did not in fact recognise OVA and 
the antigens these endogenous CD4+ T cells recognise still remains unknown. 
In summary, the experiments presented in this chapter aimed to provide evidence 
for antigen recognition in the early phases of experimental arthritis and to determine 
whether antigen recognition occurs in the joint and to joint specific antigens. The 
data demonstrated the possibility of CD4+ T cell antigen recognition in the joint itself 
and that this antigen recognition may be associated with the breach of tolerance 
resulting from periarticular administration of HAO. Although a significant percentage 
of endogenous CD4+ T cells were found to respond to OVA ex vivo, the antigen 
specificities of the majority of the endogenous CD4+ T cells cultured remains 
unknown, suggesting that these cells may indeed respond to autoantigens. In 
addition, the data presented elaborates on the evolution of CD4+ T cell clonality 
observed in the previous results chapter (Chapter 4) by providing information on 
the functional state of the CD4+ T cells in pLNs and joints at different stages of the 
disease. This again highlights the importance of site specific and temporal 
differences of antigen specific CD4+ T cell responses during the development of 
inflammatory arthritis. Moreover, the different functional states of the CD4+ T cells 
in the pLNs and joints can perhaps inform us of how these cells should be targeted 
– in their respective tissue sites - in order to effectively evoke the desired 
immunological responses. This would result in more efficient tolerogenic therapies 
and a firm step towards drug-free remission. 
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Chapter 6 General Discussion 
Treatments targeting RA have improved drastically over the past two decades, 
however, a significant proportion of patients still fail to improve or show partial 
remission to current therapeutics. Moreover, those who do achieve remission are 
required to take the prescribed medication indefinitely, which is not only impractical 
and unpleasant for the patient, but also places a large economic burden on society. 
Consequently, current therapeutic objectives have been to develop more effective 
therapies to achieve long lasting, drug-free remission for all RA patients. One 
approach to achieve this is to develop antigen specific tolerogenic therapies to 
reinstate tolerance to self-antigens, which has shown promise in mouse models of 
autoimmune diseases as well as in some clinical trials, as discussed in section 1.5 
of the introduction. However, the unknown nature of the antigens recognised, a poor 
understanding of which CD4+ T cells to target, and the delay between breach of 
self-tolerance and presentation of clinical symptoms in RA patients have impeded 
development of effective tolerogenic therapeutics for RA. The current requirement, 
therefore, is to investigate how antigen specific CD4+ T cell responses develop and 
evolve with the progression of RA and the role autoreactive CD4+ T cell responses 
play in shaping the antigen specific response in RA patients. This will further our 
understanding of the roles autoreactive CD4+ T cells play in RA progression, 
potentially contributing to the advancement of more effective tolerogenic therapies. 
 Summary of key findings 
The aims of this study were to investigate the development of antigen specific CD4+ 
T cell responses after the induction of breach of tolerance, to examine how these 
responses evolved with disease progression and to determine whether 
accumulation of CD4+ T cells is a result of breach of tolerance to joint antigens in 
the joint itself. To achieve this, TCR clonality of CD4+ T cells was examined in the 
OVA induced breach of tolerance model of experimental arthritis, which allows for 
the investigation of antigen specific CD4+ T cell responses under conditions where 
autoreactive responses have been shown to develop. The initial CD4+ T cell 
infiltrate was found to be oligoclonal in nature, enriched with CD4+ T cells 
expressing the Vβ4 TCR chain. Moreover, this enrichment was found to be 
associated with antigen specific responses, specifically implying the contribution of 
joint derived antigens to the observed repertoire. CDR3β sequencing analysis 
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highlighted the dynamics of clonal responses between the inflamed joint and its 
associated draining lymph node and how these responses evolved with the 
progression of experimental arthritis. Inflamed joints displayed similar CD4+ T cell 
repertoire diversity at early and late stages of the disease, while inflamed lymph 
nodes displayed increased repertoire diversity with disease progression. Moreover, 
the number of CD4+ T cell clones shared between the inflamed joint and lymph 
node decreased with time. However, correlation analyses of highly abundant clones 
between inflamed joints and lymph nodes suggested continued migration of CD4+ 
T cell clones from inflamed lymph nodes to the joints.  
To address whether the changes in CD4+ T cell clonality observed was due to 
antigen recognition in the inflamed joint itself and whether the endogenous CD4+ T 
cells recognise joint autoantigens, the Nur77GFP reporter mouse was employed. A 
greater number of Nur77GFPhi endogenous CD4+ T cells were isolated from early 
inflamed pLNs and joints, which may reflect antigen recognition in the joint, but more 
specifically, reflect recognition of joint autoantigens as a consequence of the breach 
of tolerance induced. To verify this, endogenous CD4+ T cells isolated from 
Nur77GFP mice undergoing the early and late OVA models of experimental arthritis 
were co-cultured with BMDCs either pulsed with non-antigen induced inflamed joint 
extract, with OVA, or candidate joint antigens collagen II and aggrecan. At the early 
timepoint Nur77GFP, ICOS, and cytokine expression was significantly higher in 
endogenous CD4+ T cells isolated from inflamed pLNs only when cultured with 
OVA, while no significant increase was observed in CD4+ T cells isolated from 
inflamed joints when cultured with any antigens. However, the opposite was 
observed in endogenous CD4+ T cells isolated from inflamed pLNs and joints at the 
late timepoint; expression of Nur77GFP, ICOS, and cytokines was increased in cells 
isolated from joints cultured with OVA, while no increase in expression was 
observed from cells isolated from late inflamed pLNs. 
 Development of autoreactive responses in RA 
Overall, my results have a number of potential implications for understanding the 
fundamentals of the development of articular inflammation and potential implications 
for clinical practice. These are summarised in Figure 6-1, which depicts a potential 
mechanism for the role antigen specific autoreactive responses in initiating and 
propagating RA. The disease begins with priming or reactivation of autoreactive 
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CD4+ T cells in joint draining lymph nodes to antigens potentially originating from 
the joint. The inciting antigen is unlikely to be new and has probably been 
encountered for a second or third time at this time point, as suggested by Firestein 
and McInnes82. The Th1 polarised OT-II cells used in the model, and the subsequent 
immunisations with OVA/CFA and HAO, behave as cells primed and reactivated by 
the inciting antigen in RA. This results in an expansion of oligoclonal CD4+ T cell 
populations in the lymph node (Figure 6-1 A). Expanded autoreactive CD4+ T cells 
then migrate to and accumulate in the joint, due to recognition of cognate antigen, 
and potentially execute their effector functions and cause damage (Figure 6-1 B). 
This is supported by data obtained at the early timepoint where both Vβ analysis 
using flow cytometry and CDR3β sequencing analysis of endogenous CD4+ T cells 
revealed similar CD4+ TCR clonalities between the inflamed pLN and joint. 
Moreover, the seeming lack of correlation between expanded clones in the early 
inflamed pLN compared with the joint could indicate that a small number of 
autoreactive clones that have breached self-tolerance initiate the damage inducing 
proinflammatory responses. The expansion and migration of autoreactive CD4+ T 
cells from the lymph node to the joint would eventually lead to increased joint 
damage and the subsequent release of neo antigens, and/or cause epitope 
spreading to the primary inciting antigen(s) due to perpetuation of proinflammatory 
responses. This would further prime other autoreactive CD4+ T cells in the lymph 
node, changing the CD4+ T cell diversity and repertoire clonality in the lymph node 
(Figure 6-1 C). This process can be postulated when analysing data obtained from 
the late inflamed timepoint as both Vβ and CDR3β analysis revealed changes in 
endogenous CD4+ T cell clonality; Vβ analysis showed that the clonality of 
endogenous CD4+ T cells isolated from late inflamed pLNs displayed a “switch” in 
clonality compared to those isolated from early inflamed pLNs, with endogenous 
CD4+ T cells with Vβ6 TCR chain dominating the response compared to Vβ4 in 
early inflamed pLNs. In addition, CDR3β sequencing analysis clearly demonstrated 
that late inflamed pLNs had highly diverse CD4+ T cell repertoires composed of a 
large number of clones present in low frequencies compared to early inflamed pLNs. 
Simultaneously, CD4+ T cells from the initial wave of migrating cells continue to 
migrate and be retained in the joint in an antigen dependent manner and/or expand 
locally in the joint due to antigen recognition. This is indicated by the increasing 
numbers of Vβ4 endogenous CD4+ T cells in the joint at the late timepoint as well 
as correlation data at the late timepoint, suggesting continued migration of CD4+ T 
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cells from late inflamed pLNs to late inflamed joints. This phenomenon is further 
highlighted when considering the endogenous CD4+ T cell/BMDC co-culture data 
showing a large increase in OVA specific endogenous CD4+ T cells at the late 
timepoint. Both mechanisms of continued migration of cells responding to the 
primary inciting antigen(s) and local expansion of these cells in the inflamed joint 
would cause an overall increase in the number of CD4+ T cells in the joint while 
maintaining the clonality observed in the earlier phases of the disease. As the 
disease progresses, autoreactive CD4+ T cells of different clonalities that have been 
primed in the lymph node eventually migrate to the joint, thus mirroring the increased 
diversity and clonality of the lymph node CD4+ T cell repertoire (Figure 6-1 D). 
Although this final step was not observed in the experiments presented due to the 
resolving nature of the model, Klarenbeek et. al46 demonstrated a reduced number 
of highly expanded CD4+ T cell clones in synovia of patients with established RA 
compared to those classified as early RA patients, implying an increase in the CD4+ 
T cell clonal and repertoire diversity. An increase in TCR diversity with disease 
severity was also reported by Bucht et. al317, reiterating that CD4+ T cell repertoire 
diversity in the joint may eventually reflect the diversity observed in the lymph node.  
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Figure 6-1 Development of the antigen specific CD4+ T cell response in RA. 
Schematic representing potential mechanism of the development of antigen specific CD4+ T cell 
responses in RA. A) Autoreactive CD4+ T cells are primed or reactivated in the lymph node by an 
unknown antigen. This antigen is unlikely to be new, and is likely to have been encountered a 2nd or 
3rd time at this point, as suggested by Firestein and Mcinnes82. B) Expanded autoreactive CD4+ T 
cells then migrate to the joint and are accumulate there by antigen induced retention mechanisms, 
increased survival, and/or proliferate in the joint itself due to antigen recognition. The CD4+ T cells 
possibly execute their effector function in the joint and perpetuate joint damage. C) Increased joint 
damage results in the release of neo antigens, or cause epitope spreading to the primary inciting 
antigen(s) due to the perpetuation of proinflammatory responses, which further primes other 
autoreactive CD4+ T cells in the lymph node. This causes a change in the CD4+ TCR clonality and 
diversity in the lymph node. Simultaneously, CD4+ T cells from the initial wave of migrating cells 
continue to migrate and be retained in the joint in an antigen dependent manner and/or expand locally 
in the joint due to antigen recognition. D) As the disease progresses, autoreactive CD4+ T cells of 
different clonalities that have been primed in the lymph node then migrate to the joint, thus mirroring 
the increased diversity and clonality of the lymph node CD4+ T cell repertoire, resulting in a more 
polyclonal CD4+ T cell repertoire in the joint. 
 Implication for the development of antigen specific 
therapies 
These results suggest that antigen specific therapies would be best targeted to 
autoreactive CD4+ T cells in joint draining lymph nodes as quickly as possible after 
diagnosis to prevent the development of a polyclonal CD4+ T cell repertoire, which 
may be indicative of epitope spreading to other epitopes of the protein from which 
the primary inciting antigen was derived, and/or priming of autoreactive CD4+ T cells 
to neo self-antigens originating from different proteins. Targeting pathogenic CD4+ 
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T cells early would curb development of autoreactive responses and subsequent 
damage to joint tissue. There are several hurdles to implementing this approach in 
humans however, one of which is identifying at-risk patients who would benefit from 
antigen specific tolerogenic therapies. Currently, at-risk patients are identified as 
those who have increased levels of ACPA and RF without clinical signs of joint 
damage318–320. However, using these antibodies as biomarkers for RA prognosis is 
unreliable and controversial as patients display differing antibody responses that 
cannot be correlated to disease activity319. Thus more reliable biomarkers to stratify 
at-risk patients are required as this would better identify where along the at-risk 
phase patients stand in order to provide more effective antigen specific therapies 
tailored for that individual. Perhaps a biomarker relying on CD4+ T cell clonality may 
be more effective in identifying where on the “at-risk spectrum” these patients stand. 
Given the results of this research, observing changes in CD4+ TCR clonality in 
human inguinal lymph nodes would be a good place to start monitoring changes in 
CD4+ T cell clonality and how that correlates with disease activity. Ultrasound 
guided lymph node core biopsies have been as diagnostic tools for lymphomas for 
over 20 years321 and have also been evaluated for use in RA as a method for 
monitoring disease progression322. In a study by Rodriguez-Carrio et. al139 RA 
patients and at-risk individuals who were classified as those with significant titres of 
IgM RF and ACPA, but who do not display any clinical symptoms of RA, had their 
inguinal lymph nodes screened for changes in ILC subsets. They found that ILC 
profiles of at-risk individuals and early RA patients displayed more of an 
inflammatory phenotype compared with healthy controls. The results of these 
studies indicate two important things: firstly, it is feasible to screen lymph nodes of 
at-risk, pre-RA patients for cellular changes. Secondly, the lymph node does in fact 
change in at-risk individuals before any clinical symptoms are manifest. It would be 
interesting to monitor changes in CD4+ T cell clonality in LNs of at-risk patients, as 
well as in LNs and joints of early and established RA patients and determine whether 
the changes in CD4+ T cell clonality mirror those observed in this study. Moreover, 
monitoring changes in clonality can also be used to determine a patient’s response 
to therapeutics and to determine whether current therapeutics can “reset” the CD4+ 
TCR clonality to reflect the clonality observed at earlier stages of disease, as 
depicted in Figure 6-1 A. This is beneficial as the application of antigen specific 
therapies would more likely be easier at a stage where the CD4+ T cell response is 
oligoclonal, increasing the chances of targeting the dominant autoreactive CD4+ T 
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cell population and prevent subsequent damage possibly caused by the migration 
of these cells to the joint where they can execute their effector functions. 
This brings us to the next hurdle of applying antigen specific therapies which is 
knowing the antigens the autoreactive CD4+ T cells respond to in order to target 
them with antigen specific therapies. In an effort to identify what antigens the 
endogenous CD4+ T cells recognise, I attempted to generate CD4+ T cell 
hybridomas from endogenous CD4+ T cells isolated from pLNs and joints of 
Nur77GFP mice undergoing the OVA model of experimental arthritis, with the aim 
of using the Nur77GFP reporter to identify when a TCR bound to its cognate antigen. 
By having a library of endogenous CD4+ T cells isolated from inflamed joints, 
numerous peptides can be screened without the hindrance of having a limited 
number of cells for screening, as hybridomas can be maintained indefinitely. 
Unfortunately, attempts to generate these hybridoma cell lines failed. However, 
progress has been made in identifying antigens of unknown TCRs. Studies by 
Birnbaum et. al323 and Gee et. al324 used yeast-display of peptide/HLA libraries to 
identify cross-reacting peptides of known TCRs and identify antigens of “orphan” 
TCRs from tumour infiltrating lymphocytes. In addition, this method was used by 
Salingrama et. al325 to identify antigens recognised by a CD8+ T cell population from 
mice undergoing the EAE model, which when immunised with the synthetic peptide, 
resulted in the expansion of the regulatory CD8+ T cells, resulting in resistance to 
EAE325. An important point raised by this study is the fact that the protein from which 
these antigens were derived was never identified, but synthetic peptides were used 
to target a specific clonal population of T cells. This would be particularly beneficial 
for RA as antigens priming autoreactive CD4+ T cells have been difficult to identify 
and are also likely to be different across patients. Designing synthetic peptides for 
RA tolerogenic therapies would therefore overcome the necessity in knowing the 
peptide for targeting the autoreactive CD4+ T cells. Moreover, synthetic peptides 
can be modulated to bind to the TCR with different affinities and can potentially be 
tailored to deliver the desired response. An example of the use of an artificial peptide 
to treat an autoimmune disease is glatiramer acetate (GA) - a multimer with the 
same amino acid sequence as an MBP epitope - which is a first line therapy for 
relapsing remitting MS. GA was found to modulate the immune response from a Th1 
to a Th2 driven response via inhibition of pro-inflammatory responses from 
DCs326,327. 
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 The function of endogenous CD4+ T cells in early 
arthritis 
Changes in CD4+ TCR repertoire clonality were observed in this study, however, 
this research raises questions about the function of the endogenous CD4+ T cells 
accumulating in inflamed joints. Growing evidence suggests the presence of an 
antagonistic Th1-Th17 relationship in RA patients as well as in mouse models of 
RA155–158, with some suggesting that Th1 cells may in fact regulate pro inflammatory 
Th17 responses in RA. In addition, unpublished work by Clay et. al. (personal 
communication) demonstrated reciprocal dynamics of Th17 and Th1 responses, 
governed by different Treg subsets, correlated with the progression of a model of 
colitis. Thus, changes in CD4+ TCR clonality may in fact be a reflection of changing 
functional responses and reflect regulation rather than the development of pro-
inflammatory responses. Without understanding the function of CD4+ T cells in the 
inflamed joint and with no knowledge of the phenotype of expanding CD4+ T cells 
in the lymph node, therapies targeting these cells may exacerbate rather than 
ameliorate symptoms. Indeed, a study by Saligrama et. al325 demonstrated the 
development of regulatory CD8+ responses as a result of induction of autoreactive 
CD4+ T cells responses in the EAE model. Moreover, Treg populations have been 
identified in RA patients177–179, suggesting that regulatory responses do develop to 
control disease progression. 
Another consideration is that cells with the same TCR can result in the generation 
of cells with heterogenous functional phenotypes. Indeed, a study by Gerlach et. 
al328 demonstrated that individual naïve CD8+ T cells yield both effector and memory 
T cell subsets. Moreover, in a different study, Gerlach et. al329 also demonstrated 
how individual cells from a monoclonal population displayed varied capacities for 
expansion, differentiation, and recall during an infection. In addition, studies 
published from Steven L Reiner’s lab have shown evidence of asymmetric CD8+ T 
cell division upon pathogen re-encounter and demonstrated the asymmetric 
distribution of CD25 and Tbet during cell division330,331, suggesting that asymmetric 
division of a single cell may give rise to progeny with different effector functions. 
Further evidence of the “one cell, multiple fates” theory has been provided by 
Becattini et. al332. who demonstrated that a monoclonal population of human naïve 
CD4+ T cells can produce Th1, Th2, and Th17 CD4+ T cell subsets. 
  
 
186 
 
And so, experiments that simultaneously look at T cell clonality and function are 
required to better understand the relationship between changing CD4+ TCR 
repertoire clonality and the resulting effector responses. With the advent of single 
cell RNA sequencing technologies, such experiments are feasible and have been 
conducted to analyse clonality and function of T cells isolated from colorectal cancer 
patients333. Single cell RNA sequencing has also been conducted on cells isolated 
from RA synovia195,334, however, neither of these studies looked at T cell clonality, 
nor did they focus on CD4+ T cells – an important aspect to consider for a more 
complete representation of the CD4+ T cell repertoire. Thus, the method developed 
by Han et. al333,which was optimised to specifically amplify TCR sequences and key 
gene transcripts relevant to T cell function and specific T cell subtypes, could be 
adapted to investigate the effector function of clonally expanded CD4+ T cells in 
inflamed joints and pLNs in the model, as well as in arthritic joints and lymph nodes 
in humans. The advantage of such experiments is that they can also address the 
function of bystander CD4+ T cells in arthritic lymph nodes and joints and dissect 
the contribution antigen specific and bystander CD4+ T cells to the inflammatory 
environment and to tissue damage. Indeed, Prendergast et. al191 showed that 
although a subset of the endogenous CD4+ T cell population in the OVA model of 
experimental arthritis displayed behaviour indicative of antigen recognition, the 
remainder of the endogenous CD4+ T cells displayed scanning behaviour. In the 
same study, Prendergast et. al. also demonstrated that activated CD4+ T cells of 
known antigen specificity irrelevant to joint antigens and to OVA infiltrated the joint. 
Additionally, data presented in Chapter 5 showed that the average frequency of 
Nur77GFPhi CD4+ T cells is approximately 15%, consistent with the data presented 
by Prendergast et. al. Why these bystander cells infiltrate the joint and how they 
contribute to the development of inflammatory responses would indeed be an 
interesting question to ask and would provide a more complete picture of the 
development of CD4+ T cell responses in arthritic joints. 
 Final conclusions 
The research presented in this thesis provides a detailed examination of the 
evolution of CD4+ T cell clonality and antigen specific responses in the OVA induced 
breach of tolerance model of experimental arthritis and how this may emulate 
development of antigen specific responses in the early phases of RA. In addition, 
the results presented highlight the important differences in the diversity of site 
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specific and temporal responses during disease. Further work is warranted to 
understand the function of these autoreactive CD4+ T cells in joints and LNs of RA 
patients, which will ultimately guide the development of more effective antigen 
specific tolerogenic therapies for RA and bring treatments closer to providing drug-
free remission.  
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